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Abstract 
Whilst tremendous progress has been made in breast cancer research, 
substantial gaps still remain which require urgent attention. Behind the majority 
of them lies the general lack of understanding of the biology underlying the 
disease. For this reason, it is imperative to interrogate all players involved in the 
initiation, maintenance and progression of breast tumourigenesis.  
For a long time, the RUNX family of genes has been linked to different types of 
human cancers, with the more recent appreciation of a role in breast cancer. 
Following the discovery of genetic alterations affecting RUNX1 and its binding 
partner CBFβ in biopsies of breast cancer patients, studying the function played 
by the RUNX-CBFβ transcription factor complex in breast tumourigenesis has 
become extremely important.  
In the present thesis, the use of different experimental in vivo and ex vivo 
systems has been exploited in an endeavour to investigate the putative tumour 
suppressive and/or pro-oncogenic properties of the Runx1 gene in the context of 
breast cancer. This has been achieved through characterization of the effects of 
Runx1 deletion in the MMTV-PyMT breast cancer mouse model, followed by a 
thorough analysis of how Runx1 loss affects a novel Wnt/β-catenin-driven model 
of mammary tumourigenesis. In the latter, the role of the Runx2 gene was also 
interrogated, highlighting the tantalizing interplay existing between the two 
homologous transcription factors in controlling cell fate decisions and 
differentiation potential of mammary epithelial cells.  
Based on the obtained results, a working model of the putative role played by 
RUNX1 and RUNX2 upon the mammary epithelial cell hierarchy is discussed. This 
is intended to emphasize how changes affecting the function of the RUNX family 
of transcription factors could lead to loss of mammary tissue homeostasis and 
eventually breast cancer.  
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LP   luminal progenitor 
LPR   low-density lipoprotein-related protein 
LTR   long terminal repeat 
M   molar 
Ma-CFC  mammary colony forming cell 
MaSC   mammary stem cell 
MDTF   mouse-derived tumour fragment 
MEC   mammary epithelial cell 
MG   mammary gland 
ml   millilitre 
mM   millimolar 
MMEC   mouse mammary epithelial cell 
MMTV   mouse mammary tumour virus 
µg   microgram 
µl   microliter 
µM   micromolar 
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µm   micrometer 
MP   multiparous 
mRNA   messenger ribonucleic acid 
MRU   mammary repopulating unit 
MYO   myoepithelial 
NE   normal epithelium 
ng   nanogram 
NGS   next generation sequencing 
nm   nanometer 
NP   nulliparous 
PBS   phosphate buffered saline 
PDTX   patient-derived tumour xenograft 
PI3K   phosphoinositide 3’-kinase 
PR   progesterone receptor 
ProcR   protein C receptor 
PSQ   penicillin/streptomycin/L-glutamine 
PyMT   polyoma virus middle T antigen 
PyV   polyoma virus 
qPCR   quantitative polymerase chain reaction 
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RANK   receptor activator of nuclear factor k-B 
RANKL   receptor activator of nuclear factor k-B ligand 
RFP   red fluorescent protein 
RNA   ribonucleic acid 
RT   reverse transcription 
RT-qPCR  reverse transcription quantitative polymerase chain reaction 
RUNX1  runt-related transcription factor 1 
RUNX2  runt-related transcription factor 2 
RUNX3  runt-related transcription factor 3 
SC   stem cell 
Sca-1   stem cell antigen 1 
SCD   symmetric cell division 
SD   standard deviation 
SL   synthetic lethality 
SNP   single nucleotide polymorphism 
SNV   single nucleotide variant 
SSC   side scatter 
TBST   Tris-buffered saline Tween 
TCF   T-cell factor 
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TDLU   terminal ductal lobular unit 
tdRFP   tandem dimer red fluorescent protein 
TE   total epithelium 
TEB   terminal end bud 
TIC   tumour initiating cell 
TME   tumour microenvironment 
TN   triple negative 
U   unit 
wt   wild type 
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Summary 
Given the recent discovery of RUNX1 somatic mutations in biopsies of breast 
cancer patients, the overall purpose of the present thesis consists of using 
different in vivo and ex vivo experimental systems in the attempt to answer two 
main questions: firstly, if the Runx1 gene plays any causative role in the context 
of breast cancer; and secondly, if its putative function is symptomatic of a 
tumour suppressor gene and/or of a pro-oncogene.  
By characterizing the effects of Runx1 deletion in two different breast cancer 
mouse models (i.e. the MMTV-PyMT and the Wnt/β-catenin-driven models of 
mammary tumourigenesis), this thesis provides the first in vivo evidence of a 
dualistic role played by the gene in the context of breast cancer. Runx1 would in 
fact appear to act as a tumour suppressor at early stages of the disease, whilst 
as a pro-oncogene at later stages of mammary tumourigenesis. 
To fully comprehend the significance of these major findings, the introduction 
will first provide a brief description on the RUNX family of genes, as well as on 
the state-of-the-art knowledge of RUNX1’s role in both mammary gland and 
breast cancer biology. As such, particular attention will then be given not only 
to the ontogeny, endocrine regulation and composition of the murine mammary 
gland, yet also to the high degree of heterogeneity, the putative “cell-of-
origin(s)” and the different experimental models commonly used to study breast 
cancer. 
Through the aforementioned rationale, it is hoped that the introduction will 
serve as a platform which may hold the key for unveiling the controversial role 
played by RUNX1 in the context of breast cancer.  
 
 
 
1 Introduction 
Cancer has historically been given several different names. Starting with the 
Greek word karkinos (i.e. crab), Hyppocrates first described a tumour with its 
vessels as a 'crab dug in the sand with its legs spread in a circle', as early as 400 
BC. Afterwards, even the term oknos (i.e. load, mass) has been used to describe 
the disease with its connotations as a 'burden carried by the body'. But what do 
all these terms have in common? The idea that cancer was a terrible unspoken 
malignancy, whose cause(s) was unknown and for which there was no cure. What 
was unclear to our ancestors was the fact that cancer originated from the 
uncontrolled growth of cells, a process which was only described in the 20th 
century by the German researcher Rudolf Virchow with the word neoplasia 
(Siddhartha, 2010). 
1.1 Cancer and its “players” 
[For this section, the text has been adapted from Riggio and Blyth (2017)]. 
Generally regarded as a genetic disease, cancer arises from the dysregulation of 
normal gene expression, which is mainly caused by the sequential accumulation 
of deoxyribonucleic acid (DNA) alterations (mostly somatic mutations) affecting 
tumour suppressors, oncogenes and stability genes (Vogelstein and Kinzler, 
2004). Aided by the advent of next-generation sequencing (NGS), the 
identification of many novel cancer players and the determination of their 
genetic alterations have become possible, thus leading towards a more 
comprehensive picture of the cancer genome. The genomic landscape of most 
common cancers has been eloquently described as composed of a few 
‘mountains’, which represent the frequently mutated genes, and many ‘hills’, 
being the less frequently altered genes (Wood et al., 2007). Nevertheless, while 
the causative link between highly mutated genes (e.g. TP53 and KRAS) and 
cancer is well documented, discovering the relationship between infrequently 
mutated genes and tumourigenesis still remains a big endeavour (Vogelstein et 
al., 2013). But why should we care about these ‘hills’? Firstly, although 
substantial progress has been made over the past decade to decrease cancer 
morbidity, the incidence of many cancers still remains high (Torre et al., 2016). 
Secondly, the presence of these less frequently altered genes numerically 
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dominates the landscape of most tumours (Wood et al., 2007), thus 
strengthening the pressing need to investigate their putative function. However, 
given that the majority of the reported genetic abnormalities may be incidental 
to the neoplastic process, how do we know which ‘hills’ take an active part in 
the transformation of a benign cell into an incipient malignant one? The answer 
comes from the “driver-versus-passenger” concept whereby only driver genes 
are capable of conferring a selective growth advantage to the insulted cells 
(Greenman et al., 2007).  As such, coupling NGS data with structural analysis to 
look at the pattern and pathogenicity of the detected mutations in cancer 
(rather than just at their frequencies), a list of driver genes including 74 tumour 
suppressors and 64 oncogenes has been compiled (Vogelstein et al., 2013). One 
of these reported driver genes, RUNX1, which is found to be altered in 9.2% of 
all tumours (Vogelstein et al., 2013), is of particular interest to our lab and 
forms the basis of this thesis. 
1.1.1 The RUNX1 “hill” in the genomic landscape of female-
related cancers 
[For this section, the text has been adapted from Riggio and Blyth (2017)]. 
The Runt-related transcription factor 1 gene (RUNX1) belongs to an evolutionary 
conserved family of three related genes (RUNX1, RUNX2 and RUNX3) (Ito et al., 
2015), which encode transcription factors that bind to DNA in partnership with 
the core binding factor β (CBFβ) (Kamachi et al., 1990), itself responsible for 
enhancing DNA-binding activity (Ogawa et al., 1993) and stability (Huang et al., 
2001) of the RUNX proteins. These transcription factors are involved in the 
regulation of cell fate determination and lineage differentiation during 
development, as well as cancer (Ito et al., 2015), with RUNX1 being absolutely 
required for definitive haematopoiesis (Okuda et al., 1996).  
For a long time RUNX1 has been intensively studied in haematological cancers, 
where it gathered attention as a tumour suppressor, being the most common 
locus of numerous chromosomal translocations (Blyth et al., 2005). With the 
advent of NGS technologies and the generation of conditional knockout mouse 
models, RUNX1 has been found to have a more widespread role in cancer than 
previously thought. Indeed, RUNX1 downregulation has been reported in gastric 
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cancer (Sakakura et al., 2005) and hepatocellular carcinoma (Miyagawa et al., 
2006), while RUNX1 single nucleotide polymorphisms (SNPs) have been 
associated with colorectal (Slattery et al., 2011), as well as prostate cancer 
(Huang et al., 2011). Additionally, RUNX1 appeared to be a factor essential for 
the initiation and maintenance of skin and oral squamous cell carcinoma (Hoi et 
al., 2010) and highly focal RUNX1 deletions were observed in almost 15% of 
oesophageal cancers (Dulak et al., 2012).  
To date, RUNX1 genetic alterations are reported in almost 50% of all cancer 
genomic studies listed in cBioPortal (Figure 1. 1). Albeit, as expected, 
haematological cancers are at the top of the list, a plethora of epithelial cancers 
also appear. Among the latter, is striking the preponderance of RUNX1 genetic 
alterations in hormone-associated cancers, where the majority of female-related 
studies (including breast, ovarian and uterine cancers) are among the top 20 hits 
(Figure 1. 1). Whilst male-specific cancers (e.g. prostate and testicular) also 
feature in this list, most of those are grouped with tumours showing less 
frequent RUNX1 genetic perturbations, with the exception of a rare and 
aggressive form of prostate cancer, termed neuroendocrine prostate cancer 
(Parimi et al., 2014), in which RUNX1 is frequently altered (Figure 1. 1). But 
what role does the RUNX1 ‘hill’ play on the genomic landscape of female-related 
cancers? Several pieces of evidence suggest that RUNX1 contributes to ovarian 
and uterine cancer (Riggio and Blyth, 2017), as well as having an important role 
in breast cancer.  
To elucidate the function of RUNX1 in the genomic landscape of breast cancer, it 
would be useful to take a step back. If Farber’s sixth sense was true, that is in 
order to study leukaemia one should first understand how normal blood cells are 
generated (Siddharta, 2010), then equally to study breast cancer, one should 
figure out how mammary cells are formed in the first place. Thus applying the 
concept of confronting breast cancer “in reverse”, it is important to delve into 
the deeper understanding of a specific organ: the murine mammary gland.  
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Figure 1. 1 Frequency of RUNX1 genetic alterations across all cancer types. 
Depicted is the frequency of RUNX1 genetic alterations in 71 out of 144 cancer genomic studies. 
No RUNX1 genetic perturbations were detected in 73 cancer studies (data not shown). Female-
related cancers of the breast, ovary, uterus and cervix are shaded in pink and generally appear 
high on the list. Male-related cancers of the prostate and testis are shaded in blue and also 
appear, but with less frequent percentages with the exception of a very rare, aggressive form of 
prostate cancer. Data obtained through cBioportal for Cancer Genomics, 
http://www.cbioportal.org/ (Cerami et al., 2012; Gao et al., 2013). ACC, Adrenocortical 
Carcinoma; ACyC, Adenoid Cystic Carcinoma; AML, Acute Myeloid Leukemia; ccRCC, Kidney Renal 
Clear Cell Carcinoma; CSCC, Cutaneous Squamous Cell Carcinoma; DESM, Desmoplastic 
Melanoma; DLBC, Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; hnc_mskcc, recurrent and 
metastatic head and neck cancer; GBM, Glioblastoma Multiforme; LGG-GBM, Merged Cohort of 
Low-Grade Glioma and Glioblastoma Multiforme; MDS, Myelodysplasia; MM, Multiple Myeloma; 
NEPC, Neuroendocrine Prostate Cancer; NSCLC, Pan-Lung Cancer; PCPG, Pheochromocytoma and 
Paraganglioma; pRCC, Kidney Renal Papillary Cell Carcinoma. Taken from Riggio and Blyth 
(2017). 
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1.2 The ontogeny of the mammary gland  
During evolution, the appearance of mammary glands has profoundly 
distinguished the class of Mammalia from other animals, by giving them the 
opportunity to nourish their offspring through the production and secretion of 
milk. As such, it should not be surprising that the anatomical and morphological 
features of this organ, as well as the highly regulated endocrine system which 
controls it, are all devoted to the sole physiological function of lactation 
(Medina, 1996). 
1.2.1 The murine mammary gland 
Due to the high level of similarities between mice and humans, the murine 
mammary gland represents an attractive experimental system to study, as its 
uniqueness relies on several factors. Firstly, it is the only organ of the mouse 
whose development mainly takes place postnatally, a precious advantage for 
biologists to “watch” and study the growth of the organ in “real-time” (Medina, 
1996). Secondly, it allows performing orthotopic experiments without the 
confounding presence of the endogenous tissue, which can be easily removed 
from 3 weeks old recipient mice in a process known as depithelized (cleared) 
mammary fat pad (DeOme et al., 1959). Thirdly, being situated just underneath 
the skin, it is very easily accessible and amenable to different sorts of 
experimental manipulations (Brisken and O'Malley, 2010). Lastly, it is very 
abundant in mice, which are characterized by five pairs of mammary glands, 
located in the neck region (1st), the chest wall (2nd and 3rd), the abdominal wall 
(4th) and the inguinal region (5th) (Figure 1. 2), thus providing ample tissue for 
research analysis (Cardiff and Wellings, 1999). However, it is important to 
mention that morphological and structural differences exist between the murine 
mammary gland and the human breast. Firstly, humans only have one pair of 
mammary glands located on the anterior chest wall, which anatomically would 
correspond to the 3rd pair of murine mammary glands. Secondly, the human 
stroma, or parenchyma, is constituted by more fibrous connective tissue and less 
adipose tissue as compared to the murine mammary fat pad (Cardiff and 
Wellings, 1999). Thirdly, the ramified network of human ducts ends in small 
clusters of ductules, which are usually referred to as terminal ductal lobular 
units (TDLUs). Similar to terminal end buds (TEBs), TDLUs undergo dynamic 
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morphological changes during development, passing from undifferentiated 
lobules (Lob1) characteristic of virgin glands, through differentiated structures 
with more ductules (Lob2 and Lob3) and secretory acinar types (Lob4) seen 
during pregnancy, to then return to less differentiated ones (Lob 1 or Lob2) after 
lactation (Russo et al., 2005). The murine mammary gland is a very 
heterogeneous organ made up of two compartments: the stroma, better known 
as fat pad, formed by adipocyte, fibroblast, vascular and immune cells; and the 
epithelium, a bilayered structure comprised of luminal and basal cells 
(Hennighausen and Robinson, 2005). The luminal compartment of the mammary 
epithelium is composed of tightly connected apically oriented luminal cells of 
the ductal and alveolar subtypes, the latter of which produce milk during 
lactation. The basal compartment, lying between the luminal layer and the 
basement membrane, is made up of highly elongated contractile myoepithelial 
(MYO) cells, which help luminal cells in milk ejection and circulation throughout 
the ductal tree (Macias and Hinck, 2012). Of note, while luminal cells can be 
identified by expression of cytokeratin (CK) 8 and CK18, basal cells can be 
distinguished for the presence of CK5, CK14 and α smooth muscle actin (αSMA) 
(Inman et al., 2015) (Figure 1. 2). 
 
Figure 1. 2 The bi-layered epithelial structure of the murine mammary gland. 
Schematic representation of the five different pairs of murine mammary glands, each one 
consisting of a bi-layered structure of luminal and basal/myoepithelial cells. Luminal cells are 
characterized by the presence of CK8 and CK18, whilst basal/myoepithelial cells can be 
distinguished for the expression of CK5, CK14 and αSMA. αSMA, α smooth muscle actin; CK, 
cytokeratin. 
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1.2.2 The developmental stages: embryonic, pubertal, and 
reproductive  
The growth of the murine mammary gland, a derivative of the ectoderm, is 
multistage and encompasses three main developmental phases: embryonic, 
pubertal, and reproductive. The embryonic development of the mammary gland 
starts at embryonic (E) day 10 with the formation of bilateral milk lines 
composed of multi-layered ectoderm. By day E11.5, these give rise 
(asynchronously, yet at specific locations) to five pairs of placodes constituted 
by a thickened plate of ectoderm made up of columnar-shaped cells. By E14, 
placodes expand forming a ball of cells which infiltrates the underlying 
mesenchyme. By E16, this leads to the appearance of a rudimentary tree-like 
structure, known as the anlage, which remains quiescent until puberty. By E18, 
the nipple is formed and a ductal lumen becomes apparent, as a result of 
autophagy, apoptosis and cellular remodelling (Macias and Hinck, 2012).  
Because of the absence of any overt phenotype shown by several hormone 
receptors (HRs)-deficient mice, the isometric growth of the anlage from birth to 
puberty is believed to be hormone-independent (Figure 1. 3A) (Brisken and 
O'Malley, 2010), although HRs are expressed beforehand, prior to maturation of 
the ovaries (Shyamala et al., 2002; Stumpf et al., 1980). At the onset of puberty, 
the anlage starts to proliferate expansively, as its growth becomes totally 
dependent on ovarian and growth hormones (GHs), which define the so-called 
hormone-dependent phase (Figure 1. 3C, D, E, F) (Brisken and O'Malley, 2010). 
Major players of this stage are TEBs: spoon-shaped structures located at the tips 
of growing ducts and representing the hormone-sensitive engines of the pubertal 
mammary tree. Following the release of hormones, these motile buds start 
invading the empty mammary fat pad, allowing the elongation of the ducts and 
the simultaneous formation of the forked architecture typical of the mammary 
gland. With TEBs regression occurring at the end of puberty, the mammary 
epithelial tree is thought to have filled up to 60-80% of the stroma (Figure 1. 3) 
(Hinck and Silberstein, 2005). Importantly, from puberty onwards, the mammary 
gland undergoes subtle morphological changes in response to the oestrous cycle, 
which is made up of four different phases: proestrous, oestrus, metestrous and 
diestrus (Caligioni, 2009). Diestrus, for example, is characterized by the 
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formation of progesterone-driven short tertiary side branches, which are 
necessary to prepare the mammary gland for a putative pregnancy (Figure 1. 3).  
During the reproductive stage, with the arrival of pregnancy hormones, primarily 
progesterone and prolactin, alveologenesis takes place, leading to the formation 
of small alveoli which culminate in the production of milk during lactation. When 
the demand from new-borns ceases, the mammary gland undergoes an involution 
phase, characterized by extensive apoptosis and tissue remodelling, in order to 
return to a virgin-like resting state (Figure 1. 4) (Macias and Hinck, 2012). 
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Figure 1. 3 Pubertal mammary gland development in wild-type female mice. 
Whole-mounts of #4 mammary glands from wild type females at 3, 6 and 9 weeks of age. Scale 
bar, 1000 µm. (A) From birth to early puberty (3 weeks), the rudimentary epithelial tree (anlage) 
grows in the absence of hormones (hormone-independent phase). Right hand side – Higher 
magnification of the anlage. Scale bar, 500 µm. (B) At 6 weeks, the growth of the mammary 
gland becomes dependent on oestrogens and progesterone (hormone-dependent phase), 
responsible for ductal elongation, bifurcation and side branching. Right-hand side - Higher 
magnification of TEBs (see arrowheads). Scale bar, 500 µm. (C, D, E, F) By 9 weeks, the 
mammary gland has formed a ramified ductal structure which undergoes subtle morphological 
changes at each oestrous cycle. Diestrous-staged (c), proestrous-staged (d), oestrous-staged (e) 
and metestrous-staged (F) mammary glands. Scale bar of inserts, 500 µm. TEB, terminal end 
bud. 
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Figure 1. 4 Reproductive mammary gland development in wild-type female mice. 
Whole-mounts of #4 mammary glands (left column) and corresponding H&Es (right column) from 
mature virgin (A), D8 pregnancy (B), D7 lactation (C) and D4 involution (D) wild type females. 
Scale bar of whole-mounts, 1000 µm. Scale bar of H&Es, 500 µm. (A) In mature virgin, the 
mammary tree presents with a forked network of primary and secondary ducts. (B) During 
pregnancy, the release of prolactin and progesterone causes an increase in cell proliferation 
accompanied by the formation of alveolar buds (see arrow). (C) At lactation, mature alveoli (see 
arrow) synthetize and secrete milk components into the lumen. (D) During involution, when pups 
are weaned, an extensive remodelling programme of the mammary gland restores the epithelial 
ductal tree seen in mature virgin. H&E, haematoxylin and eosin. 
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1.2.3 Temporal and spatial expression of the Runx genes in the 
murine mammary gland 
[For this section, the text has been taken from Riggio and Blyth (2017)]. 
Runx1 has been shown to be the most abundantly expressed among all Runx 
genes in murine mammary epithelial cells (MMECs) (Blyth et al., 2010). Within 
the latter, its mRNA was found to be more elevated in the basal as compared to 
the luminal compartment (McDonald et al., 2014; van Bragt et al., 2014), whilst 
its protein was detected in both lineages of the murine gland (van Bragt et al., 
2014) and the human breast epithelium (http://www.proteinatlas.org/). 
Nevertheless, RUNX1 expression seems to be very dynamic throughout the 
development of the organ, reaching a peak at virgin and involution, whilst 
decreasing at mid-gestation and lactation, when it seems lost by alveolar 
luminal cells, yet retained by MYO cells (van Bragt et al., 2014). Akin to Runx1, 
expression of Runx2 fluctuates during different physiological stages of the 
murine mammary gland (Blyth et al., 2010) and is enriched in the basal 
compartment, albeit at a lower extent than Runx1 (McDonald et al., 2014; van 
Bragt et al., 2014). Indeed, RUNX2 seems to have a central role during 
development of the organ, as suggested by its function in mammary stem cells 
(Ferrari et al., 2013; Ferrari et al., 2015) and the impaired growth of the 
mammary epithelial tree shown by Runx2 deletion and overexpression mouse 
models (McDonald et al., 2014; Owens et al., 2014). However, the picture is not 
quite so clear for RUNX3 with one school of thought documenting lack of 
expression in isolated MMECs (Kendrick et al., 2008; McDonald et al., 2014; van 
Bragt et al., 2014), while others reporting protein expression in human breast 
tissue (Chen et al., 2007) and downregulation during breast tumorigenesis (Bai et 
al., 2013; Hwang et al., 2007; Jiang et al., 2008). 
1.3 The endocrine regulation of the mammary gland 
The importance of hormonal regulation and its impact on mammary gland 
development traces back to the 19th century with G. T. Beatson, who first 
identified the important role of endocrine ablation in breast cancer management 
(Beatson, 1896). Fascinated by the topic of lactation, Beatson realized that the 
elevated mammary epithelial cells’ proliferation taking place at this stage 
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closely resembled the one occurring during breast cancer. In addition, he 
learned a very basic principle known to all farmers, whereby removal of the 
ovaries in cows after calving allowed indefinite production of milk. This 
suggested an intimate relationship between two fairly distant organs: the ovaries 
and the mammary glands. Thus, if removal of the ovaries was halting cow’s 
mammary glands in a lactation-stage, then oophorectomy (removal of the 
ovaries) in breast cancers’ patients might have stopped tumour’s growth. 
Indeed, Beatson became the first surgeon who started performing oophorectomy 
in women with advanced breast cancers, laying the foundation for a new way of 
managing the disease (Beatson, 1896). It was only in the 20th century that 
steroid hormones were discovered and that the mechanisms underpinning their 
tissue-specificity revealed to be based on the presence of nuclear receptors 
(Shyamala et al., 2002). 
1.3.1 Oestrogens and progesterone in regulating mammary 
development 
Hormonal regulation of the mammary gland occurs via binding of ovarian 
hormones 17-β-estradiol (E2) and progesterone to their cognate nuclear HRs, 
oestrogen receptor α (ERα) and β (ERβ) (Jensen, 1984; Saji et al., 2000) and 
progesterone receptor A (PRA) and B (PRB) (Giangrande and McDonnell, 1999; 
Mulac-Jericevic et al., 2003), respectively. However, mounting evidence 
suggests that only ERα and PRB isoforms represent the main players in the 
mammary epithelium (Macias and Hinck, 2012; Mallepell et al., 2006). As such, 
both ERα and PRB are predominantly present in the luminal compartment, 
wherein their patterns of expression fluctuates during mammary gland 
development, increasing from birth to puberty, remaining elevated in virgin, 
decreasing during pregnancy and lactation, and returning to basal levels at 
involution (Shyamala et al., 2002). The reason behind this fluctuation was 
unveiled when ovariectomized mice displayed high levels of ER expression and 
low levels of PR expression, while the opposite effect was seen upon E2 
administration. These findings highlighted an intricate role exerted by E2 (yet 
not by progesterone), whereby the hormone would act as a negative regulator of 
ER and a positive regulator of PR expression, without altering the total 
percentage of positive cells (Shyamala et al., 2002).  
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As demonstrated by the absence of mammary gland development beyond a 
rudimentary ductal tree in ERα-/- mice (Mallepell et al., 2006), E2 is the first 
mitogenic stimulus of the hormone-dependent phase, responsible for the 
tremendous surge in ductal elongation and bifurcation occurring in pubertal 
mammary glands. Importantly, whilst achieving these aims, E2 is also responsible 
for inducing the expression of PR, a process known as oestrogen priming (Haslam 
and Shyamala, 1981). This sets the stage for progesterone, which instead 
represents the major proliferative stimulus of the adult mammary gland. As 
shown by PR-/- mice (Lydon et al., 1995), the hormone appears to stimulate 
extensive ductal side branching and alveologenesis, which are necessary to 
prepare a lactation-competent mammary gland (Brisken et al., 1998). In 
conjunction with the latter, prolactin signalling is required to complete 
alveologenesis at mid-pregnancy and drive lactational differentiation during 
lactation (Brisken and O'Malley, 2010).  
In summary, endocrine regulation of the mammary gland appears to be a highly 
controlled process whereby hormones act in a sequential order on the mammary 
epithelium, thus ensuring that specific morphological steps occur in a tightly 
organized manner. However, one should always bear in mind that, albeit at 
different concentrations, hormones are all simultaneously present both 
systemically and locally, highlighting the high level of complexity and synergy 
existing among them. In line with the latter, several experiments done in 
ovariectomized mice have repeatedly shown that it is only with the 
combinatorial administration of E2 and progesterone that a biological effect is 
achieved (Asselin-Labat et al., 2010; Beleut et al., 2010; Joshi et al., 2010). 
1.3.2 The effects of hormonal paracrine circuits on ductal 
morphogenesis 
What is fascinating about the endocrine regulation of the mammary gland is the 
fact that only a subset (50%) of luminal cells is believed to ‘sensor’ circulating 
hormones through expression of ERα and PRB (Shyamala et al., 2002). A similar 
scenario appears to hold true for the human breast, wherein ‘sensor’ luminal 
cells (7-15%) were found to be surrounded by a larger proportion of HR-negative 
cells, knows as the ‘effectors’ (Clarke et al., 1997). Additionally, a plethora of 
both murine and human studies have demonstrated that the vast majority of 
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proliferation seems to occur in effector, rather than in sensor cells (Clarke et 
al., 1997; Mallepell et al., 2006). Thus, how can hormonal proliferative signals 
be conveyed from sensor to effector cells? The answer relies on the presence of 
paracrine circuits acting within each epithelial layer, between the luminal and 
basal layers, and between the epithelial and stromal compartments of the 
mammary gland (Brisken and O'Malley, 2010; Macias and Hinck, 2012).  
At the onset of puberty, circulating oestrogens bind to ERα+ sensor cells, 
stimulating proliferation of neighbouring ERα- effector cells (Figure 1. 5) 
(Mallapel et al., 2006). This regulated process is elicited through the release of 
paracrine molecules, primarily amphiregulin (AREG), a transmembrane protein 
of the epidermal growth factor (EGF) family, that gets cleaved and released by 
the metalloproteinase ADAM17/TACE (Ciarloni et al., 2007; Sternlicht et al., 
2005). Following this event, AREG travels through the MYO layer and the 
basement membrane to reach the stromal compartment, where it binds to the 
EGF receptor (EGFR) expressed on fibroblasts (Schroeder and Lee, 1998; Wiesen 
et al., 1999). This leads to the subsequent production and release of fibroblast 
growth factor molecules (FGFs), including FGF7 and FGF10, which bind to FGF 
receptor 2 expressed by luminal cells (Brisken and O'Malley, 2010). In parallel, 
GH release from the pituitary gland and the binding to its receptor GHR 
stimulates insulin-like growth factor 1 (IGF1) production both systemically, in 
the liver; and locally, in the mammary gland. The binding of IGF1 to IGF 1 
receptor (IGF1R) expressed on luminal cells then act in concert with E2, 
culminating in ductal elongation and bifurcation (Figure 1. 5) (Macias and Hinck, 
2012). Through similar paracrine mechanisms, circulating progesterone binds to 
PRB+ sensor cells (Brisken et al., 1998), leading to the transcription of several 
target genes, including the tumour necrosis factor member receptor activator of 
nuclear kB ligand (RANKL) (Figure 1. 5) (Beleut et al., 2010; Mulac-Jericevic et 
al., 2003). Importantly, the same scenario holds true for humans, wherein a 
correlation between high levels of RANKL and high levels of progesterone in the 
blood was found (Tanos et al., 2012). As a pivotal progesterone-induced 
paracrine mediator, RANKL travel to the basal compartment of the mammary 
gland to bind to its cognate receptor RANK. By means of yet unknown 
mechanisms, this axis impinges on luminal PR-negative effector cells, triggering 
their proliferation and culminating in the formation of short side branches in 
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virgin mice and alveoli during pregnancy (Figure 1. 5) (Mukjerjee et al., 2010). It 
is important to mention, however, that progesterone also induces proliferation 
of a subset of PRB+ cells via a cell-autonomous mechanism involving Cyclin D1. 
Thus, it is tempting to speculate that these PRB+ proliferating cells might 
represent stem or progenitor cells (Beleut et al., 2010).  
Such coordinated mode of paracrine action has two very important 
consequences: firstly, it does not require high amount of hormones, as the 
proliferating signal gets amplified at each sequential step; and secondly, it 
regulates mammary gland development by fine-tuning the proliferation of 
different MMECs at a specific time and space (Brisken et al., 2010). As such, 
through the use of paracrine circuits, HRs are able to convey systemic signals 
into fine-tuned local ones, thus achieving a tight control upon ductal 
morphogenesis. Interestingly, more than 90% of breast tumours appear to be 
ductal in origin (Russo et al., 2005). Given that many pathways observed during 
breast cancer progression mirror the physiological ones, a deep understanding of 
the biology underlying ductal morphogenesis might also offer insights into the 
fascinating, yet not fully explained biology of breast tumourigenesis.  
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Figure 1. 5 Model of the paracrine circuits engaged by oestrogen and progesterone. 
The release of ovarian oestrogen at pro-oestrus and oestrus allows the hormone to engage with 
ER expressed by luminal sensor cells. This results in the production of AREG, which translocates 
to the cell membrane where it gets cleaved by ADAM17. Soluble AREG travels through the basal 
compartment to bind to EGFR expressed by stromal cells. This leads to the production and 
release of FGFs, which signal back to luminal compartment via binding to FGFR2. In concert with 
the latter, binding of GHs (released from the pituitary gland) to GHR present in the liver and in 
stromal cells of the MG triggers the production and release of IGF1, which binds to IGF1R in the 
luminal compartment. Altogether, these two axes foster the proliferation of luminal ER- 
(effector) cells, resulting in ductal elongation and bifurcation at puberty. Please note that 
oestrogen would also stimulate the transcription of PR (oestrogen priming). The release of 
ovarian progesterone at metestrus and diestrus allows the hormone to engage with PR expressed 
by luminal sensor cells. This leads to the production of two main paracrine molecules, RANKL 
and WNT-4, whose binding to RANK and FZ/LRP5/6 co-receptors present on basal cells drive 
MaSCs expansion during diestrus and pregnancy. In addition, the RANKL/RANK axis generates a 
signalling cascade which feeds back to the luminal layer, stimulating the proliferation of luminal 
PR- (effector) cells, resulting in side branching at puberty and alveologenesis during pregnancy. 
AREG, amphiregulin; BM, basement membrane; EGFR, epidermal growth factor receptor; ER, 
oestrogen receptor; FGF, fibroblast growth factor; FGFR2, fibroblast growth factor receptor 2; 
FZ, frizzled; LRP5/6, low-density lipoprotein-related protein; MG, mammary gland; GH, growth 
hormone; GHR, growth hormone receptor; IGF1, insulin-like growth factor 1; IGF1R, insulin-like 
growth factor 1 receptor; PR, progesterone receptor; RANK, receptor activator of nuclear factor 
k-B; RANKL, receptor activator of nuclear factor k-B ligand. 
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1.3.3 The mammary interplay between RUNX1 and oestrogens  
[For this section, the text has been adapted from Riggio and Blyth (2017)]. 
According to the classical paradigm, diffusion of steroid hormones through the 
plasma and nuclear membranes results in the formation of activated oestrogen-
ER complexes that directly bind to consensus oestrogen response elements 
(EREs) of hormone-responsive genes (Hewitt et al., 2003). However, since the 
initial discovery of this direct DNA binding (ERE-dependent) model, alternative 
mechanisms of oestrogen function have become apparent. These include an ERE-
independent pathway involving ‘tethering’ of ligand-activated-receptor 
complexes by transcription factors already bound to the DNA through their 
respective response elements (Kushner et al., 2000; Safe and Kim, 2008).  
With the discovery of RUNX among the top five most enriched motifs in ERα 
tethering sites of breast cancer cell lines, a “non-classical” interplay between 
RUNX1 and the oestrogen/ER signalling pathway has been unveiled (Stender et 
al., 2010). In line with this, co-immunoprecipitation studies demonstrated the 
presence of a basal interaction between RUNX1 and ERα, which was further 
enhanced upon oestrogen stimulation. Given the connection between RUNX1 and 
chromatin modifier enzymes (Yamagata et al., 2005), and its occupancy of ERα 
tethered binding sites even prior to oestrogen stimulation, RUNX1 might 
facilitate the recruitment of ERα to permissive remodelled chromatin loci 
(Figure 1. 6), thereby mediating the transcriptional regulation of specific 
oestrogen-responsive genes (Stender et al., 2010). Albeit insufficient to direct a 
full hormonal response in mice, the ERE-independent tethering mechanism 
appears to regulate up to 25% of ERα-responsive genes, thus perhaps acting 
complementary to the classical oestrogen signalling (Ahlbory-Dieker et al., 2009; 
Hewitt et al., 2016). 
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Figure 1. 6 The RUNX1-ERα interplay. 
Model showing two possible mechanisms by which RUNX1 might act as a fine-tuning orchestrator 
of oestrogen-ERα genomic responses in ERα-positive cells. (A) Tethering mechanism: RUNX1 
(together with CBFβ) binds to its respective RUNX motif on the DNA and acts as a tethering 
factor for the oestrogen-ERα complex to modulate transcription of Locus X. (B) Non-tethering 
mechanism: RUNX1 (together with CBFβ) binds to its RUNX motif on the DNA and interacts with 
the oestrogen-ERα complex, bound to an ERE site, to modulate transcription of Locus Y. Further 
details and references can be found in the text. Taken from Riggio and Blyth (2017). 
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1.4 Mammary epithelial stem cells 
Unlike any other cells in the body, stem cells (SCs) are devoted to three main 
biological processes: organ development, tissue homeostasis and tissue repair 
(Reya and Clevers, 2005). This unique capability arises from the fact that SCs are 
defined by two main properties, self-renewal and multi-potency (or multi-
lineage differentiation), which in turn depend on the instructive signals present 
in the surrounding “SC niche” (Lin, 2002). The first one refers to the ability of 
SCs to replenish themselves, while the second one to SCs’ differentiation into 
terminally mature cells through intermediate progenitors (Chen et al., 2017). Of 
note, these two key features are intimately linked to SCs capability of 
undergoing different types of cell division (CD), i.e. symmetric (SCD) or 
asymmetric (ACD). During SCD, a SC would divide equally to generate two 
identical daughter cells, namely two SCs (self-renewal). In ACD, instead, a SC 
would divide unequally to generate two daughter cells with different fates, that 
is a SC and a committed progenitor or transient amplifying cell, which will then 
give rise to a differentiated cell (multi-potency) (Knoblich, 2010; Smith, 2005). 
Of note, this has been shown to depend on the partitioning of the molecular 
components of the cell. Additionally, a SC could also generate two different 
daughter cells through SCD if, following mitosis, these are differentially placed 
in the surrounding environment (extrinsic ACD) (Ballard et al., 2015). 
Importantly, the interplay between Wnt/β-catenin, Notch and Hedgehog 
signalling pathways, coupled with the activation of key transcription factor 
genes including Myc, Slug and Sox9, have been shown to be critical for the 
maintenance of the stemness phenotype (Chen et al., 2017; Guo et al., 2012). 
1.4.1 The discovery of mammary repopulating units 
The remarkable outgrowth of the mammary epithelium at puberty and its 
extensive remodelling capability of undergoing multiple cycles of proliferation, 
differentiation and apoptosis hinted at the presence of SCs in the mammary 
gland, the so-called mammary SCs (MaSCs) (Macias and Hinck, 2012). It was only 
in the 1960’s that this hypothesis could be tested when injection of pieces of 
mammary tissue into cleared fat pads of recipient mice resulted in outgrowth of 
complete epithelial ductal trees (DeOme et al., 1959; Faulkin and DeOme, 1960; 
Hoshino et al., 1964). A decade later, the existence of a “growth-regulating 
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system”, as it was called hitherto, was further confirmed through serial 
engraftments of mammary epithelium for up to seven generations, after which 
time senescence occurred, probably due to the exhaustion of MaSC(s) contained 
in the original fragment (Daniel et al., 1968). Of note, the innate regenerative 
capacity of the engrafted mammary tissue did not seem to depend on the 
regional location of the original tissue, nor by the age, hormonal status and 
reproductive history of donor mice (DeOme et al., 1959). When the same 
experiments were repeated by retrovirally tagging mammary epithelial 
fragments with mouse mammary tumour virus (MMTV), it was realized that this 
‘growth-regulating ability’ could be inferred to a single epithelial cell, which (if 
transplanted in vivo) was able to reconstitute an entire functional ductal tree 
comprised of its progeny (Kordon and Smith, 1998).  
Collectively, these data indicated that repopulating cells, inferred to be MaSCs, 
were indeed present in the mammary gland, scattered throughout the epithelial 
tree and capable not only of multi-lineage differentiation but also of a 
remarkable, yet limited self-renewing potential. Undoubtedly, these findings 
represented a breakthrough in the mammary SC field, as corroborated by the 
fact that the gold standard assay to detect MaSCs still consists in the ability of a 
single cell to reconstitute a fully competent mammary tree upon serial 
transplantations in vivo (Visvader, 2009). Overtime, however, criticism has 
significantly arisen when trying to extrapolate the biological significance of the 
aforementioned results. In fact, by mimicking a forced regenerative state, it has 
been argued that transplantation assays could have led to misleading findings, 
whereby the regenerative potential shown by transplanted cells might not have 
necessarily been the same to the one owned by the same cells under 
physiological conditions (Blanpain and Fuchs, 2014). For this reason, scientists 
reckoned a more appropriate term to refer to these cells would be as mammary 
repopulating units (MRUs) (Shackleton et al., 2006; Stingl et al., 2006). 
Nevertheless, to avoid further confusion, in the present text MRUs will mostly be 
referred to as MaSCs. 
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1.4.2 Phenotypic and functional characterization of mammary 
stem cells 
With the advent of single-cell based methods, such as flow cytometry and 
fluorescence-activated cell sorting (FACS), MMECs started to be molecularly 
characterized for the first time by the presence of two distinct cell surface 
markers: CD24 (heat stable antigen) and either CD49f (α6-integrin) or CD29 (β1-
integrin). By doing so, the CD24+CD29lowCD49flow population was found to be 
enriched in luminal cells, based on the high prevalence of K18+ cells, whereas 
the CD24+CD29highCD49fhigh were predominantly in basal cells, based on the high 
prevalence of K14+ cells (Asselin-Labat et al., 2010; Shackleton et al., 2006; 
Stingl et al., 2006). 
1.4.2.1 Insights from FACS-based studies 
When transplantation assays were carried out at limiting dilutions to test the 
reconstitution efficiency of different sorted MMEC populations, the vast majority 
of MaSCs was found to lie within the CD24+CD49fhigh/CD29high subset (Shackleton 
et al., 2006; Sleeman et al., 2007). Furthermore, when primary outgrowths were 
dissociated and their cells re-transplanted in limiting dilutions, secondary 
outgrowths appeared, further confirming the self-renewal potential of MaSCs 
(Shackleton et al., 2006; Stingl et al., 2006). Lastly, when the same assay was 
repeated on sorted foetal MaSCs (fMaSCs), isolated at E18.5 from the anlage, 
they showed a higher regenerative potential compared to adult MaSCs (aMaSCs) 
(Spike et al., 2012). Collectively, these data led to two important conclusions: 
firstly, that MaSCs with multi-lineage and self-renewal potential could be 
isolated from both foetal mammary rudiments and adult mammary glands; and 
secondly, that, based on their molecular profile which clustered them together 
with basal cells,  MaSCs were thought to reside in the basal layer of the 
mammary gland. However, due to the low prevalence of MaSCs in sorted 
CD24+CD49fhigh/CD29high cells and the degree of heterogeneity shown by this 
cluster, which also contains MYO cells and putative basal progenitor 
intermediates; efforts have been put into refining the molecular identification 
and subsequent isolation of MaSCs.  
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Stem cell antigen 1 (Sca-1), routinely used as a cell surface marker for 
enrichment strategies of haematopoietic stem cells (HSCs) (Goodell et al., 1996; 
Spangrude et al., 1988), did not appear to be enriched in the CD24+CD49fhighSca-
1+ subset when tested, and shows a lack of reconstitution when Sca-1-expressing 
cells are transplanted in vivo (Shackleton et al., 2006; Stingl et al., 2006). 
Therefore, perhaps counterintuitively, Sca-1 negativity has been used as a 
marker to enrich for MaSCs. Another breakthrough arrived with the discovery of 
the Wnt3a target protein C receptor (ProcR) (Wang et al., 2015). Generation of a 
knock-in allele for ProcR found the protein to be expressed in the basal 
epithelium of the mammary gland, with positive cells present in an actively 
cycling state and characterized by low levels of K5 and K14. More importantly, 
when their stem-like features were tested both in vitro and in vivo, 
CD24+CD29highProcR+ displayed increased colony forming cell (CFC) ability and a 
remarkable reconstitution capacity, respectively (Wang et al., 2015). Given the 
well-known role played by the Wnt/β-catenin signalling pathway in SCs (Reya 
and Clevers, 2005), other scientists started using the leucine-rich repeat-
containing G-protein-coupled receptor 5 (Lgr5) as a marker for MaSCs. Known to 
be a key Wnt/β-catenin target gene expressed by cycling SCs of several 
epithelial tissues (Barker et al., 2013), Lgr5 was also found to be present in the 
mammary gland, particularly in the basal layer. Yet, its use yielded inconsistent 
data. On one side, CD24+CD49fhighLgr5+ cells showed an outstanding repopulating 
activity upon serial transplantations compared to their parental population (de 
Visser et al., 2012; Plaks et al., 2013), yet on the other, Lgr5+ cells were found 
to fall within the basal ProcR- subset characterized by very low regenerative 
potential (Wang et al., 2015). Lastly, a very recent study demonstrated that, 
albeit Lgr5 can be found in both fMaSCs and aMaSCs, its expression appears to be 
dispensable for SC activity (Trejo et al., 2017). In conclusion, despite some 
contrasting findings, these studies have led to a significant refinement of the 
molecular profile displayed by MaSCs, which appear to be enriched within the 
CD24+CD49fhigh/CD29highProcR+Sca-1- subset of MMECs. 
1.4.2.2 Insights from lineage-tracing studies 
Notwithstanding the progress achieved by FACS-based approaches, these are not 
without caveats. Firstly, they allow the molecular characterization of cells ex 
vivo that is freshly extracted from the primary tissue, yet not in their 
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physiological context. Secondly, as the properties displayed by MRUs might differ 
from the properties of MaSCs in vivo (Blanpain and Fuchs, 2014), these methods 
have not been able to assess the natural multi-lineage potential of MaSCs. For 
these reasons, the use of lineage-tracing studies, coupled with genetically 
engineered mouse models (GEMMs), offered a better way to interrogate the 
physiological regenerative potential of MaSCs. This technique is primarily based 
on the in situ labelling of a putative SC, with either a fluorescent or a 
histochemical reporter, and on the possibility to track its fate and ascertain its 
relative contribution to mammary gland development. As such, being that the 
label permanently expressed by the targeted cell, it is possible to assess its uni- 
or bi-potential depending on whether its progeny is made up of linage-restricted 
clones or of both basal and luminal cells, respectively (Lloyd-Lewis et al., 2017). 
On one side, according to some of the first lineage-tracing experiments, the 
growth of the mammary gland from embryonic to early pubertal stage was shown 
to depend on the presence of multipotent embryonic K14+ SCs, able to 
differentiate into the basal and luminal lineage. However, the extensive 
postnatal mammary gland development occurring during puberty, as well as the 
homeostatic control of the organ during adulthood, was found to be governed by 
lineage-restricted K14+ and K8+ progenitors, which were only capable of 
generating either basal or luminal progeny, respectively (Van Keymeulen et al., 
2011). Similar results have recently been reported for Lgr5, whose expression 
appeared to mark bipotent fMaSCs, while becoming restricted to basal unipotent 
progenitors during adulthood (Trejo et al., 2017). Additionally, evidence for the 
presence of restricted progenitors in the adult mammary gland holds true for the 
E74-like factor 5 (Elf5) transcription factor, which has been shown to label a 
subset of luminal cells found to contribute to ductal morphogenesis in puberty, 
mammary gland maintenance in virgin and alveologenesis during pregnancy (Rios 
et al., 2014). On the other side, more recent studies tracing the fate of K5-
expressing cells, highly abundant in TEBs, as well as in basal and luminal cells of 
terminal ducts, supported the presence of bipotent SCs in pubertal mammary 
glands. Additionally, the presence of K5+ biclonal patches found in the adult 
organ indicated that long-lived K5+ bipotent basal MaSCs were also actively 
involved in ductal morphogenesis and homeostasis during adulthood. Notably, 
similar results were also obtained when tracing K14-and Lgr5-expressing cells 
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(Rios et al., 2014), albeit in contrast to what previously reported (Trejo et al., 
2017; Van Keymeulen et al., 2011). Ultimately, bipotent ProcR+ MaSCs (K5-low, 
K14-low) were also shown to be able to self-renew through SCD and differentiate 
through ACD, giving rise to committed progenitors of the luminal and basal 
lineage (Wang et al., 2015). 
Notwithstanding the potential of lineage-tracing techniques, these have led to a 
high degree of discrepancies between studies, even when the same promoter 
was selected. In this regards, however, it is worth mentioning that part of these 
inconsistencies may arise from technical differences in the experimental 
settings. These include the type and dose of induction agents used, the type of 
promoter and reporter gene employed, as well as the chosen labelling times. 
Also, both knock-in and transgenic mice have been shown to be differently prone 
to insertion-sites effects, which could alter gene expression from the selected 
promoter leading to misleading results (Rios et al., 2016). Additionally, when 
dealing with heterogeneous population of cells wherein SCs only represent a tiny 
fraction, one should bear in mind that the most prevalent cell type will tend to 
have the highest chance to be labelled. As such, in the case of the mammary 
gland, these could be represented by unipotent progenitors (Visvader and Stingl, 
2014). In summary, whilst there is no doubt on the existence of bipotent fMaSCs 
responsible for the formation of the anlage, confusion has concerned so far the 
presence of bipotent SCs in the postnatal mammary gland. Based on the results 
accumulated hitherto, there is evidence for both long-lived bipotent SCs and 
unipotent progenitors in the adult organ, where they seem to play an active role 
in governing pubertal development and organ homeostasis (Rios et al., 2014). Of 
note, the distinct properties of these two cell types are intimately linked to 
their ACD, which in the case of bipotent MaSCs will give rise to cells with 
different self-renewal in different cell lineage, whereas in the case of unipotent 
progenitors will give rise to daughter cells of the same cell lineage, yet with 
different self-renewal potential (Ballard et al., 2015). By confirming the 
presence of bipotent MaSCs in the adult organ, these findings have also 
mitigated some of the criticisms over transplantation assay. Furthermore, as no 
MRUs were found to be enriched in the luminal population, likewise no bipotent 
MaSCs were seen to reside in the luminal layer of the mammary gland, yet only 
in the basal layer (Visvader and Stingl, 2014). 
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1.5 The hormonal milieu of the stem cell niche  
Albeit deemed to reside in the basal compartment of the mammary gland 
(Shackleton et al., 2006; Stingl et al., 2006), mounting evidence suggests that 
MaSCs might be sensitive to ovarian hormones. Support of this hypothesis dates 
back to transplantation experiments, when older hosts did not allow the growth 
of transplanted mammary fragments as compared to young hosts; a phenotype 
attributed to an impairment of their endocrine system (Young et al., 1971). 
Additionally, although ovariectomy was shown to reduce the number of luminal 
cells, yet not of MaSCs, the latter subpopulation displayed a marked decrease in 
its regenerative ability when transplanted in vivo (Asselin-Labat et al., 2010). 
MaSCs were shown to lack ER and PR expression in both mice and humans 
(Asselin-Labat et al., 2006; Lim et al., 2009) and also are generally thought to lie 
in the mammary epithelium in a resting-quiescent state, unless activated during 
puberty and pregnancy (Shackleton et al., 2006; Stingl et al., 2006). Therefore, 
it may be counterintuitive that HR-negative MaSCs should be so exquisitely 
influenced by ovarian hormones. 
1.5.1 A “stemness” role for progesterone 
Given the similarity between the murine oestrous cycle and the human 
menstrual cycle, studying changes occurring in the murine mammary gland upon 
hormonal exposure has been instrumental to investigate the hormonal regulation 
of MaSCs. In fact, as the surge in circulating oestrogens during the human 
follicular phase is mirrored by the murine pro-oestrus/oestrous phase, the rise in 
progesterone levels typical of the human luteal phase is reflected by the murine 
diestrus phase (Caligioni, 2009). Evidence gathered from both mice and humans 
points towards progesterone as the main regulator of MaSCs and cellular 
turnover in the mammary gland. In mice, a high proliferative and apoptotic 
index, coupled with a pronounced side branching morphology of mammary 
whole-mounts, were shown to characterize diestrous-staged mammary glands 
compared with other oestrous phases (Joshi et al., 2010). In addition, serial 
engraftments of mammary epithelial fragments from PR-/- mice were found to 
result in an impairment of their regenerative potential at the 3rd generation of 
passages (Rajaram et al., 2015). In humans, breast proliferation in parous 
women was shown to be significantly higher during the luteal as compared to the 
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follicular phase of the menstrual cycle (Masters et al., 1977). Moreover, 
mounting evidence has reported a role for progesterone in inducing 
alveologenesis during pregnancy, a process which is known to require a marked 
yet temporary expansion of MaSCs (Asselin-Labat et al., 2010). As mentioned 
above, progesterone action strictly relies on the presence of paracrine 
molecules, primarily RANKL and Wnt-4 (Fernandez-Valdivia and Lydon, 2012). On 
one hand, both luminal RANKL and basal RANK mRNAs were shown to reach very 
high levels during pregnancy, consistent with the well-known expansion of MaSCs 
and the extensive alveologenesis occurring at this reproductive stage (Asselin-
Labat et al., 2010). On the other hand, when pieces of virgin mammary 
epithelium from Rankl-/- mice were serially engrafted in the cleared fat pad of 
recipient mice, these showed the same regenerative potential as the wild type 
counterpart, albeit with a lessened degree of side branching. On the contrary, 
Wnt4-/- embryonic epithelial buds displayed a significant impairment in their 
ability to engraft. Indeed, WNT-4 ligand was recently shown to be critical for the 
activation of canonical Wnt/β-catenin signalling in the MYO (Rajaram et al., 
2015). Therefore, progesterone might hijack specific paracrine signals to drive 
MaSCs expansion at different developmental stages of the mammary gland. As 
such, the hormone would preferentially engage the RANKL-RANK axis to drive 
alveologenesis during pregnancy, while it would depend on WNT-4 when 
controlling MaSCs expansion during ductal morphogenesis and possibly mammary 
gland homeostasis. 
Importantly, whichever way progesterone acts, it certainly does not do it on its 
own. In fact, when ovariectomized mice were treated with E2, progesterone or 
E2 and progesterone, an expansion of basal and luminal cells, as well as luminal 
increase in the levels of both RANKL and Wnt-4, could only be observed when 
the combination of both hormones was used (Asselin-Labat et al., 2010; Joshi et 
al., 2010). This data would suggest that the action of progesterone in the adult 
mammary gland would mainly rely on the presence of E2, which in fact appears 
to be a potent inducer of PR expression (Beleut et al., 2010; Haslam and 
Shyamala, 1981; Shyamala et al., 2002). A model might then be envisioned in 
which E2 would induce PR expression on luminal sensor cells, so that 
progesterone could bind to its receptor, in order to trigger the production and 
release of its paracrine target Wnt4. The latter would then travel to the MYO 
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layer to activate canonical Wnt/β-catenin signalling, which would result in a 
transient, yet profound expansion of MaSCs in postnatal mammary glands, at 
both diestrus and reproductive stage (Rajaram et al., 2015) (Figure 1. 5). 
1.5.2 The link between ovarian hormones and breast cancer 
The endocrine regulation of MaSCs becomes of crucial importance if we think 
that the hormones that control mammary gland postnatal development and 
homeostasis, i.e. E2 and progesterone, are also the same which influence breast 
tumourigenesis. In line with the latter, it is generally believed that a women’s 
risk of developing breast cancer is tightly linked with her lifetime hormonal 
exposure and reproductive history (Brisken and O'Malley, 2010). On the other 
side, as firstly shown by G.T. Beatson (1896), ovarian ablation has a protective 
effect against the disease. If at each diestrus cycle, as well as at each 
pregnancy, progesterone induces the expansion of MaSCs, would not the latter 
accumulate over time and be susceptible to oncogenic transformation? In a 
physiological setting the answer appears to be no, in line with the fact that the 
increased proliferative index observed in diestrus-staged mammary glands is also 
accompanied by a high degree of apoptosis (Joshi et al., 2010). Similarly, the 
expansion of the MaSCs pool occurring during pregnancy is followed by the 
increased apoptotic rate seen in involution (Inman et al., 2015). Therefore, by 
means of compensatory mechanisms, mammary gland homeostasis is always 
been at the end of each estrous and reproductive cycle. Nevertheless, if the 
homeostatic regulation of the mammary gland gets impaired, one could envision 
the possibility of MaSCs accumulating overtime, and becoming more susceptible 
to additional hits, eventually leading to tumourigenesis. In this regard, 
pregnancy has been shown to be one of the strongest risk factor for breast 
cancer. According to one of the current hypotheses, the long-term protective 
effect conferred by an early pregnancy (before the age of 20) could be due to a 
reduction in the number and activity of MaSCs (Meier-Abt et al., 2013). 
Nevertheless, in view of the tendency of modern women to delay childbirth, the 
incidence of pregnancy-associated breast cancer, that is breast cancer occurring 
during or post-partum, is unfortunately expected to increase (Lyons et al., 
2009). Collectively, these results highlight the importance of understanding the 
paracrine mechanisms of hormonal regulation and how they impinge on the 
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activity of MaSCs. This might then shed light on how dysregulation of the system 
underpins breast cancer initiation, progression and possibly relapse.   
1.6 The mammary epithelial cell hierarchy 
Along with the discovery of a “growth-regulating system” within the mammary 
gland (Faulkin and DeOme, 1960) came the hypothesis that a differentiation 
hierarchy, analogous to the one found in the haematopoietic system, might also 
exist in this organ (Visvader, 2009). This idea was further corroborated by the 
remarkable degree of heterogeneity characterizing the gland, made up by two 
epithelial lineages (basal and luminal) present at different differentiation stages 
(stem, progenitor and differentiated cells). In view of their ability to 
differentiate into basal and luminal cells through a series of intermediate 
progenitors, bipotent MaSCs were placed on the top of the mammary epithelial 
cell hierarchy (Chen et al., 2017). Nevertheless, if what depicted could hold true 
for the formation of the anlage by bipotent fMaSCs, the same picture could not 
fully explain mammary gland pubertal development or its homeostasis during 
adulthood. With the advent of FACS-based and lineage-tracing studies, a further 
level of complexity was added to the mammary epithelial cell hierarchy, starting 
to shed light on the profound cellular heterogeneity existing within each 
compartment of the mammary gland (Visvader and Stingl, 2014). 
1.6.1 The heterogeneity of the stem cell compartment 
Although all believed to be enriched within the CD24+CD29high/CD49fhigh subset of 
MMECs, there are phenotypic and functional disparities within MaSCs. One of the 
most striking differences is between foetal and adult MaSCs (Visvader and Stingl, 
2014). Firstly, fMaSCs are found in the embryonic bud and in the anlage of the 
mammary gland, whereas aMaSCs are present in the adult organ. Secondly, while 
fMaSCs are believed to be responsible for the formation of the mammary 
rudiment, aMaSCs would be devoted to mammary gland pubertal development 
and tissue homeostasis during adulthood. Thirdly, although they both display a 
basal-like gene signature characterized by lack of HRs expression, fMaSCs have 
also been shown to express a few genes specific of the luminal lineage (e.g. 
Elf5). Fourthly, when challenged in transplantation assays, fMaSCs exhibited a 
significantly higher regenerative ability compared to the adult counterpart 
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(Spike et al., 2012). For the above reasons, fMaSCs were proposed to lay the 
foundation of the mammary epithelial cell hierarchy, whereas aMaSCs are likely 
derivatives of the former (Figure 1. 7A). Whether fMaSCs would also persist in 
the adult organ is still a matter of debate. However, due to the embryonic SC-
like gene signature shown by certain types of undifferentiated and aggressive 
breast cancers, it is tempting to speculate that fMaSCs, or alternatively any cell 
which would revert to an embryonic SC-like state, might be putative targets for 
oncogenic transformation (Ben-Porath et al., 2008).  
An additional layer of MaSC heterogeneity refers to their proliferative status. As 
mentioned above, there are specific developmental stages of the mammary 
gland (e.g. ductal morphogenesis and alveologenesis) which require the presence 
of active pools of MaSCs (Asselin-Labat et al., 2010). Indeed, via the use of the 
s-SHIP marker, cycling MaSCs were found in the cap layer of TEBs (Bai and 
Rohrschneider, 2010). Likewise, when following the fate of proliferating K5+ 
MaSCs, these appeared to give rise to luminal body cells of TEBs (Rios et al., 
2014). However, despite being the most proliferative units of the mammary 
gland, TEBs are not the only place where actively cycling MaSCs were found. In 
recent years, lineage-tracing studies have reported the presence of proliferative 
bipotent MaSCs both in TEBs and terminal ducts of pubertal and adult mammary 
glands (Visvader and Stingl, 2014). An active population of MaSCs has also been 
identified during pregnancy, where it appears to govern the process of 
alveologenesis. Yet, when challenged in serial transplantation assays, 
“pregnant” MaSCs showed a lower regenerative and self-renewal potential 
compared to “virgin” MaSCs. As such, they have been proposed to represent an 
active, yet short-term repopulating pool of MaSCs, which could even be 
responsible for the transient increase in breast cancer risk associated with 
pregnancy (Visvader and Stingl, 2014). Unless activated during puberty or 
pregnancy, MaSCs are believed to reside in the mammary gland in a resting, 
slow-cycling state. Several studies using label-retention approaches support the 
hypothesis that MaSCs, due to their slow rate of proliferation and apoptosis, 
would have had a higher chance to retain the label as compared to actively 
cycling cells. Accordingly, the MaSC population has often appeared to be 
enriched for label-retaining cells (Shackleton et al., 2006; Welm et al., 2002). In 
addition to quiescent MaSCs, there also seems to be a category of MaSCs, which 
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remain dormant during mammary development, while retaining its regenerative 
potential upon forced regenerative conditions or even cancer. To distinguish 
them from the previously discussed “professional MaSCs”, these cells were 
referred to as potential or facultative MaSCs (Visvader and Stingl, 2014), as they 
potentially bear all MaSCs properties, albeit they do not generally display them 
in physiological conditions (Lloyd-Lewis et al., 2017). Due to the low prevalence 
of MaSCs and the lack of consensus regarding their molecular profile, studying 
the cycling status of MaSCs does not represent an easy task to accomplish. There 
is evidence for the presence of both quiescent and actively cycling aMaSCs in 
postnatal mammary glands. However, while, by definition, quiescent SCs are all 
long-lived cells, not all actively cycling MaSCs bear the same self-renewal 
potential, thus encompassing both short and long-term repopulating cells 
(Visvader and Stingl, 2014).  
1.6.2 The distinctive features of progenitor cells 
In addition to the presence of MaSCs, the mammary gland contains several types 
of progenitor cells, namely daughter cells originating from the ACD of MaSCs and 
usually characterized by a lower regenerative potential and restricted cell fate 
(Knoblich, 2010; Smith, 2005). In support of the parent-progeny relationship 
between MaSCs and progenitor cells, in vitro assays have represented extremely 
valuable tools (Smalley et al., 1998). Of note, depending on the cultivation 
system used, stem/progenitor cells have been ascribed different names, being 
labelled as mammospheres, owing to their ability to form spheres in suspension 
or as mammary colony forming cells (Ma-CFCs), in view of their ability to form 
colonies in 3D (Stingl et al., 2006). The discovery that multipotent 
undifferentiated neural SCs could be cultured in suspension as neurospheres 
(Reynolds and Weiss, 1992) had a huge impact on the cultivation of human and 
mouse MECs. Hitherto, culture of primary cells on solid surfaces appeared to 
induce their differentiation and subsequent senescence. The use of non-
adherent conditions was instead found to privilege the survival of 
undifferentiated stem/progenitors, whilst causing the death of differentiated 
cells through a process known as “anoikis” (Frisch and Francis, 1994; Streuli and 
Gilmore, 1999). In reminisce of neurospheres, the colonies formed by surviving 
MMECs were called mammospheres, if originating from non-transformed cells, or 
tumourspheres, if originating from transformed cells. In line with the 
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undifferentiated status of the cells was the ability of primary-derived spheres 
to: 1) generate mixed colonies (composed of MYO, ductal and alveolar cells), if 
plated on a collagen substratum in the presence of serum; 2) form complex 
functional structures, if grown in matrigel; and 3) give rise to secondary spheres 
with multi-lineage differentiation potential, if re-plated in suspension. This led 
to the hypothesis that spheres stemmed from the ability of MaSCs to undergo a 
few SCDs versus several ACDs: through the former, MaSCs were able to maintain 
their self-renewal potential and generate secondary spheres; through the latter, 
they could give rise to progenitor cells with multipotent differentiation potential 
(Dontu et al., 2003). With the concomitant transplantation of MMECs in vivo and 
cultivation in vitro, resulting in both outgrowth of mammary trees and discrete 
colonies, respectively, a link between MaSCs/MRUs and Ma-CFCs was found 
(Smith et al., 1996). Albeit arising from the division of MaSCs, Ma-CFCs have 
been shown to display a distinct molecular phenotype, being enriched in the 
luminal (CD24+CD49flow) versus the basal (CD24+CD49fhigh) subpopulation. This 
was corroborated by transcriptomic analysis which confirmed the enrichment of 
luminal CK8, CK18 and CK19 transcripts in Ma-CFCs, versus basal CK5, ck14 and 
αSMA transcripts in MRUs and MYO subpopulations. Furthermore, when 
challenged in a 3D CFC assay, Ma-CFCs and MRUs displayed different 
morphological types of colonies, that is more spherical acinar-like in the first 
case, while more irregular solid-like in the second (Stingl et al., 2006). What 
emerged from these studies was the presence of an additional layer of 
heterogeneity affecting the mammary epithelial cell hierarchy. What remained 
to be assessed was the regenerative potential of these cells. Using lineage-
tracing, two different pools of unipotent cells appeared to populate both the 
pubertal and the adult mammary gland: basal progenitors (BPs) and luminal 
progenitors (LPs). These lineage-restricted pools of progenitors have proven to 
be fundamental for the maintenance and replenishment of differentiated MMECs 
(Figure 1. 7B). 
1.6.3 The different subsets of luminal cells 
Akin to the MaSC and progenitor compartment, the luminal layer of the 
mammary gland has also been shown to display a remarkable degree of 
heterogeneity (Visvader and Stingl, 2014). Whilst all luminal cells are 
characterized by the CD24+CD29low/CD49flow phenotype, this cluster is believed 
56 
 
to contain different types of LPs and differentiated luminal cells (Figure 1. 7B, 
C). Luminal cells are generally subdivided into the ductal and alveolar subtypes, 
as well as in the ER+/PR+ (sensor) or ER-/PR- (effector) subsets. For a long time, 
the majority of HR+ cells were believed to be mature cells, as it was postulated 
that only ER- cells were able to proliferate upon the release of ovarian hormones 
(Clarke et al., 1997; Russo et al., 1999). Nonetheless, other studies have argued 
against this hypothesis, claiming that rare ER+ luminal cells were also found to 
proliferate in vivo (Beleut et al., 2010; Booth and Smith, 2006) and display 
clonogenic potential in vitro (Shehata et al., 2012; Sleeman et al., 2007). The 
heterogeneity of the luminal compartment was corroborated by the presence of 
multiple cell surface markers found to be expressed by these cells, including 
CD61 (Asselin-Labat et al., 2007), c-kit (Asselin-Labat et al., 2011), Sca-1 and 
CD49b (Shehata et al., 2012). As such, CD61 (β3-integrin) was shown to label a 
larger proportion of ER- LPs (Asselin-Labat et al., 2007; Sleeman et al., 2007), 
whereas Sca-1 expression appeared to be present in a more differentiated subset 
of LPs, characterized by high levels of ER expression (Shehata et al., 2012). 
Luminal Sca-1+ cells were found to incorporate bromodeoxyuridine (BrdU) during 
pregnancy and adulthood, albeit not to the same extent of their negative 
counterpart (Van Keymeulen et al., 2017). The c-kit and CD49b (α2-integrin) 
markers, instead, were found to be present in a common LP, being expressed by 
both Sca-1+ and Sca-1- cells (Regan et al., 2012), whereas the combinatorial use 
of Sca-1 and CD49b appeared to better discriminate between ER- and ER+ LPs. 
While the Sca-1-CD49b+ subset was found to be enriched in ER- LPs, the Sca-
1+CD49b+ subpopulation was deemed to mark a small fraction of ER+ LPs (9%). 
Notwithstanding the higher clonogenic ability displayed by Sca-1-CD49b+ cells 
(40%), the Sca-1+CD49b+ subset was also shown to be characterized by a 
moderate degree of CFC ability in vitro (25%). Major differences, however, were 
related to their transcriptomic profiles, whereby Sca-1+CD49b+ displayed high 
levels of luminal specific genes (e.g. Esr-1, FoxoA1, Gata3, CK8 and CK18), 
whereas the Sca-1-CD49b+ subset was characterized by an intermediate levels of 
expression of both luminal and basal genes, thus placing the latter population in 
between basal MaSCs and more differentiated ER+ LPs (Shehata et al., 2012) 
(Figure 1. 7B, C). 
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Whilst these data were supportive of profound molecular and functional 
differences between ER- and ER+ LPs, it was unclear whether the maintenance 
of the corresponding mature luminal cells within the adult mammary gland could 
be ascribed to both cell types or not. Through the use of lineage tracing studies, 
whey acidic protein-tagged ER- luminal cells during a first pregnancy were shown 
to generate ER- cells during the following pregnancy (Chang et al., 2014), as 
Notch1- and Sox9-labelled ER- luminal cells were found to give rise to ER- ductal 
and alveolar cells only (Rodilla et al., 2015; Wang et al., 2017). Likewise, ER+ 
cells were shown to originate exclusively via the presence of ER+ LPs, yet not 
ER- LPs. Thus, during mammary gland pubertal development and tissue 
homeostasis, mature luminal ER- and ER+ cells would be maintained via the 
presence of lineage-restricted ER- and ER+ LPs (Figure 1. 7B, C) (Van Keymeulen 
et al., 2017). The moderate, yet significant proliferation reported in ER+ LPs is 
of particular interest in view of the increased number of proliferating ERα+ cells 
found to occur in the human breast of older women (particularly after 
menopause), where they often appear in contiguous patches of positive cells 
(Shoker et al., 1999). This observation has led to hypothesize that dysregulation 
of the ERα signalling pathway may occur with ageing, thus leading to the clonal 
expansion of a putative ER+ LP population, which was also reported to be the 
least sensitive to hormone deprivation (Shehata et al., 2012). Likewise, 
proliferation of ER+ cells has also been found in HR+ tumours (Clarke et al., 
1997), a subtype of breast cancer particularly abundant in older versus younger 
women (Gradishar et al., 1998). Thus, these data emphasize the urgent need to 
study the mechanisms underpinning the tight control over ER+ cell proliferation, 
as well as its tantalizing link with ageing.  
Altogether, these findings have remarkably refined our understanding of the 
mammary epithelial cell hierarchy, wherein the luminal layer of the mammary 
gland is more heterogeneous than initially perceived, being comprised of 
multiple LPs as well as different mature luminal cells. In view of the belief that 
the majority of human breast cancers are thought to originate within this 
compartment (see below), the identification of new cell-surface markers as well 
as a greater knowledge of the distinctive features of each of these luminal 
subpopulations might help unveil the cell-of-origin of many breast tumours. 
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Figure 1. 7 The mammary epithelial cell hierarchy. 
 
Working model depicting the distribution and parent-progeny relationships between MMECs, 
subdivided into three main developmental stages (stem, progenitor and differentiated) across 
two epithelial compartments (basal and luminal). (A) Bipotent MaSCs are at the origin of the 
mammary epithelial cell hierarchy and comprise fMaSCs, found in the embryonic bud and 
responsible for the formation of the anlage (hormone-independent growth), and aMaSCs, found 
within the virgin organ onwards and responsible for MG pubertal development and homeostasis 
(hormone-dependent growth). (B) Unipotent BPs and common LPs arise from MaSCs asymmetric 
cell division. BPs lie in the basal compartment, while common LPs are in the luminal layer, 
where they divide into distinct ER+ and ER- LPs. (C) Nullipotent MYO cells (expressing high levels 
of CK5 and CK14) arise from the differentiation of BPs, while nullipotent ER+ ductal and ER- 
alveolar cells (expressing high levels of CK8 and CK18) come from the differentiation of ER+ and 
ER- LPs, respectively. In red are indicated the cell-surface markers used by FACS studies, in blue 
those by lineage tracing. Curved arrow indicates self-renewal. Straight dotted arrow indicates 
differentiation. BP, basal progenitor; FACS, fluorescence activated cell sorting; LP, luminal 
progenitor; MaSC, mammary stem cell; aMaSC, adult MaSC; fMaSC, foetal MaSCs; MG, mammary 
gland; MMEC, mouse mammary epithelial cells; MYO, myoepithelial. 
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1.7 Breast cancer 
Whilst being an essential organ of food supply, due to its evolutionary ability to 
produce milk to nourish the offspring, the mammary gland is also an important 
site of diseases, first and foremost breast cancer (Cardiff and Wellings, 1999). As 
a human illness, breast cancer was first recorded in a papyrus of the 17th century 
BC (itself a transcription of a manuscript dated 2500 BC) attributed to the 
Egyptian physician Imhotep, who described a case of “bulging masses in the 
breast”, with no therapeutic cure. Two millennia after this (440 BC) the 
historian Herodotus in his Histories reported that the queen of Persia Atossa 
suddenly noticed “a bleeding lump in her breast” (Siddharta, 2010). Nowadays, 
breast cancer represents the most commonly diagnosed cancer in women 
worldwide and the most frequent cause of cancer-related female deaths in both 
developed and developing world (Torre et al., 2016). 
1.7.1 Risk factors and prevention  
Different breast cancer risk factors have been identified, including genetic and 
epigenetic causes, as well as the hormonal and reproductive status of a woman. 
Among the genetic causes, several known breast cancer genes (BRCA1, BRCA2, 
TP53, PTEN, CDH1, etc.) are thought to be responsible for 25-30% of the 
heritability, together with SNPs and copy number variants (CNVs) (28%) (Eccles 
et al., 2013). Epigenetic factors have also been recognized as important 
biomarkers for breast cancer risk. As such, epigenetic alterations might be 
hijacked by hormonal signalling to drive breast tumourignesis. Indeed, in utero 
exposure to diethylstilbestrol has been shown to increase the risk of breast 
cancer perhaps through alteration of the epigenome (Hoover et al., 2011). 
Recent studies suggested the possibility to evaluate DNA methylation levels of 
white blood cells (Brennan et al., 2012) and circulating tumour DNA (Han et al., 
2017) in peripheral blood, as a diagnostic and perhaps prognostic indicator of the 
disease. Breast cancer risk is intimately linked to the endocrine system of a 
woman, as well as to all the conditions affecting the latter, including age, 
menopausal status and reproductive history. Early and late menarches, 
nulliparities or late pregnancies are all among the strongest risk factors for 
breast cancer development (Veronesi et al., 2005). Conversely, women who give 
birth at young ages are believed to have a decreased risk of the disease, which 
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appears to be further improved with subsequent pregnancies, due to the long-
term protective effects of the latter (Russo et al., 2005). Lastly, although not 
incorporated into the current risk prediction models, it is believed that 
mammographic density represents a very strong breast cancer risk factor 
(McCormack and dos Santos Silva, 2006), in which changes might potentially be 
used as a biomarker for patient response to preventive treatment, albeit it does 
not seem to be linked with any molecular subtypes (Eriksson et al., 2012). 
As for many other types of cancer, detecting breast cancer at early stages 
significantly increases patients’ chances of being cured. However, the major 
challenges faced by the preventive field are: firstly, to precisely identify those 
individuals who have a high likelihood of developing the disease; and secondly, 
to tailor the most appropriate preventive method for each of these high-risk 
people (Eccles et al., 2013). Mammography represents a commonly used 
diagnostic technique which allows early detection of abnormal masses or micro-
calcification within the breast tissue via the use of low-energy X-rays (Sree et 
al., 2011). According to the current “work-up” process, women would usually 
face three sequential steps: screening mammography, diagnostic mammography 
and biopsy. If areas of concerns appear during the first screening mammography, 
women are called back (diagnostic mammography) to better monitor the results. 
If the cause of the concern is not believed to be benign, a core biopsy with local 
anaesthetic is then highly recommended in order to microscopically examine the 
abnormal tissue. Of note, mammography screening is currently offered to 
women between 50-70 years old, every one, two or three years, depending on 
the country. As such, the small yet significant increase in breast cancer risk 
induced by radiation exposure and the 10% rate of false-positive results, often 
due to the presence of dense tissue and leading to unnecessary treatment and 
psychological distress, have rendered the potential use of universal 
mammography screening a matter of huge debate (Defrank and Brewer, 2010). 
Additionally, chemopreventive agents including selective oestrogen receptor 
modulators, such as tamoxifen and raloxifene, have been shown to reduce breast 
cancer in high-risk women during the five years of treatment and up to five 
years afterwards. Nevertheless, the fact that their efficacy is often accompanied 
by toxic side-effects means that none of them have been approved by the Food 
and Drug Administration as preventive agents as yet. Whilst nothing is currently 
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available for the prevention of ER-negative disease (Cuzick et al., 2013), 
prophylactic mastectomy represents instead the method of choice to reduce 
breast cancer risk in women with a BRCA1/2 mutations (Heemskerk-Gerritsen et 
al., 2007). Last but not least, caloric restriction, reduction in alcohol intake and 
physical exercise are all believed to have beneficial effects on disease 
prevention, even though their underlying mechanisms of action are still unclear 
(Eccles et al., 2013). 
1.7.2 Breast cancer’s heterogeneity 
Our lack of knowledge of the exact cause(s) of breast cancer, together with the 
development of disease in women with no apparent risk factors, clearly reflects 
a poor understanding of the underlying biology of the disease. As for many other 
tumours, breast cancer is not just one disease, but rather it comprises several 
different malignancies displaying a very high degree of heterogeneity. This is 
reflected by the existence of different levels of breast cancer classifications. 
1.7.2.1 Histopathological classification 
Traditional methods for the histopathological assessment of breast cancer take 
into account different parameters, including histological type, tumour size and 
grade, and axillary lymph-node involvement (Dawson et al., 2013). 
Histologically, breast cancer can be broadly classified in two categories: in situ 
carcinoma or invasive carcinoma. In situ carcinoma is composed of both the 
ductal or lobular subtypes. Ductal in situ carcinoma, commonly known as DCIS, is 
more frequent than lobular in situ carcinoma (LCIS) and comprises at least five 
different subgroups (Comedo, Cribiform, Micropapillary, Papillary and Solid). 
Invasive carcinoma represents instead a very heterogeneous class of breast 
tumours, of which ductal, lobular, ductal/lobular, mucinous, medullary and 
tubular represent the major subtypes (Malhotra et al., 2010). Tumour size gives 
an indication of the dimension of a tumour at diagnosis, while tumour grade 
refers to the proliferative and differentiation indexes of the cancer (Rakha et 
al., 2010). Last but not least, the axillary lymph-node involvement informs on 
the extent of the disease, depending on whether cancer cells have left or not 
the primary site to reach surrounding lymph nodes (Jatoi et al., 1999). Whilst 
informative of the type and extent of the disease, no clinician could ever select 
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the appropriate treatment for a breast cancer patient if based solely on the 
aforementioned parameters. Remarkable improvements in this regard were 
achieved following the discovery of the molecular mechanisms underpinning the 
endocrine regulation of the mammary gland and the existence of similar 
parallels in certain breast tumours. Thereafter, immunohistochemistry (IHC) and 
fluorescence in situ hybridization became commonly used techniques to assess 
the expression levels of ER, PR, as well as amplification and/or overexpression 
of the Human epidermal growth factor receptor type 2 (HER2), respectively. 
Routinely used in the clinic since 1970s in the case for ER and PR (Osborne et al., 
1980), and for more than a decade in the case of HER2 (Ross et al., 2009), these 
three markers represent the most important indicators of patients’ subtypes of 
breast cancer and predictors of clinical response (Norum et al., 2014). In fact, 
on the basis of the receptor status of the tumour, breast cancer patients are 
currently treated with different therapeutic regimens. ER-positive and/or PR-
positive breast cancers, representing the majority of cases (75-80%), usually rely 
on hormone-based therapies (e.g. tamoxifen and aromatase inhibitors); HER2-
positive patients (10-15%) are generally administered anti-HER2 molecularly 
based therapies (e.g. Trastuzumab or Herceptin), with half of those cases co-
expressing one or both HRs receiving a combination of both compounds. For the 
remaining patients (10-15%), referred to as triple negative (TN) due to lack of 
ER, PR and HER2 expression, standard-of-care is currently the only line of 
therapeutic option available. For this reason, TN breast cancer patients 
represent the most aggressive subgroup above all (Gu et al., 2016). Although 
additional predictive markers have been recently identified, none of these have 
been implemented into clinical practice yet. Thus, ER, PR and HER2 remain the 
only three biomarkers which set the stage for breast cancer patients’ diagnosis 
and prognosis (Dawson et al., 2013). 
1.7.2.2 Transcriptomic classification  
As proposed by Perou and Sorlie (Perou et al., 2000; Sorlie et al., 2001), the 
phenotypic heterogeneity shown by breast cancers is linked to a corresponding 
diversity in their gene expression patterns. With the use of DNA microarray, 
coupled to hierarchical clustering to group samples according to similarity in 
their gene expression patterns, the very first “molecular portrait” of human 
breast cancer was proposed. This was comprised of five different groups, namely 
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luminal A, luminal B, basal-like, HER2+ and normal-like, whose major 
determinants were the presence or absence of ER, PR expression and HER2 
amplification and/or overexpression (Visvader, 2009). Accordingly, luminal 
tumours display a gene expression profile similar to luminal epithelial cells, 
being characterized by high levels of K8/18 and low HER2 expression. The 
luminal A subtype, however, includes low-grade tumours characterized by the 
highest levels of ER and GATA3 expression and a moderate proliferation rate, 
whereas luminal B tumours include high-grade malignancies with moderate to 
low levels of ER expression and a high proliferative index (Inic et al., 2014). By 
clustering together with basal epithelial cells, basal-like tumours show positive 
expression for K5/6 and 17, while lack of ER, PR and HER2. As implied by the 
name, HER2+ tumours are characterized by amplification and expression of the 
HER2 gene, together with expression of genes present within the same amplicon. 
In addition, HER2+ breast tumours display low levels of ER expression, a feature 
which places them closer to basal-like tumours. Lastly, normal-like tumours 
show a gene expression profile similar to basal (rather than luminal) epithelial 
cells, as well as to adipose and other non-epithelial tissues (Perou et al., 2000; 
Sorlie et al., 2001). In addition to the latter, more recent unsupervised analysis 
of both mouse and human data led to the identification of a potentially new 
subtype of breast cancer, referred to as “claudin-low”. As implied by the name, 
this subset appeared to be characterized by low levels of tight junction and cell-
cell adhesion proteins (e.g. Claudins 3, 4 and 7, Occludin and E-cadherin). 
Besides the absence of ER expression, these tumours showed low levels of 
luminal genes and inconsistent expression of basal markers (Herschkowitz et al., 
2007). By unveiling the molecular mechanisms underpinning the inter-tumoural 
heterogeneity, these studies paved the way for a new method of classifying 
breast tumours. Moreover, each of these newly identified intrinsic molecular 
subtypes of breast cancer, characterized by a surprising degree of stability and 
homogeneity, should be treated as a distinct biological entity accompanied by 
unique clinical features (Perou et al., 2000). Significant differences in relapse-
free (as time to distant metastasis) and overall survival could now be attributed 
more robustly to specific breast cancer subtypes. Univariate Kaplan-Meier 
analysis reported HER2+ and basal-like tumours with the shortest relapse-free 
and the worst overall survival, a finding proposed to be linked to the higher 
frequency of TP53 mutations found in both subgroups (Sorlie et al., 2001). 
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Likewise, the tendency of BRCA1 tumours to fall within the basal-like subtype of 
the disease was also noted, highlighting how different breast cancer 
susceptibility genes may preferentially predispose to specific subtypes of the 
disease (Sorlie et al., 2003). Patients with luminal A like tumours displayed the 
longest relapse-free and the most favourable overall survival, whereas luminal B 
tumours showed an intermediate outcome (Sorlie et al., 2001; Sorlie et al., 
2003). Of note, a slightly different finding emerged in a study involving 1,000 
women followed for a period of 20 years, wherein reduced overall survival was 
displayed by HER2+ and luminal B patients, rather than basal-like breast cancer 
women which showed intermediate survival times (Haque et al., 2012). 
Notwithstanding its favourable prognosis, it is important to highlight that luminal 
A tumours, representing the vast majority of breast cancers (40%), display the 
highest level of molecular heterogeneity. This is also reflected in the clinical 
setting, as some luminal A patients are often over-treated unnecessarily, 
whereas some others will face the highest risk of local and/or distant relapse in 
the long-term (over a 20 years follow-up period) as compared to other subtypes 
(Haque et al., 2012). A more recent analysis was able to split the luminal A 
subtype of breast cancer into two different cohorts on the basis of a 
differentially expressed 71 microRNA signature. When the prognostic value of 
each signature was investigated using different breast cancer datasets, the two 
luminal A clusters showed clinically distinct behaviours in terms of overall 
survival and freedom from any recurrence (Aure et al., 2017).  
1.7.2.3 Integrated classification 
With the emergence and widespread use of high-throughput technologies, it 
became possible to dissect tumours not only at their histopathological and 
transcriptomic levels, but also at their genetic level. By characterizing the 
mutational landscape of breast cancer, these studies emphasized the importance 
of inherited genetic variation, including the SNPs and CNVs discussed earlier, as 
well as of acquired genomic aberrations, such as single-nucleotide variants 
(SNVs) and copy number aberrations (CNAs), as being equally involved in the 
initiation, maintenance and progression of carcinomas (Dawson et al., 2013). On 
one side, this allowed the identification of new breast cancer-associated genes, 
but on the other the discovery that the majority of alterations in these putative 
players were relatively infrequent. With the realization that CNAs could have a 
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huge impact on gene expression by acting either in cis (on genes in close 
proximity to the aberration) or in trans (on genes in distant sites), distinct 
cellular pathways began to be linked to specific patterns of genomic aberration, 
rather than to alterations in individual genes. Thus, when it was realized that 
genomic aberrations could inform on the tumour phenotype and its underlying 
biology, the intrinsic transcriptomic classification was further refined to provide 
a more comprehensive profiling of breast cancer, which could also capture the 
genomic landscape of the disease. By integrating both transcriptomic and 
genomic data of 2,000 breast tumours included in the METABRIC (Molecular 
Taxonomy of Breast Cancer International Consortium) study (Curtis et al., 2012), 
a novel breast cancer classification composed of ten integrative clusters 
(IntClust 1-10) was proposed (Dawson et al., 2013). A very concise look at each 
one of these clusters, characterized by distinct gene expression profiles and 
CNAs, is summarized in (Table 1. 1). Some of the most profound refinements 
emerging from this analysis referred to luminal A and HER2+ tumours.  While 
luminal A tumours could be split into multiple groups, characterized by either 
worst disease-free survival (IntCluster2), or favourable prognosis (IntCluster3, 7 
and 8), HER2+ tumours, partly represented by the HER2+ intrinsic subtype, were 
now grouped together. The significance of such refinement could potentially 
lead to some luminal A patients (those with good prognosis) being spared from 
unnecessary systemic chemotherapy, while more HER2+ individuals benefit from 
the use of HER2-targeted therapies in the future (Curtis et al., 2012; Dawson et 
al., 2013). By turning the spotlight on new putative breast cancer drivers and 
emphasizing the clinical features of each IntCluster, this new classification has 
improved our understanding of the aetiology of breast cancer. Nonetheless, 
biology is not as simple as it seems and, besides the inter-tumoural 
heterogeneity highlighted above, there is a more subtle level of diversity within 
each individual neoplasm referred to as intra-tumoural heterogeneity. In 
essence, this means that “one size” does not “fit all” and perhaps treating each 
IntCluster as a biologically and clinically different entity might not be the 
solution. With this in mind, clinical management of breast cancer has slowly 
started to embrace the concept of personalized medicine, whereby each 
individual patient represents a biologically and clinically distinct entity which 
requires custom-tailored treatment. 
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Table 1. 1 Summary of the 10 Integrative Clusters of breast cancer. 
IntCluster Intrinsic subtype2 IHC group Clinical features Prognosis (10-year DFS) Molecular features 
IntCluster 1 Luminal B ER+ve High grade Intermediate 
Amplification of the 17q23 locus; 
overexpression of cis-adjacent genes (RPS6KB1, PPM1D, PTRH2 and APPBP2) 
     
Highest prevalence of GATA3 mutations 
IntCluster 2 Luminal A ER+ve - Worst of all ER+ve (50%) Amplification of the 11q13/14 locus (CCND1, EMSY and PAK1) 
 
Luminal B 
   
Enrichment of genes involved in cell-cycle regulation (G1/S transition) 
IntCluster 3 Luminal A 
 
Low grade  Best (90%) Highest frequency of PIK3CA, CDH1 and RUNX1 mutations 
   
No LN involvment 
 
Low prevalence of TP53 mutations 
IntCluster 4 Luminal-A ER+ve Low grade Good (80%) CAN-devoid  
 
Basal-like ER-ve High immune response 
 
Deletions at the T-cell receptor (TCR) loci (20%)  
IntCluster 5 ERBB2+ve ERBB2+ve/ER+ve (42%) High grade Worst (45%) Amplification of the 17q12 locus (ERBB2) 
  
ERBB2+ve/ER-ve (58%) LN involvement 
 
High proportin of TP53 mutations (>60%) 
   
Younger age 
  
IntCluster 6 Luminal A ER+ve - Intermediate (60%) Amplification of the 8p12 locus 
 
Luminal B 
   
Lowest prevalence of PIK3CA mutations across all ER+ve tumours 
IntCluster 7 Luminal A ER+ve/PR+ve 
Low grade  
(Well-differentiated) 
Good (80%) Amplification of the 8q locus, 16p gain, 16q loss 
     
Highest frequency of MAP3K1 and CTCF mutations 
IntCluster 8 Luminal A ER+ve 
Low grade  
(Well-differentiated) 
Good (80%) 1qgain/16qloss (common unbalanced translocation event) 
     
High levels of PIK3CA, GATA3 and MAP2K4 mutations 
IntCluster 9 Luminal B ER+ve High grade Intermediate (60%) 8q cis-acting alterations and 20q amplification 
     
Highest levels of TP53 mutations among the ER+ve subgroup 
IntCluster 10 Basal-like TN 
High grade  
(Poorly differentiated) 
Bad in the first 5 yrs 8q, 10p and 12p gain 
   
Younger age Good after the first 5 yrs Deletion of the 5q locus  
     
Highest rate of TP53 mutations 
 
ER+ patients did not receive chemotherapy; All ER- patients received chemotherapy; None of the HER2+ patients received Trastuzumab. ER, oestrogen receptor; 
HER2, human epidermal growth factor receptor type 2; PR, progesterone receptor, TN, triple negative. Adapted from Dawson et al., 2013.
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1.7.3 Clinical management of the disease 
Current clinical therapies for breast cancer encompass surgery, radiotherapy or 
systemic therapy, the latter of which encompasses chemotherapy and 
molecularly targeted therapy (Caley and Jones, 2012). Importantly, the type of 
therapy, the order of administration, the ideal timing and the optimal duration 
are all factors decided by a multidisciplinary team of experts on an individual 
basis, depending on several variables including patient’s age, tumour grade, 
stage and subtype of the disease (Eccles et al., 2013).  
1.7.3.1 Surgery and radiotherapy 
As for all other solid tumours, surgery is the mainstream treatment of localized 
breast cancers, aiming at removing all malignant cells via mastectomy or breast 
conservation surgery (plus whole breast radiotherapy to reduce the risk for local 
recurrence). Importantly, the operation is carried out together with sentinel 
node biopsy, a widespread procedure which identifies and removes what it is 
thought to be the first nearby lymph node to which cancer cells might have 
spread. By checking for the presence of any axillary metastasis, this technique 
helps define the stage and extent of the disease (Eccles et al., 2013). 
Additionally, early-stage tumours can be further reduced preoperatively using 
neoadjuvant therapies (including chemo, hormonal and targeted therapies), with 
the beneficial effects of improving the rate for breast conservation, assessing 
drug efficacy and safely delaying the timing of surgery in specific circumstances. 
However, not all breast cancer patients might benefit from neoadjuvant 
therapies, highlighting the need to carefully assess its use on a case by case 
basis (Chatterjee and Erban, 2017). It should be noted, however, that surgery is 
usually only applied to early-stage patients, 80-99% of which are estimated to 
survive up to five years (https://www.cancerresearchuk.org/). 
1.7.3.2 Chemotherapy and molecularly targeted therapies 
The idea of using a “cocktails of chemical drugs” to cure cancer dates back to 
1947, when Dr. Sidney Farber started treating leukaemic patients with 
aminopterin (an antifolate), dreaming about the possibility to eradicate such an 
aggressive systemic disease with a “medicine” (Siddharta, 2010). What was 
unknown to Farber was the principle behind the mechanism of action of these 
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cytotoxic agents, which strictly rely on the cell division properties owned by 
normal and cancer. Indeed, by interfering with DNA synthesis or with key 
proteins of the cell cycle, chemotherapy aims at specifically targeting highly 
proliferative tumour cells by inducing their cell death (Caley and Jones, 2012). 
This is usually achieved via a combination of more than one cytotoxic agent (e.g. 
cisplatin, gemcitabine, 5-fluorouracil), depending on several factors, including 
the subtype of breast cancer, the likelihood of its relapse and the presence of 
other medical conditions. Unfortunately, however, the cytotoxic effects exerted 
by chemotherapy can often target normal dividing cells, particularly those 
characterized by a high turnover rate (e.g. lymphocytes) (Caley and Jones, 
2012). Thus, to maximize its efficacy whilst minimizing its side effects, 
chemotherapy is usually administered in period of 3 to 4 weeks, also known as 
cycles, in order to give patients’ body enough time to repair and replenish all 
pools of disrupted normal cells. Furthermore, according to the current clinical 
management of breast cancer, this treatment is usually given either before or 
after surgery. In the first case, chemotherapy, better known as neo adjuvant 
therapy, is used with the aim of reducing locally advanced diseases, whilst in the 
second (adjuvant therapy), to prevent the relapse of aggressive forms of breast 
cancer in case cancer cells might have disseminated away from the primary site. 
Of note, given the fundamental role played by immune cells in fighting 
infections and diseases, the combinatorial use of immunotheraphy (aiming at 
reinforcing the body’s immune system) with chemotherapy has been recently 
considered as a valuable option in cancer treatment 
(www.cancerresearchuk.org). 
Targeted therapies refer instead to the use of molecular agents (monoclonal 
antibodies and small molecule inhibitors), which often rely on the concept of 
oncogene addiction (Torti and Trusolino, 2011). First described in 2002 by 
Bernard Weinstein, oncogene addiction states that, despite the “multi-hit” 
nature of cancer, some tumours rely on the function of a single dominant 
oncogene to proliferate and survive. Hence, by identifying such oncogene and 
preventing their function, tumour stabilization and/or regression could, at least 
in principle, be achieved (Weinstein, 2002). In breast cancer, the dependency 
shown by certain tumour subtypes towards ER, PR and HER2 signalling pathways 
laid the foundation for the design of molecularly targeted therapies towards 
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these targets. TN patients, however, currently lack any targeted treatment 
options and rely on standard-of-care (e.g. surgery, radiotherapy and 
chemotherapy) intervention. Recently, new evidence has shown promising 
results for the treatment of rare forms of TN tumours via the use of cyclin-
dependent kinase 4/6 (CDK4/6) inhibitors (e.g. Palpociclib) (Asghar et al., 2017). 
It was shown, in fact, that sensitivity of TN tumours to CDK4/6 inhibitors is 
inversely correlated to the level of CDK2 after mitosis. Thus, cells which exit 
mitosis with low levels of CDK2 (quiescent cells) would strictly depend upon 
CDK4/6 function to re-enter the cell cycle, whereas cells which exit mitosis with 
high levels of CDK2 (proliferating cells) would by-pass the requirement for 
CDK4/6 activity. Importantly, this study heralds new possibilities for the 
treatment of this disease subtype, which commonly affect 7,500 women (the 
majority of which present at young ages) each year in the UK 
(www.cancerresearchuk.org). It is worthwhile mentioning that the development 
of other targeted therapies for the treatment of inherited forms of breast cancer 
has exploited a slightly different version of the concept of oncogene addiction. 
Synthetic lethality (SL) refers to the notion that while the loss of one gene is 
compatible with life, the simultaneous loss of another gene (thought to be in a 
synthetic lethal relationship with the first one), results in death (Kaelin, 2005). 
However, since in cancer SL genes are often in their wild-type form, SL is often 
referred to as “non-oncogene addiction” (Torti and Trusolino, 2011). One of the 
best examples is represented by poly-ADP-ribose-polymerase inhibitors, the first 
drugs based on the concept of SL which have been approved for the clinical 
treatment of BRCA1 and BRCA2 mutated breast cancers (Lord and Ashworth, 
2008). Nonetheless, a common issue that spans across all clinical breast cancer 
therapies is overtreatment. In addition, there is also a significant proportion of 
women who experience the opposite problem, being often undertreated. 
Regardless of the case, this reflects the inadequate tailoring of clinical therapies 
on an individual basis, thus often culminating in more harmful effects than 
actual benefits (Eccles et al., 2013). Thus, despite the remarkable impact that 
breast cancer stratification has had in refining therapeutic treatments, the 
response of patients to either conventional or targeted therapies still remain 
dramatically unpredictable. This could be mainly attributed to the high degree 
of heterogeneity characterizing the disease. But what has remained 
unappreciated is the fact this heterogeneity is due not only to the genetic and 
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molecular mutational landscape of a patient’s tumour per se, but also to its 
“cell of origin” (Visvader and Stingl, 2014). 
1.7.4 RUNX1 in breast cancer 
[For this section, the text has been adapted from Riggio and Blyth (2017)]. 
It was only with the switch from classic Sanger sequencing, which focused on 
small cohorts of samples and lacked adequate sensitivity, to the advent of 
multiplexed NGS, targeting larger data sets, that RUNX1 was revealed as one of 
the most significantly altered genes in breast cancer (Banerji et al., 2012; 
Cancer Genome Atlas, 2012; Cornen et al., 2014; Ellis et al., 2012). Of note, 
three main observations emerged from these studies: firstly, the presence of 
somatic mutations (including point mutations and deep deletions) mainly 
affecting the gene; secondly, the fact that they seem to cluster with hormone 
receptor positive (ER+/PR+) breast cancers (Table 1. 2); thirdly, the prediction 
that these would result in loss-of-function of the protein (Li et al., 2003; van 
Bragt et al., 2014). Additionally, the gene encoding RUNX1’s DNA-binding 
partner CBFβ was also found to be frequently mutated in breast cancer (Banerji 
et al., 2012; Ellis et al., 2012), heightening the putative tumour suppressive 
function played by the RUNX1/CBFβ complex in this disease, especially in the 
ER+/PR+ subtypes. Indeed, RUNX1 mRNA downregulation was found to be part of 
a 17-gene signature associated with breast cancer metastasis (Ramaswamy et 
al., 2003) and RUNX1 protein expression was reduced in high-grade compared to 
low/mid-grade breast tumours (Kadota et al., 2010), consistent with the 
transcription factor’s ability to act as a positive regulator of E-cadherin (Liu et 
al., 2005). Moreover, RUNX1 knockdown was found to cause hyper-proliferation 
and abnormal morphogenesis of MCF10A breast epithelial cells (Wang et al., 
2011), while RUNX1 SNPs were strongly associated with breast cancer risk in a 
Moroccan study (Marouf et al., 2016). On the other hand, an increasing amount 
of evidence is indicative of a pro-oncogenic role played by the RUNX1 gene in 
breast cancer, intriguingly associated with the ER- and TN subtypes (Table 1. 2). 
Accordingly, different transcriptome studies have reported RUNX1 mRNA 
upregulation in the TN group (Karn et al., 2011; Rody et al., 2011), while RUNX1 
was found to be associated with super-enhancer elements, linked to oncogenes 
and/or genes associated with cancer pathogenesis, specifically in an ER- breast 
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cancer cell line (Hnisz et al., 2013). Expression of RUNX1 also increased with 
disease progression in patient samples, as well as in a mouse model of breast 
cancer (Browne et al., 2015). Lastly, in a tissue microarray study carried out in 
our lab (Ferrari et al., 2014), a strong positive correlation between RUNX1 
expression and poor overall survival in ER- and TN breast cancer patients was 
shown. Altogether, these studies revealed opposing and context-dependent roles 
for RUNX1 in breast cancer, culminating with recent high-throughput analyses 
which listed RUNX1 and CBFβ among the candidate driver genes relevant to 
breast cancer pathogenesis (Nik-Zainal et al., 2016; Pereira et al., 2016). 
Table 1. 2 Summary of RUNX1 dysregulation in breast cancer. 
RUNX1 dysregulation Subtype/Stage of Tumour References 
mRNA downregulation Metastasis Ramaswamy et al., 2003 
mRNA downregulation High grade  Kadota et al., 2010 
mRNA upregulation Triple negative  
Karn et al., 2011 
Rody et al., 2011 
Homozygous deletions - Banerji et al., 2012 
Missense mutations Luminal –B  (ER-positive) Ellis et al., 2012 
Truncating & Missense mutations 
Luminal-A & B (ER-positive)  Cancer Genome Atlas 
Network, 2012 
& HER2-enriched 
CNAs (deletion) & Mutations Luminal-A & B (ER-positive)  Cornen et al., 2014 
Protein expression (high) 
ER-negative &  
Triple  negative 
Ferrari et al., 2014 
Protein upregulation Invasive Ductal Carcinoma Browne et al., 2015 
Single nucleotide polymorphisms  - Marouf et al., 2016 
Mutations (driver) ER-positive & ER-negative Nik-Zainal et al., 2016 
Mutations (driver) ER-positive & ER-negative 
Pereira et al., 2016   ER-negative 
CNAs (deletion & amplification)   
 
CNA, copy number alteration; ER, oestrogen receptor. Adapted from Riggio and Blyth (2017). 
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1.7.4.1 RUNX1 in hormone-dependent tumours 
[For this section, the text has been adapted from (Riggio and Blyth, 2017)]. 
As corroborated by the reduction in ER+ cells seen upon MMTV-driven deletion of 
Runx1 (van Bragt et al., 2014), expression of the gene appears fundamental to 
the survival and maintenance of E2-responsive cells. Indeed, as a master 
regulator of cell fate decision, RUNX1 was shown to be critical in promoting the 
ER program whilst inhibiting the alveolar one. With this in mind, it is perhaps 
surprising to find RUNX1 somatic mutations in ER+ breast cancer (Banerji et al., 
2012; Cancer Genome Atlas, 2012; Ellis et al., 2012), a subtype of the disease 
thought to originate from luminal ER+ cells. Given an enrichment of the p53 
signature in Runx1-deleted luminal cells (van Bragt et al., 2014) and the 
frequent co-association between TP53 and RUNX1 dysregulation in human 
luminal B tumours (Ellis et al., 2012), perhaps loss of RUNX1-dysregulated 
luminal cells can only be rescued by the presence of additional mutations (e.g. 
TP53). To render the interplay between RUNX1 and ERα even more intriguing, 
the two transcription factors were recently shown to co-occupy a regulatory 
region of AXIN1 (Chimge et al., 2016), a tumour suppressor gene encoding a 
crucial component of the β-catenin destruction complex. Yet, the two proteins 
appeared to act as antagonists since shRNA-mediated RUNX1 suppression 
resulted in AXIN1 downregulation and increased ERα-mediated proliferation. This 
provided mechanistic evidence for a putative tumour suppressive function 
mediated by RUNX1, which was specific for ER+ and not ER- breast cell lines. 
One could then speculate that RUNX1 dysregulation in ER+ breast cancer would 
facilitate oestrogen/ERα-mediated AXIN1 suppression, leading to aberrant 
WNT/β-catenin signalling pathway. Nevertheless, the fact that the local 
interaction between RUNX1 and ERα at the AXIN1 locus seemed to occur through 
a non-tethering mechanism (Figure 1. 6) and that RUNX1 transcriptional 
regulation is generally not dependent on oestrogen’s activity led to the 
speculation that perhaps the gene could acquire an oestrogen/ERα-dependent 
tumour suppressive activity only at a few critical regulatory loci. In this way, 
one could envision RUNX1 as a fine-tuning orchestrator of ERα-dependent 
transcription (Figure 1. 6). Intriguingly, this is in line with very recent findings 
depicting RUNX1 as an architectural genome regulator of local (rather than 
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global) chromatin interactions that might become dysregulated in cancer 
(Barutcu et al., 2016).  
It is important to note, however, that this is not the first time the RUNX genes 
have been associated with the oestrogen/ER signalling, where an antagonist 
relationship with RUNX2 (Chimge et al., 2012; Chimge and Frenkel, 2013) and 
RUNX3 (Huang et al., 2012) has been proposed. Given the putative tumour 
suppressive function exerted by RUNX1 in ER+ breast cancers, how can the low 
percentage of reported somatic mutations in the gene be explained? It is 
important to take into account that RUNX1 dysregulation could also arise from 
other types of alteration (epigenetic and/or post-translational), but also that it 
could be mirrored by dysregulation of its binding partner CBFβ (Banerji et al., 
2012; Cancer Genome Atlas, 2012; Ellis et al., 2012; Nik-Zainal et al., 2016; 
Pereira et al., 2016). 
1.7.5 The “cell-of-origin” of breast cancer 
Three main hypotheses have been proposed to explain the origin of breast 
cancer. According to the first one, breast tumours would arise from a common 
cell-of-origin; according to the second one, each type of breast cancer would 
originate from a different cell-of-origin; according to the third one, breast 
cancer would be the result of both processes (Stingl and Caldas, 2007).  
1.7.5.1 The cancer stem cell theory 
The cancer SC (CSC) theory refers to the belief that cancer arises from the 
dysregulation of a common cell-of-origin that is a SC. This theory is strictly 
based on the main properties characterizing the latter, such as the ability to 
self-renew and expand the pool of SCs through SCDs, as well as to give rise to 
progenitors, or transient amplifying cells, via ACDs (Chen et al., 2017; Lin, 
2002). Altogether, these unique features, ascribed among the world-famous 
cancer hallmarks (Hanahan and Weinberg, 2011), are believed to render SCs 
highly vulnerable targets for neoplastic transformation more than any other cell 
type of the body (Dontu et al., 2003). Thus, occurrence of genetic alterations in 
SCs would rapidly result in their conversion into CSCs, whose division would then 
give rise to self-renewing cells devoted to the expansion and maintenance of the 
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CSCs pool, in addition to rapidly dividing cells responsible for the proliferation of 
the bulk of the tumour (Macias and Hinck, 2012).  
As mentioned above, the use of transplantation experiments has been 
instrumental to the identification and phenotypic characterization of MaSCs, 
Hitherto, however, whether MaSCs were able to initiate cancer when exposed to 
carcinogenic agents was still unknown. One of the first evidences arrived when 
exposure of young rats to the potent carcinogen 7,12-
dimethylbenz(a)anthracene resulted in the formation of mammary lesions in 
TEBs, the most proliferating units of pubertal mammary gland found to contain a 
high number of MaSCs (Russo et al., 1983). Along with the efforts to refine the 
molecular profile of MaSCs came the discovery that transplants of CD44+CD24-/low 
cells was able to give rise to heterogeneous tumours (Al-Hajj et al., 2003). When 
expression of ProcR, a putative marker of bipotent MaSCs (Wang et al., 2015), 
was recently reported in CD44+ cells, it was hypothesized that this subset could 
have represented a likely MaSC target population for oncogenic transformation 
(Shipitsin et al., 2007). In addition, the finding of an embryonic SC-like gene 
signature characterizing certain types of undifferentiated and aggressive breast 
cancers emphasized the intriguing parallels between tumourigenesis and 
embryonic SCs (Spike et al., 2012). Thus, fMaSCs, or alternatively any cell which 
could have reverted to an embryonic SC-like state, were also hypothesized as 
putative targets for oncogenic transformation (Ben-Porath et al., 2008).  
Nevertheless, proving that MaSCs are the cell-of-origin of breast cancers, or of 
at least some subtypes of the disease, still remains a big endeavour. This is due 
not only to their low prevalence or slow-cycling state, but mainly to the absence 
of specific markers that could univocally identify their presence (Chen et al., 
2017). For this reason, it has been recently argued that CSCs, or tumour-
initiating cells, do not arise from the transformation of normal MaSCs, since they 
appeared to reside in the luminal layer of the mammary gland. This observation 
led scientists to postulate a “plasticity tumour model”, whereby transit-
amplifying cells, rather than MaSCs, would represent the most probable cell-of-
origin of tumours. As such, neoplastic transformation of progenitor cells would 
induce their de-differentiation and conversion into tumour initiating cells, whose 
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proliferation would then culminate in tumour formation (Chaffer and Weinberg, 
2015). 
1.7.5.2 Progenitor cells as tumour-initiating sources 
The idea of different subtypes of breast cancers originating from the 
transformation of a single epithelial cell type has been revisited recently. Given 
the slow-cycling state of MaSCs as compared to the proliferative ability of 
progenitor cells, LPs were proposed to give rise to luminal tumours, whereas BPs 
would yield to basal-like tumours. This hypothesis was corroborated by gene 
expression analyses which were often clustering luminal-like tumours with 
luminal cells and basal-like-tumours with basal cells (Koren and Bentires-Alj, 
2015; Perou et al., 2000). However, when more precise studies started to 
compare the five intrinsic molecular subtypes of the disease with the different 
MMEC subpopulations constituting the mammary epithelial cell hierarchy, results 
pointed towards a different direction. Accordingly, MaSCs/BPs/basal cells 
appeared closer to the claudin-low and normal-like subtypes of breast cancer 
(rather than to the basal-like one), whereas LPs/luminal cells aligned to the 
basal-like subtype of the disease (rather than to the luminal-like one) (Prat et 
al., 2010; Visvader and Stingl, 2014). Of note, the second scenario, supported 
not only by human evidences (Lim et al., 2009), but also by GEMMs (Molyneux et 
al., 2010), was revealed to be particularly true for BRCA1-driven breast cancers, 
found to originate from the re-programming of LPs towards a basal-like 
phenotype upon specific initiating genetic alterations (Chen et al., 2017; 
Visvader and Stingl, 2014).  
Altogether, these data led to three important conclusions. The first one was that 
the different subtypes of breast cancer were likely to originate from different 
cells-of-origin. The second one that LPs, more than other epithelial cell types of 
the mammary gland, were a likely target for oncogenic transformation; and the 
third one that, when transformed, LPs gave rise to very aggressive and 
heterogeneous tumours, such as basal-like breast cancers. What remained 
unclear was whether this higher susceptibility and degree of tumour 
heterogeneity stemmed from the intrinsic plasticity shown by LPs upon 
transformation or, instead, from the oncogenic targeting of different luminal 
populations of the mammary gland, i.e. ER+ or ER- (Van Keymeulen et al., 
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2017). As discussed above, the highest degree of proliferation seen in the 
luminal compartment has thus far been attributed to ER- cells (the effectors), 
which would react to the presence of paracrine signals released by ER+ cells (the 
sensors) in response to hormones. However, recent evidences for proliferation of 
ERα+ cells have also been found. Accordingly, the number of double positive 
ER/Ki67 cells increases in the breast of older women, correlating with the higher 
percentage of HR+ tumours affecting the latter. But if ERα+ cells’ main role is to 
sensor E2 to convey its proliferative message to neighbouring ERα- cells, it would 
be surprising for ERα+ cells to be TICs? It has been suggested that perhaps, 
through upregulation of both ERα and AREG, a self-propagating feeding loop 
might be generated, thus eventually fostering proliferation and oncogenic 
transformation of this otherwise quiescent cell type (Macias and Hinck, 2012).  
 
1.8 Experimental models of breast cancer 
Over time, different methods have been employed to study breast cancer, 
beginning with the establishment of human breast cancer cell lines and 
continuing with the generation of animal tumour models. Herein, pros and cons 
for each experimental model system will briefly be discussed. 
1.8.1 In vitro and ex vivo culture systems 
Since the establishment of the first human cancer cell line, the world famous 
HeLa cells coming from a patient (Henrietta Lacks) with cervical carcinoma (Gey 
et al., 1952), the use of cultured tumour cells became “viral” in the research 
field, thus significantly improving our understanding of the biology of cancer and 
of its well-described hallmarks (Hanahan and Weinberg, 2011). This discovery 
reached the breast cancer field in 1958, with the establishment of the BT-20 cell 
line (Lasfargues and Ozzello, 1958), to then continue with the commonly used 
MDA-MB series of cells (Cailleau et al., 1978) and the popular MCF-7 cell line 
(Soule et al., 1973). Since then, beside one of latest accomplishments referred 
to as the SUM series of breast cancer cells (Ethier et al., 1993), not much 
improvement has been made, partly due to the difficulty in maintaining an 
homogeneous population of cells in vitro, partly due to the tight regulation 
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regarding the research use of human tissues (https://www.hta.gov.uk/) 
(Holliday and Speirs, 2011). Furthermore, notwithstanding the possibility to 
perform experiments in a standardised format and the ease to get fast biological 
readouts, cell culture system is not devoid of caveats. First and foremost, 
established breast cancer cell lines do not represent the high degree of 
heterogeneity shown by breast cancer, thus hindering the study of certain 
subtypes of the disease. Secondly, the majority of established breast cancer cell 
lines come from metastatic or pleural effusions, leading to an over 
representation of late-stage tumours without covering the early-stages of breast 
tumourigenesis. Thirdly, 2D culture systems do not recapitulate the physiological 
environment surrounding cancer cells in vivo, not only because of the use of 
plastic dishes, but also because of the lack of the correct tumour 
microenvironment (TME). Lastly, due to the different culture methods used 
worldwide, originally identical breast cancer cell lines might have differently 
adapted overtime, thus losing their molecular and phenotypic integrity to 
acquire changes which have rendered experimental results across different labs 
not equally comparable or reproducible (Bruna et al., 2016).  
To overcome some of the aforementioned shortcomings, it is always advisable to 
use an expanded panel of cancer cell lines in order to have a better 
representation of the heterogeneity of the disease. Cell lines should also be 
passaged in culture for a minimal length of time to maintain their integrity and 
avoid any issue related to contamination. Heterotypic co-culture systems using 
cancer and host stromal cells (such as fibroblasts and immune cells) should be 
utilized more, in order to study the intimate relationships between the tumour 
and its TME. Whenever possible, cell lines (and their hosts) should be cultured in 
3D, either in solid-based matrixes (matrigel, collagen, etc..) as organoids or in 
suspension as spheres, thus closely mimicking their physiological behaviour. 
Nonetheless, whilst the development of more sophisticated in vitro systems 
remains a pressing need, a fairly remarkable level of success has been lately 
achieved in establishing the optimal conditions for “primary” culture, namely 
directly from the primary source (i.e. a patient or an animal). In brief, by 
harvesting cells from core biopsies or from the blood, scientist have been able to 
culture primary murine and human cancer cells, either in 3D or in suspension, 
whilst maintaining their integrity as close as possible to the physiological setting. 
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For this reason, ex vivo systems are currently deemed to provide the best 
condition to characterize the behaviour of cancer cells and predict their 
response to therapy. This is particularly exciting for breast cancer research, 
especially in view of the under-representation shown by HR+ breast cancer 
models and the difficulty to study the endocrine regulation of the mammary 
gland in vitro. In regards to the first point, culture of circulating tumour cells 
from ER+ breast cancers has now become possible, thus allowing 
characterization of their mutational landscape and discovery of the most 
effective drug therapy that could predict patients’ response (Yu et al., 2014). In 
regards to the second point, albeit ER+ breast cancer cell lines (e.g. MCF-7 or 
T47D) have been instrumental for understanding the molecular mechanisms of E2 
and progesterone signalling, target genes modulated by the latter are often 
different from the ones induced in vivo (Fernandez-Valdivia et al., 2008). 
Limitations are also encountered when primary human breast epithelial cells are 
cultured in vitro, as they either seem to lose expression of steroid HRs in 2D or 
show a different transcriptional profile in response to progesterone in 3D, 
without induction of Wnt-4 or RANKL (Graham et al., 2009). As such, based on 
the knowledge that hormone signalling strictly relies on paracrine mechanisms, 
an ex vivo system based on fresh explants of intact breast “tissue 
microstructures” was recently developed, enabling to maintain the physiological 
integrity of the human breast (Tanos et al., 2012). 
1.8.2 In vivo animal models 
In the lookout for experimental systems which could be more relevant to the 
human scenario, since the early 1900s scientists have turned their head towards 
the development and implementation of the so-called in vivo cancer models. 
Herein, two of the most commonly used animal models in the cancer field will 
be discussed, highlighting their pros and cons particularly in relation to breast 
cancer research. 
1.8.2.1 Transplantation-based models 
Cancer transplantation models generally refer to the injection of tumour cells in 
living model organisms, most commonly mice. Importantly, the injection of 
these cells, of murine (allotransplantation) or human (xenotransplantation) 
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origin, can occur either in the anatomical site of tumour formation (orthotopic 
graft) or in a different site (allotopic grafts), such as the subcutaneous 
compartment of the skin. So far, breast cancer orthotopic grafts have been 
usually generated through injection of cancer cells in the fat pad of the 
mammary gland, albeit some laboratories have successfully attempted to 
perform the injection in the ductal compartment of the gland (Richard et al., 
2016; Sflomos et al., 2016). Such technique has proven to be a valuable tool to 
assess the function of a gene on tumour’s growth, survival and progression (often 
even to a metastatic stage). However, due to the intrinsic nature of the system 
which involves inoculation of already established cancer cells, the use of 
transplantation models does not allow investigation into how genes and their 
encoded proteins affect the early-stages of tumourigenesis. Furthermore, by 
often employing the use of cultured cell lines, they carry most of the in vitro 
caveats outlined above. In addition, to avoid rejection of the inoculated cells, 
transplantation models mainly rely on the use of immune-deficient mice (but for 
allotransplantation), hindering the study of the crosstalk between the immune 
system and cancer (Holen et al., 2017).  
A remarkable improvement has been achieved with the direct inoculation of 
human cancer cells freshly extracted from patients into mice, the so-called 
patient-derived tumour xenografts (PDTXs), which allowed functional 
characterization of the properties of human primary tumours in a physiological 
setting while preserving histological and molecular heterogeneity (Hidalgo et al., 
2014). One of the first attempts to create breast cancer PDTXs occurred with 
work led by (DeRose et al., 2013), who started grafting human breast tumours 
into the fat pad of the murine mammary glands, showing the predictive nature 
of such system which could inform on patient’s clinical outcomes. More recently, 
the biggest breast cancer biobank comprising 83 PDTXs was generated (Bruna et 
al., 2016). Albeit the majority of PDTXs were from ER+ tumours, a huge 
variability in terms of proliferative rate upon initial engraftment and subsequent 
passages was reported, with ER-negative tumours displaying the fastest take and 
growth rate. Importantly, through a comprehensive molecular analysis, 
established PDTXs were shown to fall within the same IntCluster of the original 
tumour (Curtis et al., 2012) and to retain the same histopathological features 
through serial passaging, confirming the reliability of such system. Lastly, PDTXs 
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represent a robust platform to perform pre-clinical drug screening in the 
attempt to predict patient’s response (Bruna et al., 2016). In the near future, 
the implementation of a new generation of PDTXs, known as “Mouse Avatars”, 
might allow the identification of a personalized therapeutic regimen in “real-
time” that is while the patient is still alive (Malaney et al., 2014).  
Whilst heralding a new era of breast cancer research and setting the stage for 
precision cancer medicine, PDTXs are not devoid of shortcomings. One of the 
main ones refers to the presence of over-represented TN and under-represented 
ER+ PDTXs, due to the intrinsic take and growth rate differences of these 
subtypes (Landis et al., 2013). Furthermore, there is increasing evidences 
reporting discrepancies in the metastatic pattern of tumour cells seen in PDTXs 
as compared to the one observed in the patient (Holen et al., 2017). Lastly, like 
for all transplantation-based models, PDTXs rely on the use of immune-deficient 
mice, although lately there has been a great interest in generating more 
humanized mice through the engraftment of CD34+ haematopoietic stem and 
precursor cells into immune-deficient animals (Holzapfel et al., 2015). Of note, 
humanized PDXs have been recently made available by the Jackson Laboratories 
which presented them as “the next big thing in cancer modelling” 
(www.jax.org/news-and-insights). To conclude, even though transplantation-
based models represent the most common system used in the preclinical setting 
to rapidly validate new cancer drug targets as well as optimise dosing and 
treatment regimens, there has been a need for more relevant in vivo models of 
breast cancer. 
1.8.2.2 Genetically engineered mouse models 
The origin of GEMMs traces back to the 1980s when the first oncogene was 
cloned into the mouse genome, giving birth to the so-then-called “oncomice” 
(Hanahan et al., 2007). With the advent of gene targeting technology, it was 
then the turn of tumour suppressor genes to be targeted, leading to the 
generation of the first knockout mice (Jacks, 1996). By targeting the expression 
of an oncogene or the inactivation of a tumour suppressor to all cells of the 
body, first-generation GEMMs did not truly recapitulate the origin of sporadic 
human tumours (Kersten et al., 2017). It was only with the introduction of the 
Cre-loxP system, which enabled targeted genetic events to occur specifically in 
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the organs of interest, that conditional GEMMs could be created (Jonkers and 
Berns, 2002). This step represented a milestone in the cancer field as it allowed 
studying “naturally occurring” cancers by targeting clinically relevant genetic 
abnormalities (e.g. BRCA1 mutations or HER2 overexpression) in the correct 
anatomical location of immune-proficient mice. However, being the Cre 
recombinase constitutively expressed by tissue-specific promoters, conditional 
GEMMs did not allow any temporal control over the targeted genetic event. 
Consequently, in the presence of multiple “hits”, the latter would have likely 
occurred simultaneously without mimicking the sequential multistep progression 
of human cancer (Kersten et al., 2017). Over recent years, more sophisticated 
GEMMs implemented by high-throughput genetic approaches (e.g. CRISPR/Cas9 
gene editing system) have been generated, thus significantly improving our 
understanding of the molecular mechanisms underpinning cancer biology. 
Nowadays, GEMMs represent extremely valuable tools for preclinical research, as 
they allow the evaluation of new therapies, the refinement of treatment 
strategies and the study of drug resistance (Kersten et al., 2017). There are of 
course pitfalls with this model system. Firstly, creation of GEMMs can be very 
laborious and their husbandry not cost-effective. In addition, some GEMMs are 
characterized by long tumour latency, which render their use very time-
consuming. Secondly, GEMMs do not cover the wide heterogeneity shown by 
breast cancer, thus hampering the study of certain subtypes of the disease 
(Holen et al., 2017). Thirdly, not all GEMMs will progress to the metastatic 
stage, which represents the major cause of breast cancer morbidity, affecting 
almost 40% of patients in the whole UK (http://breastcancernow.org/). 
Moreover, even when they do metastasize, secondary tumour sites do not always 
occur at clinically relevant organs, and almost never represent the cause of 
primary death due to tight government regulations. Lastly, given their short life-
span, very few GEMMs would enable the study of long-term tumour dormancy, a 
recurring issue responsible for the majority of patients’ relapse (Kersten et al., 
2017). Overall, this urges the development of novel mouse model strategies in 
order to better recapitulate the heterogeneity of breast cancer, improve our 
knowledge on the biology of this enduring disease and hopefully accelerate the 
in vivo validation of new drug targets. In summary, if all the advantages and 
disadvantages of in vitro, ex vivo and in vivo models were to be considered, 
there is no perfect model system to study breast cancer. 
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1.9 Aims of the thesis 
Breast cancer currently remains the leading cause of cancer-related death 
among women worldwide. As for all other types of tumour, this genetic disease 
arises from the interplay between highly mutated genes (more commonly known) 
and infrequently altered ones (less commonly known). With the advent of NGS, 
the identity of the vast majority of these less commonly altered players has 
been finally unveiled. What remains to be elucidated, however, is the putative 
role played by these “uncommon” genes in the initiation, maintenance and 
progression of the disease. In this regards, following the discovery of RUNX1 
genetic alterations in biopsies of breast cancer patients, it became imperative to 
turn the spotlight on the function owned by this new pawn in the chess game of 
breast cancer.  
Thus far, the state-of-the-art knowledge of RUNX1 depicted the gene as a crucial 
regulator of cell fate determination and lineage-specific differentiation, 
particularly in the context of the haematopoietic system. As such, RUNX1 has 
been renowned as one of the most common site of chromosomal translocations 
in haematological malignancies. Over time, however, the cumulative discovery 
of RUNX1 genetic alterations in several solid tumours, including breast cancer, 
has led to the realization that the function owned by the gene in tumourigenesis 
was more widespread than previously thought. Further to that, what appeared 
to be rather surprising was the fact that RUNX1 could act as a tumour suppressor 
or as an oncogene depending on the specific context. 
Therefore, on the basis of what has been previously discussed and of the 
evidence gathered so far, the overall aim of the present thesis is to unveil what 
role could the Runx1 gene possibly play in the context of breast cancer. In an 
endeavour to do so, the first experimental approach to be outlined consists in 
the characterization of the effects following Runx1 deletion in the MMTV-PyMT 
breast cancer mouse model. In the latter, expression of RUNX1 interestingly 
appears to be restricted to early-stage mammary lesions, whilst lost in 
established tumours. Intriguingly, this finding may provide mechanistic insights 
into why Runx1 loss results in an accelerated onset of breast tumourigenesis, 
without affecting the overall survival of MMTV-PyMT mice. 
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Given the presence of a putative interplay between the RUNX and β-catenin 
transcription factors, the second experimental approach investigates how 
deletion of Runx1 and Runx2 may impinge on a novel Wnt/β-catenin-driven 
model of breast tumourigenesis. Herein, Runx1 loss results in a similar decrease 
of the time from birth to tumour onset, without again affecting the overall 
survival of Wnt/β-catenin-driven mice. This time, however, a remarkable 
acceleration of pre-neoplastic mammary lesions is seen upon concomitant 
deletion of Runx2, as confirmed by the profound disruption of mammary 
anlages, as well as by the dramatic increase in tumour burden. These latter 
results offer the rationale for further challenging the stemness capability of 
Runx1- and Runx2-deficient Wnt/β-catenin-driven mammary lesions through the 
use of transplantation- based models. 
Finally, the third experimental approach comprises of a variety of ex vivo 
experimental techniques implemented to delve into the molecular roots of the 
tumour suppressive functions shown by the Runx genes at early stages of breast 
tumourigenesis. Thus, through the use of colony-forming cell assays and flow 
cytometry analysis, the Runx genes unveil their identity as guardians of the 
mammary epithelial cell hierarchy.  
Altogether, the results presented in this thesis are intended to shed light on the 
crucial role played by the Runx “hills” in the genomic landscape of breast 
cancer. By highlighting the detrimental consequences of Runx1 and Runx2 loss, 
resulting in an impairment of mammary tissue homeostasis and eventually 
tumour development, this work whishes to improve the poor understanding of 
both mammary gland and breast cancer biology 
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2 Materials and Methods 
 
2.1 Animal procedures 
All animal works were performed with ethical approval from University of 
Glasgow under the revised Animal (Scientific Procedures) Act 1986 and the EU 
Directive 2010 (PPL 70/8645). All mice were housed in a pathogen-free animal 
facility within appropriate ventilated cages. Mouse health check was carried out 
at least two times a week. General husbandry (food, water and housing) and 
mouse ear notching were carried out by the Biological Services Unit at the 
Beatson Institute for Cancer Research. Genotyping was performed through ear-
notching by Transnetyx, Inc. (Cordova, TN, USA). Animals were euthanized by 
carbon dioxide asphyxiation. 
2.1.1 Mouse lines and generation of cohorts 
The MMTV-Cre line was kindly provided by the laboratory of WJ Muller 
(Andrechek et al., 2000), as was the MMTV-PyMT line (Guy et al., 1992); the 
betalactoglobulin (BLG)-Cre line was obtained from AR Clarke (Selbert et al., 
1998); the K14-Cre line (Dassule et al., 2000) was bought in from The Jackson 
Laboratory (USA); the stabilized β-catenin line (Catnbwt/lox(ex3)) was kindly 
provided by OJ Sansom (Harada et al., 1999); the tandem dimer red fluorescent 
protein (tdRFP) line (Gt(ROSA)26Sortm1Hjf) was obtained from the EMMA archive and 
was generated as previously described (Luche et al., 2007); the Runx1 line 
(Runx1fl/fl) was generated in the lab of Professor Nancy Speck (Growney et al., 
2005) and kindly given to us by Marella De Bruijn, Oxford; and the Runx2 line 
(Runx2fl/fl) was created by Theresa Higgins and Ian Rosewell in the lab of 
Professor Mike Owen (ICRF labs, London). To study the effect of Runx1 deletion 
using the MMTV-PyMT model, MMTV-PyMT mice were crossed onto MMTV-
Cre;Runx1fl/fl mice. To use a reporter gene as a surrogate marker for MMTV-Cre 
expression and Runx1 recombination, MMTV-PyMT;MMTV-Cre;Runx1fl/fl mice 
were crossed onto tdRFP mice. All mice were backcrossed for up to 10 
generations onto a pure FVB background. To study the effect of Runx1 and Runx2 
deletion in the context of activated Wnt/β-catenin signalling, BLG-
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Cre;Catnbwt/lox(ex3) mice were crossed with Runx1fl/fl and Runx2fl/fl conditional 
knock-out mice. All mice were maintained on a mixed background. For 
subcutaneous transplantation experiments, all CD1 nude and athymic nude mice 
used were obtained from Charles River Research Models & Services (UK). 
2.1.2 Staging of the oestrous cycle 
To stage the oestrous cycle of the mice, animals were euthanized and their 
vagina gently flushed three to five times using a plastic pipette filled with 
phosphate buffered saline (PBS). The collected flush (vaginal smear) was spread 
onto a glass slide [VWR, UK] to dry and slides were then subjected to H&E stain 
using the ST5020 Leica Autostainer. The specific stage of the oestrous cycle was 
determined based on the proportion of three different cell types: epithelial 
cells, cornified cells and leukocytes. When there was a higher abundance of 
nucleated cells, mice were staged at pro-oestrus; when there was a higher 
abundance of cornified cells, mice were staged at oestrus; when there was an 
abundance of all three cell types, mice were staged at metestrous; and when 
there was an abundance of leukocytes, mice were staged at diestrous (Caligioni, 
2009). 
2.1.3 Survival analysis 
For survival analysis, mice were kept under enhanced monitoring in order to 
assess for the formation of mammary tumour lesions by palpation. Once a lesion 
was noticed, its size was recorded and the tumour measured twice a week with 
the use of a caliper. Mice were sacrificed when a tumour lesion reached clinical 
end point, that is when its length or width equalled 15 mm or if the tumour 
ulcerated. The body weight of the mouse was then recorded and all mammary 
glands dissected out and weighed to calculate tumour burden (expressed as a 
percentage of mammary gland weight divided by the body weight of the mouse). 
Mammary tumours were then formalin-fixed paraffin-embedded for histological 
analysis and frozen down at -80°C for molecular analysis. For survival analysis, 
data were plotted using Kaplan-Meiers curves. Importantly, mice culled due to 
other pathologies (including gasping, runty mice or animals with cystic tumours) 
were censored and marked on the respective curves. 
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2.1.4 Transplants of mouse-derived tumour fragments  
Clinical end-point mice of the BLG-Cre;Catnbwt/lox(ex3) cohorts were euthanized 
and their tumours removed. From the biggest lesion, five mouse-derived tumour 
fragments of 2 mm by 2 mm were generated. Each fragment was transplanted 
subcutaneously into the right flank of immunocompromised (CD1 nude and 
athymic nude) mice. Tumour growth was monitored over time by measuring 
tumour volume [(length x width x width)/2, with length>width] with the use of 
calipers. Recipient mice were euthanized when clinical end point was reached. 
Tumours were then dissected out and divided in two parts: one was frozen down 
at -80°C for molecular analysis, while the other was formalin-fixed paraffin 
embedded for immunostaining analysis. 
2.1.5 Imaging analysis of RFP expression 
Clinical end point mice of the MMTV-PyMT cohorts were euthanized, opened up 
to allow visualization of all ten murine mammary glands and imaged for red 
fluorescent protein (RFP) expression through the IVIS Spectrum in vivo imaging 
system (PerkinElmer). Mice were illuminated via the 554 nm excitation filter, 
whereas fluorescence was detected with the 581 nm emission filter.  
2.1.6 Virgin analysis of pre-neoplastic lesions 
To look for the presence of pre-neoplastic lesions, virgin mice were sacrificed at 
3, 6 and 9 weeks of age, prior to the development of palpable mammary 
tumours in some genotypes. Right-hand side mammary glands were excised for 
whole-mount analysis, whereas left-hand side mammary tissues were either 
formalin-fixed paraffin-embedded for histological analysis or frozen down at -
80°C for molecular analysis. To assess the proliferative ability of pre-neoplastic 
lesions, in vivo intraperitoneal BrdU (GE Healthcare, VWR) injection (200 µl/25 g 
body weight) was performed. Animals were euthanized two hours after injection 
and all ten mammary glands harvested and paraffin-embedded formalin-fixed for 
immunohistochemical analysis. 
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2.2 Immunohistochemistry 
Dissected mammary glands were formalin-fixed undergoing appropriate tissue 
processing and paraffin-embedded to preserve tissue architecture. Tissue blocks 
were sectioned at 4 µm on a microtome and blanks were mounted onto adhesive 
glass slides [VWR, UK]. Routine haematoxylin eosin (H&E) staining (as processed 
by the Beatson Histology Service) was carried out to check the quality of the 
sample. IHC staining was performed as followed. Slides were de-waxed through 
repetitive (3X) xylene washes and re-hydrated in decreasing concentration of 
ethanol (ETOH), i.e. 100%, 100% and 70%. Heat-induced antigen retrieval was 
performed at 95°C for 30 minutes using the Dako Target Retrieval Solution, 
Citrate pH 6 [Dako, S236984-2], followed by a cooling down period of 30 
minutes. Slides were then rinsed (2X) for 5 minutes in Tris-Buffered Saline with 
0.05% Tween (TBST) at low shaking. Sections were then blocked for 5 minutes 
using the Dako Peroxidase Block [Dako, UK] to avoid endogenous peroxidase 
activity. Following rinsing (2X), slides were blocked for 30 minutes using 5% 
Rabbit Serum [Dako, X090210-8] in PBS to avoid secondary antibody non-specific 
binding. Slides were then incubated with primary antibodies either overnight at 
4°C for anti-ERα 1:200 [Santa Cruz, SC-542] and anti-PR 1:200 [Santa Cruz, SC-
539], for 1 hour at room temperature for anti-CK5 1:500 [Cambridge, PRB-16OP-
100], anti-CK8/18 1:250 [Fitzgerald, 20R-CP004] and anti-CK14 1:100 [abcam, 
ab7800], or for 2 hours at room temperature for anti-β-catenin 1:50 [BD 
Transduction Laboratories, 610154]. Following rinsing with TBST (2X), sections 
were incubated for 1 hour at room temperature with horseradish peroxidase-
conjugated anti-rabbit secondary antibodies, except for CK8/18 and β-catenin 
for which anti-guinea pig or anti-mouse secondary antibodies were used, 
respectively [Dako, UK]. All antibodies were diluted in Dako REAL Antibody 
Diluent [Dako, UK]. Following rinsing with TBST (2X), the reaction was visualized 
with the DAB Chromogen + DAB Substrate Buffer, according to manufacturer’s 
instructions [Dako, UK]. After immersion in distilled H20 to stop the reaction, 
slides were counterstained and mounted by the Beatson Histology Service.  
The anti-RUNX1 1:75 [Cell Signalling, 8529], anti-RUNX2 1:300 [Cell Signalling, 
8486], anti-BrdU 1:150 [BD Biosciences, 347580], anti-Ki67 1:100 [Thermo, RM-
9106], anti-RFP 1:100 [Tebu, 600-401-379], anti-αSMA 1:25,000 [Sigma, A2547] 
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IHC staining were carried out by Colin Nixon and the Beatson Histology Service 
using the Dako Autostainer link48. Sections were dewaxed as previously 
described and subject to heat induced antigen retrieval using the Dako Pre-
Treatment module. The sections underwent antigen retrieval for 25 minutes at 
98°C using 10 mM pH6 Citrate retrieval buffer (Thermo, TA-250-PM1X). After 
washing in TBST, sections were placed onto the Dako Autostainer link48. Dako 
peroxidase block was applied for 5 minutes before rinsing with TBST. The 
primary antibody was applied to the sections at previously described dilutions 
for 35 minutes at room temperature. Slides were rinsed with TBST before 
application of appropriate rabbit or mouse secondary antibody (Dako, K4001; 
K4003) and rinsed again with TBST before application of 3,3 diaminobenzidine 
tetrahydrochloride (Dako, K3468) to allow visualisation of the antigen-antibody 
interaction. The sections were then removed from the autostainer, 
counterstained with haematoxylin z (CellPath, RBA-4201-00A), washed with 
water, differentiated in 2 dips 1% acid alcohol, washed with water then the 
nuclei blue'd in Scotts tap water substitute. The sections were again washed in 
water before dehydration through graded alcohols, cleared in xylene and 
mounted with a glass coverslip using DPX mountant for microscopy (CellPath, 
SEA-1300-00A). Images were captured using an Olympus CKX41 microscope. 
2.3 BrdU quantification 
Mammary glands of BrdU-injected mice were harvested, formalin-fixed paraffin-
embedded and stained with anti-BrdU antibody (see above). Three to six mice 
per genotype were analysed. Quantification of BrdU staining was achieved using 
the HALO software. Firstly, the total mammary gland area (TA) of each slide was 
measured by drawing a (thick) line around each tissue section via the pen 
annotation tool. In doing so, any empty area within the gland was carefully 
marked with a dotted line and excluded using the exclusion drawing tool (Figure 
2. 1A). Secondly, all epithelial ducts within the TA were encircled via the pen 
annotation tool, whilst their lumen (if present) excluded via the exclusion 
drawing tool (Figure 2. 1B). This allowed quantifying the total epithelium (TE) 
area as a percentage of TA. Within TE, a distinction between normal epithelium 
(NE) and abnormal epithelium (AE) was achieved through the creation of 
different color-coded layers (Figure 2. 1C). This allowed quantifying total NE and 
AE areas percentages of TE area. Once the HALO software was trained to 
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recognize a cell and distinguish between a BrdU-positive and -negative one 
(Figure 2. 1D), the proliferative density of each NE and AE layer was calculated 
by dividing the number of BrdU-positive cells by the area of the corresponding 
layer. The calculated proliferative indeces were then normalized by multiplying 
their values by the percentage of each corresponding layer. 
 
 
Figure 2. 1 Quantification of BrdU-positive cells through the HALO software. 
Representative screenshots of the different steps needed to quantify the proliferative index 
characterizing the mammary gland tissues of each BLG-Cre;Catnbwt/lox(ex3) cohort of mice upon 
loss of Runx1 and/or Runx2. Quantification of (A) total mammary gland area within each slide; 
(B) total epithelium area within each tissue section; (C) total normal and abnormal epithelia 
area within each tssue section; and (D) BrdU-positive cells within normal and abnormal epithelia 
areas. 
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2.4 Mouse mammary epithelial cell extraction 
All ten mammary gland from pubertal and clinical end-point mice were dissected 
out, after removal of lymph nodes and avoidance of surrounding muscles, and 
placed in a 50 ml falcon tube containing 10 ml serum-free working solution – F12 
Nutrient Mixture (Ham) (1X), 1% Penicillin-Streptomycin and L-Glutamine 200 mM 
(100X) (PSQ) [Life Technologies]. After finely mincing glands with the McIlwain 
tissue chopper [Mickle Lab, UK], tissue pastes were placed in a 50 ml falcon tube 
containing 15 ml serum-free digestion solution – F12 Nutrient Mixture (Ham) 
(1X), 1% PSQ, 10% Collagenase/Hyaluronidase [300 units (U)/ml Sigma, C9891; 
100 U/ml Sigma, H3506] - and incubated for 1.5 hours at 37°C in a shaking 
incubator at 100 rpm. Primary epithelial organoids were then collected through 
differential centrifugation by spinning tubes down (2X) at 350g for 5 minutes. 
Pellets were re-suspended in 1.5 ml NH4Cl (0.8%) and kept at room temperature 
for 5 minutes for red blood cells lysis. Once the reaction was stopped in working 
medium and tubes were spun down at 350g for 5 minutes, pellets were re-
suspended in 1 ml TEG dissociation solution – 1X PBS, 0.25% Trypsin 2.5% (10X) 
[Life Technologies] and 1mM EGTA – plus 0.1 mg/ml DNase I recombinant, RNase-
free 10000 U [Roche, 04716728001] and incubated at 37°C for 10 minutes in the 
water bath to obtain a single cell suspension. After the addition of 10% foetal 
bovine serum (FBS) supplemented working solution to stop trypsinization, MMECs 
were purified through filtration with 70 µm cell strainers [Greiner Bio One] and 
centrifugation at 350g for 5 minutes. Lastly, MMECs were diluted 1:2 with Trypan 
Blue Stain 0.4% [Life Technologies, T10282] and live cells were counted based on 
dye exclusion with the haemocytometer and used for further analysis. 
2.5 Flow cytometric analysis  
A maximum number of 5 x 10^6 MMECs were blocked with the Fc receptor 
antibody [Biolegend, 101319 - anti-mouse CD16/32 antibody] for 15 minutes at 
room temperature, by diluting it 1:100 in FACS buffer -  1X PBS, 2mM EDTA pH 8 
and 1% FBS. Tubes were washed with 1ml FACS buffer, spun down at 350g for 5 
minutes and supernatant was removed. MMECs were then labelled with a master 
mix containing the following antibodies at a 1:200 dilution in FACS buffer: 
Allophycocyanin (APC) anti-mouse CD31 [BD Pharmingen, 551262], APC anti-
mouse CD45 [BD Pharmingen, 559864], APC anti-mouse Ter119 [BD Pharmingen, 
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557909], Phycoerythrin (PE) anti-mouse CD24 [BD Pharmingen, 553262], PerCP-
eFluor710 anti-human/mouse CD49f [eBioscience, 46-0495], Alexa Fluor 488 
anti-mouse Ly-6A/E (Sca-1) [Biolegend, 108115]. Labelled MMECs were then 
incubated on ice in the dark for 30 minutes. Afterwards, tubes were washed with 
1ml FACS buffer, spun down at 350g for 5 minutes and supernatant was 
removed. Lastly, MMECs were labelled with 1mg/ml 4’,6-diamidino-2-
phenylindole (DAPI) [Life Technologies, D1306], incubated on ice in the dark for 
5 minutes and analysed via the Attune NxT Flow Cytometer [Life Technologies]. 
For Single labelled colour controls were done for each independent experiment 
by using UltraComp eBeads Compensation Beads [eBioscience/ThermoFisher 
Scientific, 01-2222-42], which were washed and re-suspended in Flow Cytometry 
Staining Buffer [eBioscience, 00-4222-57]. Gates were set using fluorescence 
minus one controls. Data was analysed with the FlowJo V10.2 software. MMECs 
profiling (Figure 2. 2) was achieved by following a series of sequential steps. 
These consisted in the elimination of cell debris (SSC-A vs FSC-A) (A), exclusion 
of doublets (FSC-H vs FSC-A and SSC-A vs SSC-H) (B, C), removal of dead cells 
(DAPI positive) (D) and exclusion of haematopoietic (CD45+/Ter119+) and 
endothelial (CD31+) cells, collectively called lineage positive (Lin+) cells (E). The 
remaining subset of Lin- cells was then analysed for CD24 and CD49f expression, 
in order to discriminate between the luminal (Lin-CD24+CD49flow) and basal/MYO 
(Lin-CD24+CD49fhigh) subpopulations of MMECs (F). Within each subset of MMECs, 
the percentage of Sca-1+ and Sca-1- was finally calculated.  
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Figure 2. 2 Flow cytometric analysis of mouse mammary epithelial cells. 
Gating strategy utilized for flow cytometric analysis of MMECs. Representative dot plots showing 
(A) the exclusion of debris and inclusion of all cells, (B, C) the exclusion of doublets and 
inclusion of singlets, (D) the exclusion of dead cells (DAPI positive) and inclusion of live cells 
(DAPI negative), (E) the exclusion of haematopoietic and endothelial (Lin+) cells 
(CD31+CD45+Ter119+) and inclusion of epithelial cells (Lin-), (F) the exclusion of stromal cells and 
inclusion of luminal (CD24+CD49flow) and basal (CD24+CD49fhigh) cells. MMEC, mouse mammary 
epithelial cells; Lin, lineage. A, area; FSC, forward scatter; H, height; SSC, side scatter. 
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2.6 Fluorescence activated cell sorting 
To perform FACS of RFP+ and RFP- cells from the MMTV-PyMT cohorts of mice, 
animals were euthanized when clinical end point was reached. Mammary glands 
were dissected out and processed as described above until a single cell 
suspension was obtained. Cells were then labelled with 1mg/ml DAPI [Life 
Technologies, D1306], incubated on ice in the dark for 5 minutes and run 
through the FACSARIA Z6001 [BD Bioscience]. Through elimination of cell debris 
(SSC-A vs FSC-A), exclusion of doublets (FSC-H vs FSC-A), and removal of dead 
cells (DAPI positive), live (DAPI negative) cells were sorted in two populations 
based on positive or negative expression for RFP. The RFP gate was set using an 
RFP negative MMTV-PyMT control female.  
2.7 Mammary gland whole mounts 
Murine mammary glands #4 were harvested from 3, 6 and 9 week old female, 
spread onto a glass slide [VWR] and air dried for 10 minutes prior to placement 
in 50 ml tube containing Carnoy’s fixative. Tissues were fixed overnight and 
washed in decreasing concentrations of EtOH, i.e. 70%, 50%, 25%, for 
approximately 15 minutes per wash. Mammary glands were then rinsed in 
distilled H20 for 10 minutes and stained in Carmine Alum overnight. The 
following day, tissues were washed in increasing concentration of EtOH, i.e. 
70%, 95%, 100%, for approximately 15 minutes per wash, cleared in Xylene 
overnight and mounted with Pertex Mounting Medium [HistoLab, 00801] the 
following day. After photographic documentation using a Zeiss 
stereomicroscope, mammary gland whole-mounts were analysed through ImageJ 
software. Carnoy’s fixative was prepared by mixing 6 parts of EtOH 100%, 3 parts 
of chloroform (CHCl3) and 1 part of glacial acetic acid. Carmine Alum stain was 
prepared by boiling 1g carmine [Sigma, C1022] and 2.5 g aluminium potassium 
sulphate dodecahydrate [Sigma, 237086] in 500 ml distilled H20 for 20 minutes. 
The solution was then filtered and stored in the fridge at 4°C. To quantify the 
elongation of the ductal mammary tree, the distance between three longest 
TEBs and the lymph node (taken as a reference point) was calculated and 
averaged. Four mice per genotype were used. 
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2.8 Tumoursphere assay 
Freshly extracted MMECs from 7 to 8 weeks old females of the BLG-
Cre;Catnbwt/lox(ex3) cohorts, and sorted RFP+ and RFP- cells from clinical end point 
MMTV-PyMT mice, were plated on ultra-low attachment 24-well plates [VWR, 
734-1584] at a density of 10,000 live cells per well in serum-free culture medium 
– F12 Nutrient Mixture (Ham) (1X) – supplemented with 4 µg/ml Heparin [Sigma, 
H3149], 20 ng/ml EGF [Sigma, E4127], 20 ng/ml FGF2 [Sigma, SRP4038] and B-27 
Supplement without Vitamin A (1X) [Thermo Fisher Scientific, 12587-010]. For 
each independent experiment, twelve technical replicates (wells) were used per 
cohort. At Day 3, cells were fed with the addition of fresh EGF and FGF2. At Day 
6, the number of primary tumourspheres per well was manually counted using 
the 4X objective lens of the Olympus CKX41 microscope and one representative 
picture of each replicate was taken to assess the size of the spheres. This was 
done by manually measuring the area of all visible spheres present in each 
representative picture of the 12 technical replicates using the ImageJ software. 
Measured area values, expressed in µm, were split into three groups (1500-4500, 
4500-7500 and 7500-15000) and the frequency of spheres present into each 
group was then calculated. 
For second passage, primary tumourspheres were collected and gently spun 
down at 350g for 5 minutes. The pellet was enzymatically re-suspended in 100 µl 
of 0.25% trypsin and incubated at 37°C for 15 minutes. After stopping the 
reaction with the addition of fresh medium, tubes were spun down at 350g for 5 
minutes and cells were counted based on dye exclusion with the 
haemocytometer. 5,000 live tumoursphere-derived cells per well were plated 
again on new ultra-low attachment 24-well plates using fresh tumoursphere 
serum-free medium. For each independent experiment, twelve technical 
replicates (wells) were used per cohort. At Day 3, cells were fed by the addition 
of fresh EGF and FGF2. At Day 6, the number of secondary tumourspheres per 
well was manually counted using the 4X objective lens of the Olympus CKX41 
microscope and one representative picture of each replicate was taken to assess 
the size of the spheres. Secondary tumoursphere area was measured using the 
ImageJ software. This was done by manually measuring the area of all visible 
spheres present in each representative picture of the 12 technical replicates 
using the ImageJ software. Measured area values, expressed in µm, were then 
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split into three groups (1500-3500; 3500-5500 and 5500-7500) and the frequency 
of spheres present into each group was then calculated. 
2.9 Colony forming cell assay 
Freshly extracted MMECs from 7 to 8 weeks old females of the BLG-
Cre;Catnbwt/lox(ex3) cohorts were plated on 24-well plates [VWR, UK] at a density 
of 5,000 live cells per well and embedded in a 20 µl drop of Matrigel [Corning 
Matrigel Basement Membrane Matrix Growth Factor Reduced, Phenol Red Free, 
356231]. Once matrigel had solidified at 37°C in the incubator for almost 10 
minutes, 500 µl of culture medium – F12 Nutrient Mixture (Ham) (1X) [Gibco], 
10% FBS [Gibco], 1% PSQ [Gibco], 10 ng/ml EGF [Sigma, E4127], 5 µg/ml Insulin 
solution human [Sigma, I9278], 0.25 ng/ml Fungizone [Thermo Fisher Scientific, 
15290-018], 5 ng/ml Cholera Toxin [Sigma, C8052], 50 µg/ml Gentamicin [Sigma, 
G1272] – was added to each well. For each independent experiment, twelve 
technical replicates (wells) were used per cohort. At Day 3, cells were fed with 
the addition of 500 µl of fresh culture medium. At Day 6, the number of acinar 
and solid colonies per well was manually counted using the 4X objective lens of 
the Olympus CKX41 microscope and one representative picture of each replicate 
was taken to assess the size of the colonies. This was done by manually 
measuring the diameter of all visible acinar and solid colonies present in each 
representative picture of the 12 technical replicates using the ImageJ software. 
Measured diameter values, expressed in µm, were split into three groups (0-200, 
200-400 and 400-600) in the case of acinar colonies and four groups (0-100, 100-
200, 200-300 and 300-400) in the case of solid colonies. The frequency of 
colonies present into each group was then calculated. 
2.10  RNA extraction  
Total ribonucleic acid (RNA) was extracted from MMECs using the RNeasy Mini Kit 
(QIAGEN), as per manufacturer’s instructions. Samples were lysed using the 
denaturating guanidine-thiocyanate RLT buffer, containing β-mercaptoethanol to 
prevent RNases activity and degradation of RNA. Lysed samples were 
homogenized through the use of QIAshredder Spin Columns, which were spun 
down for 2 minutes at 14680 rpm via a standard microcentrifuge. Homogenized 
samples were mixed with 70% ETOH and added onto RNeasy Mini Spin Columns, 
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where total RNA could be isolated through specific binding to silica-based 
membranes. Following sequential washing steps in the presence of supplied RW1 
and RPE Buffers, contaminants and residual ETOH were removed. Total bound 
RNA was eluted with the addition of 40 µl of supplied RNase-Free Water into 1.5 
ml collection tubes. Purified RNA was either stored at -80°C or used for the next 
application. The DNA-free DNA removal kit [Thermo Fisher Scientific] was used 
to treat the RNA prior to reverse transcription polymerase chain reaction (RT-
PCR) to eliminate genomic genomic DNA contamination, according to the 
manufacturer’s instructions (standard treatment protocol). To assess the yield 
and purity of RNA samples and calculate the amount of material needed for 
cDNA synthesis, eluted RNA was quantified using the NanoDrop 2000c 
spectrophotometer [Thermo Fisher Scientifics]. The concentration of RNA was 
determined by measuring its absorbance at 260 nm (A260), given that an 
absorbance of 1 unit corresponds to approximately 44 µg of RNA per ml (if the 
pH solution is neutral). To estimate the purity of the RNA, a ratio of the readings 
at 260 nm and 280 nm was calculated (A260/A280), since the majority of 
contaminants including proteins absorb at 280 nm. 
2.10.1 Reverse transcription  
Quantified RNA was reversed transcribed using the Superscript III Kit [Thermo 
Fisher Scientific], as per manufacturer’s protocol. 1 µg of RNA was mixed with a 
master mix containing 1 µl of 50 µM oligo(dT)20 [Invitrogen], 1 µl of 50 µM 
random hexamers (Invitrogen-Applied Biosystems), 1 µl of dNTP mix (10 mM 
each) and RNase-free water to reach a total volume of 13 µl. Samples were 
incubated at 65°C for 5 minutes using a Thermal Cycler (Bio-Rad DNA Engine) 
and quickly chilled on ice for approximately 1 minute. A master mix of 7 µl, 
containing 4 µl of 5X first-strand buffer, 1 µl of 0.1 M DTT, 1 µl of RNase 
inhibitor (40 U/µl) and 1 µl of Superscript III, was added to each sample. 
Samples were then incubated at 25°C for 5 minutes, 50°C for 60 minutes and 
70°C for 15 minutes. Newly synthetized complementary (c)DNA was diluted 1:10 
with the addition of RNase-Free Water and either stored at -20°C or used for the 
next application. 
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2.10.2 Quantitative polymerase chain reaction 
SYBR Green-based quantitative qPCR was carried out using a 20 µl reaction 
containing: 10 µl of 2X SYBR Green Jumpstart Taq ReadyMix [Sigma, S4438], 0.5 
µM of forward and reverse primers and 5 µl of diluted cDNA (or 5 µl of water for 
the no-template controls). The cycling conditions used were: 94°C for 2 
minutes, followed by 40 cycles of cDNA denaturation at 94°C for 15 seconds and 
primer annealing at 60°C for 60 seconds. To verify the specificity of each 
amplicon and the presence of primer-dimers, a melting curve analysis was 
carried out from 70°C to 95°C in 0.3°C intervals. Acquisition of the data was 
done using CFX96 Real-Time PCR Detection System [BioRad]. Data analysis was 
performed using the CFX Manager software, version 3.1 [BioRad] and the GenEx 
Standard software, version 6.1 (MultiD Analyses). The following primers were 
used for the target genes: Ccnd1 (GAGAAGTTGTGCATCTACACTG; 
AAATGAACTTCACATCTGTGGC); Cd44 (CAC ATA TTG CTT CAA TGC CTC AG; CCA 
TCA CGG TTG ACA ATA GTT ATG); Lgr5 (GAGTCAACCCAAGCCTTAGTATCC; 
CATGGGACAAATGCAACTGAAG); Myc (CCC AAA TCC TGT ACC TCG TC; TTG CCT 
CTT CTC CAC AGA CA), and Ascl2 (GAGCAGGAGCTGCTTGACTT; 
TCCGGAAGATGGAAGATGTC). Runx1 and Runx2 primers were purchased via 
QIAGEN (QT00100380 and QT00102193, respectively) and reconstituted by the 
addition of 1.1ml of d H2O. To normalize the expression of the Runx1 and Runx2 
genes in sorted RFP+ and RFP- MMTV-PyMT cells, Gapdh was used as a reference 
gene. To normalize the expression of Ccnd1, Cd44, Lgr5, Myc and Ascl2, 
reference genes were selected from a panel of 10 genes, Actb, B2m, Csnk2a2, 
Cyc1, Fbxo38, Gapdh, Htatsf1, Mon2, Pak1ip1 and Rpl13a [PrimerDesign], using 
the NormFinder method (Andersen et al., 2004). As the analysis identified Actb 
and Fbxo38 as the best candidates, these genes were used to normalise for 
differences in RNA input.  
RNA extraction, cDNA synthesis and qPCR analysis of Wnt/β-catenin target genes 
was performed by Dimitris Athineos. 
2.11 Statistical analysis 
All statistical tests were performed with GraphPad Prism 6. For in vivo survival 
analysis with Kaplan-Meiers curves, the Log-rank (Mantel-Cox) test was used. For 
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scatter dot plots of body weight, tumour burden, number of tumour burdened 
mammary gland and ductal elongation, statistical analysis was performed by the 
Kruskal-Wallis (nonparametric) test with Dunn’s multiple comparisons in 
GraphPad Prism. For scatter dot plots of tumoursphere area, colonies diameter, 
the ratio of solid/acinar colonies, the molecular heterogeneity of solid colonies 
and flow cytometry data, statistical analysis was performed by the two-way 
ANOVA test with the Dunnet’s multiple comparisons to compare all genotypes to 
the control cohort and/or the Tukey’s multiple comparisons to compare all 
genotypes with each other. Error bars represented the mean with standard 
deviation (SD). P values were considered significant if P<0.05. In particular, 
significance was set as: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. For RT-
qPCR, relative expression with the ddCq method and statistical analysis were 
carried out using GenEx. T-test, with Dunn-Bonferroni correction for multiple 
testing, was used to determine statistical significance of changes. 
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3 Investigating the role of Runx1 in the MMTV-
PyMT mouse model of breast cancer 
 
3.1 Introduction 
One of the biggest breakthroughs in breast cancer research is attributed to 
Timothy Stewart and Phillip Leder, the pioneers of the first transgenic mouse 
model of breast cancer (Hanahan et al., 2007). Around that time, scientists were 
aware of the existence of a retrovirus known as mouse mammary tumour virus 
(MMTV), able to cause mammary tumours in specific strain of mice. In addition, 
the MMTV long terminal repeat (LTR) was also known to regulate the expression 
of a fused oncogene in response to steroid hormones in cultured mammalian 
cells (Huang et al., 1981). So it was in 1984 that the expertise of the Leder 
molecular biology lab along with the transgenic skills of Stewart led to the 
generation of the first breast cancer MMTV-Myc oncomouse (Stewart et al., 
1984). Whilst on one hand this ground breaking finding reinforced the idea of 
oncogenes as causative agents of cancer, on the other the long temporal latency 
and the relatively low tumour burden showed by MMTV-Myc mice emphasized 
the “multihit” nature of the disease, which required more than one genetic 
event to arise (Vogelstein et al., 1983). With this in mind, the first double 
transgenic MMTV-v-Ha-Ras/MMTV-Myc breast cancer mouse model was created, 
thus proving that the cooperation of two oncogenes significantly accelerated 
tumourigenesis. Nonetheless, the presence of focal lesions displayed by mice 
reiterated the necessity of additional hits, perhaps stochastic changes on top of 
those programmed by the oncogenes (Sinn et al., 1987). With the concomitant 
advent of gene targeting technology, tumour suppressor genes also started to be 
targeted, either alone or in combination with already known oncogenes (Jacks, 
1996), leading to the generation of a multitude of breast cancer GEMMs. 
3.1.1 The PyMT breast cancer mouse model  
Since its discovery, the MMTV promoter has been extensively used in the GEMM 
field of breast cancer to drive expression of different oncogenes, including the 
HER2/neu gene, specifically in the mammary gland (Huang et al., 1981). 
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Nonetheless, beside the discovery of the HER2 tyrosine kinase in driving the 
development of adenocarcinoma (Muller et al., 1988), another tyrosine kinase 
was also found to dramatically transform the mammary epithelium. This refers 
to the Polyomavirus (PyV) middle T antigen (PyMT). The tumourigenic potency of 
the PyMT and its preferential targeting of the mammary gland emerged when 
infection of new-borns or nude mice with PyMT caused the formation of several 
epithelial and mesenchymal tumour types, among which mammary carcinomas 
appeared to dominate (Dawe et al., 1987; Berebbi et al., 1990). Of note, the 
oncogenic capability of PyV was ascribed to the presence of the middle T 
antigen (Israel et al., 1979), able to interact with and activate the tyrosine 
kinase activity of several proteins, including members of the c-src family 
(Courtneidge and Heber, 1987). In addition, cellular transformation was also 
found to stem from PyMT association with the 85-kDa subunit of the 
phosphoinositide 3’-kinase (PI3K) (Whitman et al., 1985; Courtneidge and Heber, 
1987; Talmage et al., 1989). Thus, in an effort to better guide the tumourigenic 
potency of PyMT exclusively to the mammary gland, expression of the transgene 
was finally put under the control of the MMTV promoter, giving rise to the MMTV-
PyMT breast cancer mouse model (Guy et al., 1992).  
Deemed as one of the most common breast cancer GEMMs used worldwide, the 
MMTV-PyMT model is characterized by several distinctive features. First and 
foremost, despite some degree of variability depending on the strain (Davie et 
al., 2007), MMTV-PyMT mice generally displays short tumour latency, with 
evidence of mammary hyperplasia detected by 4 weeks of age. Secondly, due to 
the high tumourigenicity of the PyMT oncogene, mammary tumours are shown 
with 100% penetrance and appear to arise in a multifocal way, affecting all ten 
murine mammary glands. Thirdly, albeit driven by a hormonally-regulated 
promoter, females do not require undergoing parity to increase expression of the 
oncogene. Last, but not least, it allows all stages of breast tumourigenesis to be 
studied, from the inception of lesions to dissemination of cancer cells to distant 
organs, due to the high incidence of metastatic disease (Lin et al., 2003). 
However, this conventional model is not without caveats. One of the first 
shortcomings refers to the fact that the tumourigenic signalling cascade driven 
by the PyMT oncogene does not necessarily mirror the one occurring in the 
human situation. In addition, the multifocal nature of PyMT-driven tumours 
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contrasts against the clonal features of human breast cancer. In addition, there 
is also uncertainty regarding the specific lineage wherein the not well-defined 
regulatory sequences of the MMTV promoter drive expression of the transgene 
(Holen et al., 2017). Lastly, being lungs the preferential site for PyMT-driven 
metastatic dissemination, this model does not fully mimic the pattern and 
seeding properties of human breast cancer metastasis, which also tend to occur 
in the liver and bones (Weigelt et al., 2005).  
In view of the requirement of multiple genetic events for the genesis of tumours 
(Hanahan et al., 2007), several putative cancer-associated genes have been 
investigated in the context of PyMT tumourigenesis. Following the elucidation of 
the genomic landscape of breast cancer, characterized by a few ‘mountains’ 
(frequently mutated genes) and many ‘hills’ (infrequently mutated genes) (Wood 
et al., 2007), attention has focused on the putative role played by infrequently 
mutated genes in the initiation, maintenance or progression of the disease. As 
RUNX1 was recently reported among the most significantly altered breast cancer 
genes (Banerjii et al., 2012; Cancer Genome Atlas, 2012; Ellis et al., 2012; Nik-
Zainal et al., 2016; Pereira et al., 2016), whose majority of identified mutations 
were believed to be loss-of-function (Li et al., 2003; van Bragt et al., 2014), 
investigation of the effect of Runx1 deletion in the context of PyMT 
tumourigenesis was undertaken. RUNX1 has a prominent role in the development 
of the haematopoietic system, wherein its function is required for the 
conversion of endothelial cells of the haemogenic endothelium into 
haematopoietic stem cells (HSCs) (Chen et al., 2009). RUNX transcription factors 
act in partnership with CBFβ to form a heterodimeric complex (Kamachi et al., 
1990). Within the latter, RUNX proteins bind directly to specific RUNX motifs 
scattered across the genome via their DNA binding domain (DBD), whereas CBFβ 
is responsible for increasing RUNXs’ affinity to the DNA (Ogawa et al., 1993) and 
protecting proteins from proteosomal degradation (Huang et al., 2001). Of note, 
the DBD was shown to be contained within the so-called Runt domain (RD), a 
128-amino acid region (aa 58-178) shared between the Drosophila segmentation 
Runt gene and the human AML1 gene and crucial for mediating genome binding 
and dimerization with CBFβ (Kagoshima et al., 1993; Meyers et al., 1993). In 
view of the latter, disruption of exon 4 of Runx1, encoding part of the DBD (aa 
143-178), was found to cause lethality of mice at E11.5-E12.5, due to a block in 
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definitive haematopoiesis and the presence of necrosis and haemorrhages in the 
central nervous system (Okuda et al., 1996; Wang et al., 1996).  
 
3.2 Experimental procedures 
3.2.1 Generation of a Runx1 conditional knock-out breast cancer 
mouse model  
In an attempt to overcome the embryonic lethal phenotype and study the 
function played by RUNX1 in the mammary gland, a conditional gene-targeting 
strategy based on the Cre-loxP technology was employed. This system relies on 
the function of the Cre recombinase enzyme, a bacteriophage P1-derived 
integrase able to catalyse a site specific recombination event between two DNA 
loxP recognition sites. As a result, whenever a portion of the genome is flanked 
by two loxP sites (floxed), this is efficiently excised in the presence of an active 
Cre recombinase (Hamilton and Abremski, 1984). Generation of a conditional 
knock-out Runx1 transgenic line (Runx1fl/fl) was achieved through the insertion of 
loxP-targeting sites flanking exon 4 of the murine gene (Growney et al., 2005). 
To achieve conditional deletion of Runx1 in the mammary epithelium, Runx1fl/fl 
mice were mated with MMTV-Cre mice. To then study the impact of Runx1 loss 
upon PyMT-driven tumourigenesis, MMTV-Cre;Runx1fl/fl mice were crossed with 
the MMTV-PyMT line. It has to be noted, however, that one of the caveats of the 
generated breast cancer MMTV-PyMT;MMTV-Cre;Runx1fl/fl cohort was the fact 
that PyMT-driven tumourigeneicity and Cre-driven recombination of Runx1 were 
ascribed to two separate transgenes inserted into the mouse genome. Therefore, 
albeit both guided by the hormonally-regulated MMTV promoter, these events 
could have occurred asynchronously and independently. In an effort to better 
trace MMTV-Cre expression, MMTV-PyMT;MMTV-Cre;Runx1fl/fl mice were crossed 
with a transgenic reporter line wherein the gene encoding for the tdRFP was 
preceded by a stop codon flanked by two loxP-sites (Luche et al., 2007). In this 
way, only in the presence of an active MMTV-Cre recombinase, recombination of 
the loxP-stop-loxP codon and visualization of RFP expression could be achieved. 
Finally, the MMTV-PyMT;MMTV-Cre;Runx1fl/fl;tdRFP line was backcrossed onto a 
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pure FVB background for up to ten generations to avoid the variability existing 
between mouse strains. 
 
3.3 Results 
3.3.1 Deletion of Runx1 accelerates PyMT-driven breast 
tumourigenesis without affecting overall survival  
To investigate if deletion of Runx1 impinged on PyMT-driven breast 
tumourigenesis, MMTV-PyMT;MMTV-Cre;tdRFP;Runx1fl/fl females were monitored 
for the formation of palpable mammary lesions. Once a lesion was noticed, its 
size was recorded and measured twice a week via the use of calipers. When a 
mammary tumour reached clinical end point, that is when its width or length 
equalled 15 mm or if the tumour ulcerated, the mouse was euthanized. By doing 
so, three parameters could be calculated: the time from birth to tumour notice, 
the time from tumour notice to clinical end point and the time from birthto 
clinical end point (Figure 3. 1A). Accordingly, deletion of one (Runx1wt/fl) or two 
copies (Runx1fl/fl) of Runx1 appeared to significantly accelerate the formation of 
palpable mammary lesions (54 and 48 average days, respectively), as compared 
to Runx1wt/wt control mice (64 average days) (Figure 3. 1B). This difference, 
however, was not reflected by any changes in overall survival, as both Runx1wt/fl 
and Runx1fl/fl mice were sacrificed at an average time of 91 and 87 days, 
respectively, which approached the 92 days displayed by Runx1wt/wt mice (Figure 
3. 1C). Nevertheless, when the timeframe from tumour notice to tumour end 
point was calculated, the growth of established PyMT-driven mammary tumours 
appeared lessened in the absence of Runx1. In fact, whilst Runx1wt/wt control 
mice showed an average tumour progression of 26 days, tumours from both the 
Runx1wt/fl and Runx1fl/fl cohorts reached clinical end point at an average time of 
37 and 33 days, respectively (Figure 3. 1D). In agreement with the recent NGS 
findings discussed in Chapter 1, these results provided for the first time a 
compelling evidence for a tumour suppressive function exerted by Runx1 in a 
breast cancer mouse model (Figure 3. 1B). In support of its remarkable function, 
the phenotype displayed by Runx1fl/fl mice was also found to be recapitulated by 
Runx1wt/fl mice, which only carried one copy of the recombined allele. Curiously, 
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however, whilst RUNX1 appears to halt the formation of palpable mammary 
lesions, deletion of Runx1 delayed the growth of established PyMT-driven 
tumours. In this regards, two main hypotheses are proposed. According to the 
first one, RUNX1 might display a dualistic role, acting as a tumour suppressor at 
early stages, whilst as a pro-oncogene at later stages of tumourigenesis. 
Alternatively, a compensatory tumour suppressive mechanism might take place 
in the absence of Runx1. In view of the high degree of homology existing 
between the Runx family of genes (Chuang et al., 2013), it is tempting to 
speculate that this role might be fulfilled by one of the other Runx family 
members. Importantly, it should be noted that survival analysis of MMTV-
Cre;MMTV-PyMT;tdRFP was carried out by plotting data obtained only from 
tdRFP+ mice, yet not from the negative ones. In this way, as expression of the 
tdRFP transgene might have affected the phenotype of mice, animals from 
different cohorts could be equally compared. Moreover, the presence of RFP 
positivity could have been used as a surrogate marker for MMTV-Cre expression, 
yet also to infer recombination of the Runx1 allele. Lastly, mice whose tumour’s 
size was greater than the 0.7 mm cut-off at date of notice were excluded from 
the time from birth to tumour notice parameter (Figure 3. 1B). Similarly, mice 
displaying cystic lesions, namely tumours which reached end point because full 
of liquid, were censored from the overall survival and tumour progression 
analysis. 
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Figure 3. 1 Deletion of Runx1 accelerates PyMT-driven breast tumourigenesis, yet it does not 
affect survival of the mice. 
(A) Schematic of the three parameters used to assess the impact of Runx1 deletion upon PyMT-
driven tumourigenesis. Cohort females were monitored for the development of palpable 
mammary tumours. Once a lesion was noticed, its size was recorded and measured twice a week 
with the use of calipers. When a mammary tumour reached clinical end point, the mouse was 
sacrificed. (B, C, D) Kaplan-Meier curves of MMTV-Cre;MMTV-PyMT;tdRFP mice of the Runx1wt/wt, 
Runx1wt/fl and Runx1fl/fl cohorts. (B) Time from birth to tumour notice of Runx1wt/wt (n=20), 
Runx1wt/fl (n=7) and Runx1fl/fl (n=18) mice. (C) Time from birth to end point of Runx1wt/wt (n=20), 
Runx1wt/fl (n=6), Runx1fl/fl (n=19) mice. (D) Time from tumour notice to end point of Runx1wt/wt 
(n=20), Runx1wt/fl (n=6), Runx1fl/fl (n=18) mice. Statistical analysis performed using the Log-rank 
(Mantel-Cox) test in GraphPad Prism. **P<0.01, ***P<0.001, ****P<0.0001. 
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3.3.2 Deletion of one or two copies of Runx1 does not affect 
tumour burden of MMTV-PyMT mice 
When all cohorts of MMTV-PyMT;MMTV-Cre;tdRFP mice reached clinical end 
point, the body weight and the total weight of all tumour-bearing and non-
tumour bearing mammary glands were recorded. The combination of these two 
measures was then used to calculate the tumour burden displayed by each 
mouse cohort. In doing so, no significant differences emerged in relation to both 
body weight (Figure 3. 2A), nor tumour burden (Figure 3. 2B) among the 
Runx1wt/wt, Runx1wt/fl and Runx1fl/fl cohorts. In other words, the accelerated 
appearance of palpable mammary lesions shown in the absence of Runx1 did not 
translate into increased tumour burden or number of tumour burdened 
mammary glands displayed by Runx1wt/fl and Runx1fl/fl mice as compared to 
controls (data not shown). If at a glance counterintuitive, this result further 
corroborated the delayed tumour progression displayed by established PyMT 
mammary tumour upon Runx1 loss. On the other hand, the absence of significant 
differences in relation to tumour burden could be related to the intrinsic nature 
of the MMTV-PyMT;MMTV-Cre;tdRFP;Runx1fl/fl model. Indeed, considering the 
presence of two independent transgenes (the MMTV-PyMT and the MMTV-Cre), 
the possibility of escaping Runx1-proficient tumours in the Runx1fl/fl cohort of 
mice could be envisioned.  
Representative pictures of the gross pathological changes characterizing clinical 
end point MMTV-PyMT;MMTV-Cre;tdRFP mice from the Runx1wt/wt, Runx1wt/fl and 
Runx1fl/fl cohorts are shown in Figure 3. 2C. Note the high tumourigenic 
potential of the PyMT oncogene, capable of transforming the mammary 
epithelium of almost all ten murine mammary glands. 
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Figure 3. 2 Deletion of one or two copies of Runx1 does not affect tumour burden of MMTV-
PyMT mice. 
Scatter dot plots of body weight (A), tumour burden (B) and representative pictures (C) from 
clinical end point MMTV-PyMT;MMTV-Cre;tdRFP mice of the Runx1wt/wt (n=20), Runx1wt/fl  (n=6) 
and Runx1fl/fl (n=19) groups. Cohort females were monitored for the development of palpable 
mammary lesions. Once a tumour lesion was noticed, its size was recorded and measured twice a 
week with the use of calipers. When a mammary tumour reached clinical end point, the mouse 
was sacrificed and both its body weight and tumour burden were recorded. Statistical analysis 
was performed by the Kruskal-Wallis nonparametric test with Dunn’s multiple comparisons in 
GraphPad Prism. Error bars represent mean with SD (n≥6 per each cohort). For each parameter, 
no significance was found among cohorts. 
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3.3.3 RFP imaging analysis of clinical end point MMTV-PyMT mice  
In view of the caveats displayed by the MMTV-PyMT;MMTV-Cre;tdRFP model, to 
better monitor the expression and recombination activity of the MMTV-Cre 
enzyme across all Runx1 cohorts of mice, RFP imaging was performed. To this 
end, clinical end point mice from the Runx1wt/wt, Runx1wt/fl and Runx1fl/fl groups 
were euthanized and imaged for RFP fluorescence via the IVIS Spectrum imaging 
system. By doing so, imaging analysis of the Runx1wt/wt cohort showed a 
remarkable amount of RFP positivity across specimens, with exception of only a 
few negative mice (1/9) (Figure 3. 3). Furthermore, due to the multifocal nature 
of the PyMT-oncogene, expression of RFP could be observed among the majority 
of murine mammary glands. Therefore, despite the intrinsic pitfalls of the 
model, these results suggested that PyMT-driven breast tumourigenesis and 
activity of the MMTV-Cre were likely occurring in the same targeted cell.  
A slightly different scenario applied instead to the Runx1fl/fl cohort of mice, 
wherein a higher degree of variability in RFP signal was observed (Figure 3. 4). 
As such, whilst some mice exhibited comparable levels of RFP positivity to the 
Runx1wt/wt cohort, a higher percentage of animals appeared to be completely 
negative (5/14). These results could be explained by lack of activity of the 
MMTV-Cre recombinase or by loss of Runx1-deleted (RFP+) cells during PyMT-
driven breast tumourigenesis.  
When RFP imaging analysis of the Runx1wt/fl cohort of mice was performed, mice 
displayed a pattern of RFP expression similar to the Runx1wt/wt control group, 
rather than to the Runx1fl/fl one (Figure 3. 5). It should be noted, however, that 
this latter cohort of mice was composed of the lowest number of animals.  
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Figure 3. 3 Imaging analysis of the RFP reporter gene in Runx1-proficient MMTV-PyMT mice. 
Representative snapshots of clinical end point MMTV-PyMT;MMTV-Cre;tdRFP;Runx1wt/wt mice 
(n=9) showing expression of the RFP reporter gene as detected via the IVIS Spectrum in vivo 
imaging system. Mice were euthanized, placed on a black cardboard and imaged for RFP 
fluorescence. Animals were illuminated via the 554 nm excitation filter, whereas fluorescence 
was detected with the 581 nm emission filter. Images were captured with an Auto exposure time 
using the small binning and F/Stop 2 settings. RFP, red fluorescent protein. 
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Figure 3. 4 Imaging analysis of the RFP reporter gene in Runx1-deficient MMTV-PyMT mice. 
Representative snapshots of clinical end point MMTV-PyMT;MMTV-Cre;tdRFP;Runx1fl/fl mice 
(n=14) showing expression of the RFP reporter gene as detected via the IVIS Spectrum in vivo 
imaging system. Mice were euthanized, placed on a black cardboard and imaged for RFP 
fluorescence. Animals were illuminated via the 554 nm excitation filter, whereas fluorescence 
was detected with the 581 nm emission filter. Images were captured with an Auto exposure time 
using the small binning and F/Stop 2 settings. RFP, red fluorescent protein. 
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Figure 3. 5 Imaging analysis of the RFP reporter gene in MMTV-PyMT mice carrying only one 
deleted copy of the Runx1 gene. 
Representative snapshots of clinical end point MMTV-PyMT;MMTV-Cre;tdRFP;Runx1wt/fl mice 
(n=5) showing expression of the RFP reporter gene as detected via the IVIS Spectrum in vivo 
imaging system. Mice were euthanized, placed on a black cardboard and imaged for RFP 
fluorescence. Animals were illuminated via the 554 nm excitation filter, whereas fluorescence 
was detected with the 581 nm emission filter. Images were captured with an Auto exposure time 
using the small binning and F/Stop 2 settings. RFP, red fluorescent protein. 
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3.3.4 Ex vivo characterization of MMTV-PyMT derived mammary 
epithelial cells through the use of the RFP reporter gene 
Considering the higher percentage of RFP- animals detected in the Runx1fl/fl 
group of mice in respect to the Runx1wt/wt control one (33% versus 11%), ex vivo 
characterization of the properties of RFP+ and RFP- cells was next performed. 
The presence of RFP positivity could in fact be used not only as a surrogate 
measure of MMTV-Cre expression, yet also to infer the extent of Cre 
recombinase activity over recombination of the Runx1fl/fl allele. To this end, 
clinical end point mice from the Runx1fl/fl cohort of MMTV-PyMT;MMTV-
Cre;tdRFP animals were euthanized and all tumour-bearing and non-tumour 
bearing mammary glands harvested (Figure 3. 6). Through mechanical 
dissociation of the organs via the use of a tissue chopper and enzymatic 
digestion of chopped tissues at 37°C in the presence of collagenase and 
hyaluronidase, a fine mammary tissue paste was collected. Following a series of 
washes to remove all cell debris and the majority of non-epithelial cells, 
digested mammary tissue was subjected to red blood cell lysis. After two 
sequential steps of trypsinization and filtration, a single-cell suspension was 
finally obtained. At this stage, the cell mixture was labelled with a live/dead 
marker (DAPI) and run through the fluorescence activated cell sorting (FACS) in 
order to separately collect live (DAPI-) RFP- and RFP+ MMECs. In an attempt to 
validate the activity of the MMTV-Cre recombinase and assess transcript levels of 
Runx1 by qPCR, RNA was extracted from both RFP- and RFP+ groups. In addition, 
the levels of Runx2 transcripts were also evaluated in order to investigate the 
presence of putative compensatory mechanisms between the two Runx genes. In 
view of the reduction of RFP+ cells observed in the Runx1fl/fl cohort of MMTV-
PyMT;MMTV-Cre;tdRFP mice, it was hypothesized that deletion of Runx1 could 
impinge on the survival and/or tumourigenic potential of PyMT cells. To test this 
hypothesis, RFP- and RFP+ sorted cells were challenged through the 
tumoursphere assay by plating 10,000 live cells per well in low-adherent plates 
in the presence of growth factors. Whilst differentiated cells undergo anoikis 
(Frisch et al., 1994), cells with stem/progenitor characteristic are believed to 
survive and form spheres in suspension (Dontu et al., 2003). After a week, the 
number of tumourspheres per well was manually counted and collected for RNA 
and qPCR purposes (Figure 3. 6). 
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Figure 3. 6 Pipeline for the extraction and ex vivo characterization of RFP+ and RFP- MMECs 
from MMTV-PyMT mice. 
Workflow of the nine steps required to extract and characterize the properties of RFP+ and RFP- 
MMECs extracted from MMTV-PyMT;MMTV-Cre;tdRFP;Runx1fl/fl and Runx1wt/wt mice. Clinical end 
point mice are euthanized and (1) all five pairs of tumour-bearing and nontumour-bearing 
mammary glands are collected and (2) placed in a 50 ml tube with PBS. (3) Mammary glands are 
mechanically disrupted via a tissue chopper and (4) enzymatically digested at 37°C for 1 hour 
and a half in the presence of collagenese and hyaluronidase. (5) Digested tissue is treated with 
NHCl4 for 5 minutes at room temperature to lyse red blood cells. (6) Lysate is trypsinized for 10 
minutes at 37°C and filtered through 70 µm pores. (7) A single cell suspension enriched in MMECs 
is run through FACS in order to separate live RFP+ and RFP- cells. (8) Sorted RFP+ and RFP- 
MMECs are utilized for RNA extraction purposes and/or plated at a density of 10,000 live cells 
per well using low-adherent plates in the presence of EGF and FGF2 (tumourshere assay). After a 
week, the number of tumourspheres per well is manually counted and (9) spheres from all 12 
technical replicates are collected for RNA extraction purposes. Asterisks indicate that RNA 
extraction was not always possible due to low amount of sorted MMECs or tumourspheres. FACS, 
fluorescence-activated cell sorting; MMEC, mouse mammary epithelial cell; RFP, red fluorescent 
protein. 
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Following extraction of MMECs from the Runx1fl/fl cohort of MMTV-PyMT;MMTV-
Cre;tdRFP mice, decreased levels of Runx1 expression were displayed by RFP+ 
cells as compared to RFP- ones in three independent experiments (Figure 3. 7A). 
These results confirmed the presence of an active MMTV-Cre, able to recombine 
both tdRFP and Runx1fl/fl alleles. Of note, a similar pattern of expression could 
also be observed for Runx2, with exception of sample #3 where no difference 
was found between groups (Figure 3. 7B). When the tumourigenic ability of RFP- 
and RFP+ cells was tested in seven independent experiments, five of them 
showed a significant reduction of tumoursphere formation in the RFP+ group. No 
significant difference was instead observed in samples #3 and #4 (Figure 3. 7C). 
In addition, RFP+ derived tumourspheres generally appeared to be smaller in size 
than the negative counterpart (Figure 3. 7D). Altogether, these results suggested 
that deletion of Runx1 was able to decrease the tumourigenic and proliferative 
ability of PyMT cells. In line with the latter, sample #3 was the only one to 
display the smallest fold change difference of Runx1 levels between the RFP- 
and the RFP+ groups. Interestingly, however, following RNA extraction of RFP- 
and RFP+ derived tumourspheres, a modest increase in Runx1 levels was 
detected in the RFP+ cells of all four samples tested (Figure 3. 7E). As MMTV-
Cre-mediated deletion of the Runx1fl/fl allele was not 100% efficient, this result 
was indicative of a survival advantage shown by the few Runx1-proficient cells 
present in the original mixture. Preliminary qPCR analysis of Runx2 resembled 
the levels of expression displayed by extracted MMECs, at least for the two 
samples tested (Figure 3. 7F). This data indicated not only that Runx2 expression 
remained unchanged during growth of MMECs in suspension, but more 
importantly that no compensatory mechanism occurred upon deletion of Runx1.  
To assess if expression of the tdRFP transgene could impinge upon the molecular 
and functional properties of MMECs, the same experiments were performed by 
extracting cells from the Runx1wt/wt cohort of MMTV-PyMT;MMTV-Cre;tdRFP 
mice. In doing so, a high degree of variability was found among mice in relation 
to expression of both Runx1 and Runx2 genes. As such, whilst two independent 
experiments showed comparable Runx1 levels, RFP+ cells of sample #2 displayed 
an increased Runx1 expression as compared to the negative control (Figure 3. 
8A). Similarly, a modest increase in Runx2 levels was reported by RFP+ cells of 
samples #2 and 3, whereas no change was observed in specimen #4 (Figure 3. 
                                                                                                                    115 
 
8B). Some inconsistencies were also noticed when RFP- and RFP+ Runx1wt/wt cells 
were challenged in a tumoursphere assay. In fact, whilst an equal tumourigenic 
potential between RFP+ and RFP- MMECs could be observed in samples #1 and 
#3, a significantly lower or higher number of tumourspheres was reported by 
RFP+ cells of specimens #2 and #4 (Figure 3. 8C). No difference, however, was 
observed when the size of RFP- and RFP+ derived tumourspheres was compared 
across all four independent experiments (Figure 3. 8D). Lastly, qPCR analysis of 
Runx1 levels showed no major changes between the two RFP groups in the three 
samples tested (Figure 3. 8E). A modest reduction of Runx2 levels was instead 
displayed by RFP+ derived spheres from all three independent experiments 
(Figure 3. 8F). Thus, before drawing any conclusions about the impact the tdRFP 
transgene might have on the functional and molecular features of MMECs, more 
experiments will need to be performed. This might in turn help to reduce the 
level of “noise” and allow a better interpretation of the decreased tumourigenic 
potential displayed by PyMT cells upon loss of Runx1. 
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Figure 3. 7 Characterization of RFP+ and RFP- cells from Runx1-deficient MMTV-PyMT mice. 
Bar charts of Runx1 (A) and Runx2 (B) transcript levels and tumoursphere assay (C) of RFP- and 
RFP+ MMECs extracted from MMTV-PyMT;MMTV-Cre;tdRFP;Runx1fl/fl mice. (D) Representative 
pictures of RFP-negative and RFP-positive-derived tumourspheres. One image of n=12 is shown 
per group. Pictures were taken with the 4x objective lens of the Olympus CKX41 microscope. Bar 
charts of Runx1 (E) and Runx2 (F) transcript levels of RFP- and RFP+ tumourspheres. Clinical end 
point mice were euthanized, all their mammary glands harvested, digested and sorted for RFP 
expression. RFP- and RFP+ cells were either used for qPCR analysis or plated in suspension in the 
presence of growth factors (tumoursphere assay) to test their tumourigenic potential. After a 
week, the number of tumourspheres per well was manually calculated. Tumourspheres from all 
12 technical replicates were then collected in order to extract RNA for qPCR purposes. Runx1 
and Runx2 mRNA levels are relative to the Gapdh reference gene. The number displayed below 
each graph indicates independent experiments performed by harvesting the mammary glands 
from individual mice. MMECs, mouse mammary epithelial cell; qPCR, quantitative polymerase 
chain reaction; RFP, red fluorescent protein. 
                                                                                                                    117 
 
 
 
Figure 3. 8 Characterization of RFP+ and RFP- cells from Runx1-proficient MMTV-PyMT mice. 
Bar charts of Runx1 (A) and Runx2 (B) transcript levels and tumoursphere assay (C) of RFP- and 
RFP+ MMECs extracted from MMTV-PyMT;MMTV-Cre;tdRFP;Runx1wt/wt mice. (D) Representative 
images of RFP-negative and RFP-positive-derived tumourspheres. One image of n=12 is shown per 
group. Pictures were taken with the 4x objective lens of the Olympus CKX41 microscope. Bar 
charts of Runx1 (E) and Runx2 (F) transcript levels of RFP- and RFP+ tumourspheres. Clinical end 
point mice were euthanized, all their mammary glands harvested, digested and sorted for RFP 
expression. RFP- and RFP+ cells were either used for qPCR analysis or plated in suspension in the 
presence of growth factors (tumoursphere assay) to test their tumourigenic potential. After a 
week, the number of tumourspheres per well was manually calculated. Tumourspheres from all 
12 technical replicates were then collected in order to extract RNA for qPCR purposes. Runx1 
and Runx2 mRNA levels are relative to the Gapdh reference gene. The number displayed below 
each graph indicates independent experiments performed by harvesting the mammary glands 
from individual mice. MMECs, mouse mammary epithelial cell; qPCR, quantitative polymerase 
chain reaction; RFP, red fluorescent protein. 
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3.3.5 Histopathological analysis of PyMT mammary tumour lesions  
In view of the delayed tumour progression observed in the Runx1fl/fl cohort of 
mice, it remained to be addressed if deletion of Runx1 could interfere with the 
well-described histopathology characterizing the MMTV-PyMT breast cancer 
mouse model. To this end, clinical end point mammary tumours from the 
Runx1wt/wt and Runx1fl/fl cohorts of MMTV-PyMT;MMTV-Cre;tdRFP mice were 
formalin-fixed paraffin-embedded in order to be analysed by H&E and IHC. Upon 
H&E examination, mammary glands from Runx1wt/wt mice displayed the 
characteristic pattern of PyMT breast tumourigenesis, shown to resemble the 
multi-stage progression of human breast cancer (Lin et al., 2003). Indeed, 
besides the remaining presence of a few non-transformed mammary ducts 
(Figure 3. 9A), the first sign of PyMT transformation could be recognized by 
hyperplasia, whereby densely packed lobules started protruding from normal 
ducts (Figure 3. 9B). Hyperplastic lesions were then followed by the formation of 
adenomas, defined as masses of benign tumours characterized by the 
disappearance of lumen and the appearance of solid sheets of relatively uniform 
epithelial cells. If in the initial phase of malignant transformation (early 
carcinomas), greater cytological atypia with increased nuclear pleomorphism 
could be observed (Figure 3. 9C), at later stages tumours were mainly composed 
of solid sheets of transformed epithelial cells (Figure 3. 9D). When Runx1wt/wt 
mammary tumours were analysed for Ki67, a nuclear marker of cell proliferation 
(Gerdes et al., 1983), very few positive cells could be visible in the remaining 
normal ducts (Figure 3. 9E). On the contrary, a high mitotic index was found to 
correlate with all stages of PyMT-driven tumourigenesis (Figure 3. 9F, G, H). In 
line with the well-characterized mosaicism displayed by the MMTV-Cre 
(Andrececk et al., 2000), RFP staining of Runx1wt/wt mammary tumours was found 
to be scattered over a few MMECs present in normal ducts (Figure 3. 10A). 
Consequently, a patchy pattern of RFP expression was exhibited at all stages of 
PyMT tumourigenesis, wherein fully positive lobules were found to be adjacent 
to completely negative ones (Figure 3. 10B, C, D). Interestingly, however, a 
different scenario held true for RUNX1 expression. In line with high levels of 
transcripts reported in virgin mammary glands (Blyth et al., 2010), RUNX1 
protein expression was observed in the remaining normal mammary ducts (Figure 
3. 10E). Whilst this pattern appeared to be maintained during mammary 
                                                                                                                    119 
 
hyperplasia (Figure 3. 10F), no staining could be detected in adenomas (Figure 3. 
10G) nor late carcinomas (Figure 3. 10H) of Runx1wt/wt mice. Collectively, these 
data further corroborated a tumour suppressive function exerted by RUNX1, 
present in normal mammary glands, yet absent in incipient and established PyMT 
tumours. This was supported not only by the expected absence of RUNX1 
positivity in RFP+ tumours, yet also by its lack of expression in RFP- ones. When 
the same analysis was applied to the Runx1fl/fl cohort of MMTV-PyMT;MMTV-
Cre;tdRFP mice, no major differences emerged in terms of histopathology nor 
mitotic index of mammary tumours. A degree of variability was instead found in 
regards to RUNX1. As such, whilst some mice showed detectable RUNX1 
expression in normal mammary glands, as well as in hyperplastic and late 
carcinoma lesions (Figure 3. 11A, B), in some others these were found to be 
completely negative (Figure 3. 11E, F). This variability could be ascribed to 
differential levels of MMTV-Cre expression and/or activity between mice. 
Regardless, no RUNX1 expression could be observed in adenomas or late 
carcinomas (Figure 3. 11C, D, G, H), in line with the pattern showed by 
Runx1wt/wt mice. Lastly, in view of the high degree of homology existing among 
the Runx genes and the possibility to compensate for each other, IHC analysis for 
RUNX2 was also performed. Differently from RUNX1, RUNX2 expression in normal 
mammary ducts of Runx1wt/wt mice appeared to be very faint in the epithelium, 
yet more abundant in the stroma (Figure 3. 12A). Whilst some epithelial 
expression was observed at the adenoma/early carcinoma stage (Figure 3. 12C), 
RUNX2 was observed in the stroma of late stage PyMT tumours (Figure 3. 12D). 
When mammary tumours from the Runx1fl/fl cohort of mice were analysed, 
RUNX2 expression was also found to be located in the surrounding stroma of 
normal ducts (Figure 3. 12E). Yet, this time, expression appeared to be stronger 
in intensity than in Runx1wt/wt mice. Moreover, whilst hyperplastic lesions of 
Runx1wt/wt mice showed no RUNX2 staining (Figure 3. 12B), the gene now 
appeared to be expressed in the hyperplastic epithelium of Runx1fl/fl mice 
(Figure 3. 12F). Finally, positivity for RUNX2 was shown in both the epithelium 
and stroma of adenoma and late carcinoma tumours (Figure 3. 12G). Based on 
the above and in view of the delayed tumour progression of Runx1fl/fl mice, it is 
tempting to speculate a compensatory tumour suppressive role played by RUNX2, 
able to halt progression of PyMT-driven tumour lesions in the absence of Runx1. 
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Figure 3. 9 H&Es and Ki67 protein expression analysis of MMTV-PyMT mammary tumours. 
Representative images of H&E (A, B, C, D) and Ki67 stainings (E, F, G, H) of mammary tumours 
from the MMTV-PyMT;MMTV-Cre;tdRFP;Runx1wt/wt cohort of mice. One representative image of 
n=3 is shown. Scale bar, 500 µm. The different stages of PyMT-driven breast tumourigenesis are 
depicted on the left. H&E, haematoxylin eosin. 
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Figure 3. 10 RFP and RUNX1 expression analysis of MMTV-PyMT mammary tumours. 
Representative IHC images of RFP (A, B, C, D) and RUNX1 (E, F, G, H) staining of mammary 
tumours from the MMTV-PyMT;MMTV-Cre;tdRFP;Runx1wt/wt cohort of mice. One representative 
image of n=3 is shown. Scale bar, 500 µm. The different stages of PyMT-driven breast 
tumourigenesis are depicted on the left. Arrows indicate the location of RUNX1 positive cells in 
normal mammary ducts and hyperplastic lesions. IHC, immunohistochemistry. 
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Figure 3. 11 RUNX1 expression analysis of Runx1-deficient MMTV-PyMT mice. 
Representative IHC images of RUNX1 expression shown by mammary tumour from two 
independent (#1 and #2) mice of the MMTV-PyMT;MMTV-Cre;tdRFP;Runx1fl/fl cohort. One 
representative image of n=3 is shown. Scale bar, 500 µm. The different stages of PyMT 
tumourigenesis are depicted on the left. Arrows indicate RUNX1 positive cells in normal and 
hyperplastic ducts. IHC, immunohistochemistry. 
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Figure 3. 12 RUNX2 expression analysis of MMTV-PyMT in the presence or absence of Runx1. 
Representative IHC images of RUNX2 expression shown by mammary tumour from the MMTV-
PyMT;MMTV-Cre;tdRFP;Runx1wt/wt (A, B, C, D) and Runx1fl/fl cohort (E, F, G, H). One 
representative image of n=3 is shown per cohort at each stage. Scale bar, 500 µm. The different 
stages of PyMT tumourigenesis are depicted on the left. Arrows indicate RUNX2 positive cells. 
IHC, immunohistochemistry. 
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3.4 Discussion 
Following the characterization of the genomic landscape of human breast 
cancer, the focus of research attention recently moved onto the putative role 
played by infrequently mutated genes. Interestingly, RUNX1 was found to be one 
of them (Riggio and Blyth, 2017), with somatic mutations reported in biopsies of 
breast cancer patients and predicted to cause loss-of-function of the protein. 
Due to its widespread use, high penetrance and short tumour latency, the MMTV-
PyMT breast cancer GEMM was exploited in the attempt to investigate the 
function played by RUNX1 in the initiation, maintenance and progression of 
breast cancer. As both homozygous and heterozygous deletion of the gene 
caused a significant acceleration of PyMT-driven palpable tumours formation, 
Runx1 was ascribed as a tumour suppressor gene. Surprisingly, however, this 
acceleration did not result in decreased overall survival of the mice, as growth 
of established PyMT tumour lesions appeared halted in the absence of the gene. 
In view of the latter, two possible scenarios could be envisioned. Firstly, RUNX1 
could exert a chameleon-like role, acting as a tumour suppressor at early stages 
and an oncogene at later stages of the disease. Alternatively, compensatory 
mechanisms, perhaps exerted by Runx2, might take place in the absence of 
Runx1. To test the first hypothesis, an inducible model could be exploited in 
order to either overexpress or delete Runx1 in established PyMT-driven tumours. 
If RUNX1 is an oncogene at later stages of tumourigenesis, then its 
overexpression should further accelerate the growth of PyMT mammary lesions, 
whereas its deletion would delay their progression. To test the second 
hypothesis, combined deletion of Runx1 and Runx2 would need to be performed. 
If RUNX2 acted as a tumour suppressor, then its deletion should accelerate the 
formation of palpable lesions, as well as fostering the growth of established ones 
on a Runx1-null background. Consequently, this should result in decreased 
overall survival of Runx1- and Runx2-deficient mice as compared to controls.Of 
note, the possibility of Runx2-independent compensatory mechanisms should 
also be taken into account. To this end, being RUNX1 a potent activator and 
repressor of gene transcription, a molecular analysis of Runx1 downstream 
targets might help unveil the causative players of the delayed growth showed by 
Runx1-deficient PyMT mammary tumours.  
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In line with a tumour suppressive function exerted by RUNX1 were also the 
observations gathered from IHC analysis of MMTV-PyMT mammary tumours. 
According to the well-characterized histopathology displayed by this model, four 
different stages of PyMT-driven tumourigenesis could be discerned: hyperplasia, 
adenomas, early carcinomas and late carcinomas (Lin et al., 2003). In addition 
to the latter, the presence of a few non-transformed mammary ducts could also 
be observed. In this regard, RUNX1 levels appeared to be restricted exclusively 
to normal mammary ducts and hyperplastic lesions of MMTV-PyMT mice, whereas 
no staining was seen in adenomas or early and late carcinomas. Interestingly, 
this pattern of expression did not seem to correlate with RFP positivity, not only 
because established PyMT lesions displayed a patchy pattern of RFP expression, 
but also because RFP- PyMT tumours showed lack of RUNX1 levels. In view of 
above, the decreased tumourigenic potential displayed by Runx1-deleted RFP+ 
cells should perhaps be better ascribed to the function exerted by the gene 
during the very early stages of PyMT-driven oncogenic transformation of normal 
epithelium. Collectively, these results suggested the ability of PyMT incipient 
mammary lesions to originate in RUNX1 negative cells or to downregulate 
transcription of the Runx1 gene during oncogenic transformation of the 
mammary epithelium.  
In line with the latter, RUNX1 mRNA downregulation was reported within a 17-
gene signature linked to breast cancer metastasis (Ramaswamy et al., 2003). In 
addition, RUNX1 protein expression appeared decreased in high-grade breast 
cancers versus low/mid-grade tumours (Kadota et al., 2010). Consistent with its 
ability to act as a positive regulator of E-cadherin (Liu et al., 2005), these 
observations might suggest the need of late-stage/aggressive tumours to down-
regulate RUNX1 expression in order to metastasize. If this hypothesis holds true, 
then loss of Runx1 should result in increased metastatic burden of MMTV-PyMT 
mice. Albeit macroscopic examination of lungs of Runx1fl/fl mice did not show 
signs of gross metastasis, serial H&Es of the same organ will next be assessed to 
evaluate the presence of micro-lesions and compare them with the Runx1wt/wt 
cohort of MMTV-PyMT;MMTV-Cre mice.  
Interestingly, opposite conclusions were observed by Browne et al. (2015), who 
proposed an oncogenic role played by Runx1, due to the concomitant increase of 
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RUNX1 expression along with PyMT tumourigenesis. In support of the latter were 
also complementary in vitro studies with Runx1 knock-down resulting in reduced 
migratory and invasive ability of cells. Of note, these discrepancies might arise 
to the use of different RUNX1 antibodies which, in the case of Browne et al. 
(2015), showed high level of stromal expression and elevated levels of 
background, indicating some degree of non specificity.  
Following the intrinsic molecular classification of human breast cancer (see 
Chapter 1), several gene expression based studies have been carried out in the 
attempt to compare the molecular profile of different breast cancer GEMMs 
against the five intrinsic subtypes of the human disease (Perou et al., 2000; 
Sorlie et al., 2001). Accordingly, some GEMMs were shown to develop more 
homogeneous tumours with consistent expression patterns, while some others 
were found to be characterized by a higher degree of heterogeneity, in terms of 
expression and histopathological phenotypes. Based on one of these studies 
(Herschkowitz et al., 2007), GEMMs were clustered into 10 intrinsic groups, 
including one normal mammary gland group and nine tumour groups, further 
encompassed within four main categories: normal mammary gland samples and 
mesenchymal tumours; basal/MYO tumours; luminal tumours; and tumours with 
mixed characteristics. In this regards, the MMTV-PyMT was among “the 
homogeneous models” and appeared to fall within the third category of luminal 
tumours, displaying high levels of CK8/18, as well as Occludin and Tight junction 
protein 2 and 3. Nonetheless, a level of discrepancy was found to exist between 
the mouse and human “luminal tumour” profiles. Besides expressing high levels 
of CK8/18 and GATA3 luminal markers, many of the genes found in the human 
setting, first and foremost ESTR-1, were not observed in murine tumours. Due to 
the seminal role played by hormone signalling in controlling the transcriptional 
profiles of the mammary gland, both ER-negativity and the lack of ER-regulated 
genes (e.g. PR) were proposed to account for the majority of inconsistencies 
between the two species (Herschkowitz et al., 2007).  
An intriguing link between PyMT mammary tumourigenesis and hormone 
signalling was already reported in ovariectomized mice, which showed decreased 
PyV-induced tumour burden as compared to controls (Berebbi et al., 1990). This 
phenotype, however, appeared to stem from an E2-dependency displayed by 
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incipient PyMT mammary lesions, yet not by more advanced tumours. These 
results suggested that, whilst the initial stages of PyMT-driven oncogenic 
transformation of the mammary epithelium relies on hormonal cues, progression 
of established tumours is independent of the latter. This observation was later 
confirmed by expression analysis of ERα and PR, which appeared increased in 
early stages, whilst decreased in the late stages of PyMT tumourigenesis (Lin et 
al., 2003). In view of the previously discussed tumour-suppressive role exerted 
by RUNX1 in ER+ cells (see introduction), these findings might hold the key for 
the accelerated tumourigenesis, yet delayed tumour progression of MMTV-PyMT 
mice upon Runx1 loss. 
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4 Investigating the role of Runx1 and Runx2 in a 
Wnt/β-catenin mouse model of breast cancer 
 
4.1 Introduction 
4.1.1 Canonical Wnt/β-catenin signalling 
The Wnt signalling pathway dates back to the discovery of the segment polarity 
gene Wingless in Drosophila and its homolog Int-1 in mice (Rijsewijk et al., 
1987). According to the traditional model, canonical Wnt signalling is initiated 
when Wnt ligands bind to their cognate receptor complex, composed of a 
member of the Frizzled family of genes encoding for seven-pass transmembrane 
receptors (Yang-Snyder et al., 1996) and a member of the low-density 
lipoprotein-related proteins (LPR) 5/6 (Dieckmann et al., 2010). Thus far, almost 
16 Wnt ligands and 11 Frizzled receptors have been identified in vertebrates, 
although the function of some of them still remains elusive (Wodarz and Nusse, 
1998; Polakis, 2000). The main player of canonical Wnt signalling is represented 
by β-catenin, a pleiotropic protein which exerts several functions within the 
cell. One of the first one to be described refers to its role as a cell-cell adhesion 
molecule, whereby β-catenin favours cytoskeleton-membrane interactions 
through binding of E-cadherin and α-catenin (Cowin and Burke, 1996). 
Additionally, β-catenin behaves as a signal transduction molecule in the nucleus, 
wherein it regulates gene expression programs essential for mammary gland 
biology as well as cancer (Gumbiner, 1995). Due to the latter, β-catenin 
cytoplasmic levels within the cells are tightly regulated by a multiprotein 
destruction complex wherein the adenomatous polyposis coli (APC) and Axin 
serve as scaffolds. In the absence of Wnt ligands, two kinases present within the 
complex, i.e. casein kinase 1 and glycogen synthase kinase 3β (GSK3β), act in a 
sequential manner to phosphorylate key serine and threonine residues located in 
the amino terminus of bound β-catenin. This represents a footprint which marks 
β-catenin for ubiquitination and proteosomal degradation (Incassati et al., 
2010). The arrival of secreted Wnt ligands and engagement with membrane 
receptor complex prevents these events through a series of mechanisms which 
                                                                                                                    129 
 
are still not fully understood. This leads to phosphorylation of Disheveled, which 
associates with Axin to inhibit GSKβ3 function (Kishida et al., 1999). Thus, 
unphosphorylated β-catenin can accumulate in the cytoplasm and translocate to 
the nucleus, wherein it forms a bipartite transcription factor complex together 
with the T-cell factor (TCF)/lymphoid enhancer factor (LEF) (Eastman et al., 
1999). Whilst in the absence of ligands TCF/LEF DNA binding proteins act as 
transcriptional co-repressor through binding with members of the 
Groucho/transducing-like Enhancer of split family (Chen et al., 2000), these are 
displaced upon β-catenin arrival resulting in a transient, yet potent, activation 
of gene transcription (Daniels and Weis, 2005). Recently, two additional 
Drosophila genes, which appear to be conserved in vertebrates, have been found 
to take part in the β-catenin transcriptional complex. These are Pygo 2/Pygopus 
homolog 2, required for the activation of TCF/LEF proteins, and legless/B-cell 
lymphoma 9, acting as a bridge between Pygopus homolog 2 and TCF-bound β-
catenin (Reya and Clevers, 2005). Despite the majority of β-catenin downstream 
targets being obscure, among the most common mammalian transcriptional 
candidates are Myc and Cyclin D1, whose levels appear to be intimately linked to 
activation or reduction of the pathway (Lin et al., 2000). Finally, albeit other 
effector proteins were found to mediate noncanonical Wnt signalling pathway, 
the latter plays a seminal role as a potent antagonist of β-catenin through action 
of Wnt5 and TGFβ. Equally, cumulative evidence suggests that β-catenin 
stabilization can occur via Wnt-independent routes, including the PTEN/Akt and 
the NF-kB pathways (Incassati et al., 2010). 
4.1.2 Wnt signalling, mammary stemness and the Runx genes 
The causative link between Wnt signalling and breast cancer traces back to the 
discovery of Wnt1, Wnt3 and Wnt10a, as preferential sites for MMTV insertion. 
Revealed as potent proto-oncogenes, aberrant expression of these ligands was 
shown to cause transformation of human primary epithelial cells and induction 
of mammary tumours (Nusse and Varmua, 1982; Roelink et al., 1990). One of the 
main reasons behind this phenotype relates to the crucial regulation exerted by 
Wnt signalling upon MaSC self-renewal and multipotency (Zeng et al., 2010). In 
line with the latter, this pathway was found to be essential for the specification 
and morphogenesis of the mammary gland (Cowin and Wysolmerski, 2010), being 
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detected in both the mammary lines and subsequently in the cells forming 
placodes (Chu et al., 2004). Through the use of Axin2::LacZ reporter mice, 
expression of canonical Wnt/β-catenin signalling was later confirmed at 
E12.5/13.5, both in the stroma of pubertal mice around TEBs necks, as well as in 
the MYO layer of the ducts in adult animals (Rajaram et al., 2015). As mentioned 
previously (Chapter 1), activation of canonical Wnt/β-catenin signalling is 
intimately linked to the paracrine mechanisms of action of ovarian hormones. 
Indeed, through release of RANKL and Wnt-4 by PRB+ luminal cells, progesterone 
was shown to regulate MaSC basal expansion during ductal morphogenesis and 
mammary gland homeostasis in adulthood (Asselin-Labat et al., 2010; Rajaram et 
al., 2015). On the other hand, stabilization of β-catenin in the luminal layer, an 
event essential for alveologenesis, was instead shown to rely on Wnt-
independent mechanisms (Incassati et al., 2010).  
The RUNX family of genes has been shown to interact with a wide range of 
signalling cascades, among which the Wnt/β-catenin pathway is by far one of the 
most important in terms of both mammary development and neoplasia (Ito et 
al., 2015). In line with the latter, Runx2 was found to be specifically upregulated 
in mouse models of Wnt-driven metaplastic breast tumours (Ferrari et al., 2015), 
as well as in metaplastic human breast cancer (Hennessy et al., 2010). 
Alongside, our lab has recently shown the existence of a putative interplay 
between Runx and Wnt/β-catenin in regulating the regenerative potential of the 
stem/progenitor cell population present in the mammary gland. Results showed 
that conditional deletion of Runx2 in the basal layer of the mammary epithelium 
severely compromised mammary stemness. Accordingly, addition of the Wnt3a 
ligand, responsible for fostering MaSC regenerative potential, proved unable to 
rescue the phenotype of Runx2-depleted mammospheres (Ferrari et al., 2015). 
Although RUNX2, and RUNX1, protein expressions has been reported in both 
basal and luminal layers of the murine gland and human breast 
(www.proteinatlas.org), the basal compartment showed the highest levels of 
transcripts for both genes. Nonetheless, Runx1 expression in extracted basal 
MMECs appeared to be significantly higher than Runx2, whereas Runx3 could not 
be found in either epithelial compartment (McDonald et al., 2014; van Bragt et 
al., 2014). These observations unleashed the question as to what role could 
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Runx1 and Runx2 possibly play in the basal layer of the mammary epithelium and 
how their expression impinged upon the Wnt/β-catenin signalling pathway.  
 
4.2 Experimental procedures 
4.2.1 Generation of a novel Wnt/β-catenin-driven breast cancer 
mouse model 
To study the in vivo interplay between the Runx genes and Wnt/β-catenin, it 
was first necessary to generate a GEMM of Wnt/β-catenin-driven mammary 
tumourigenesis. To achieve this aim, a line of mice carrying a stabilized form of 
β-catenin (Catnbwt/lox(ex3)) was used (Harada et al., 1999). The latter was 
characterized by the presence of loxP recombination sites flanking exon 3 of the 
gene, which contains critical residuals for β-catenin degradation. As such, 
removal of this exon allows the generation of a stabilized β-catenin protein, thus 
mimicking constitutive activation of the Wnt/β-catenin signalling pathway 
reported by many epithelial cancers (Harada et al., 1999). To allow 
recombination of the allele specifically in the mammary epithelium, 
Catnbwt/lox(ex3) mice were crossed onto a transgenic line of mice wherein the 
expression of the Cre DNA-recombinase was under the control of a mammary 
specific promoter. In view of what was discussed above, the use of a basal 
promoter (e.g. K14) may have been considered a preferred option. However, 
when choosing a driver it is imperative to bear in mind not only the specificity of 
its expression, but also the impact of the recombined genetic events in the 
targeted tissues. As K14 is ubiquitously expressed across all basal epithelial 
tissues (Byrne et al., 1994) and given the importance of the Wnt/β-catenin 
pathway in the latter compartment, the use of the ovine BLG gene promoter was 
chosen. Owned to its specific function in the mammary epithelium, wherein it 
encodes for a milk secreted protein (Selbert et al., 1998), crossing of the BLG-
Cre line with Catnbwt/lox(ex3) mice allowed conditional activation of the Wnt/β-
catenin signalling specifically in the mammary gland. Importantly, whilst BLG-
Cre and Catnbwt/lox(ex3) mice have been extensively used worldwide, our lab was 
the first one to cross these lines together, thus giving rise to a new conditional 
breast cancer mouse model. In view of the crucial role played by the Wnt/β-
                                                                                                                    132 
 
catenin pathway during mammary gland pubertal and reproductive development 
(Alexander et al., 2012), as well as the predominant activity of BLG-Cre during 
lactation (Selbert et al., 1998), all cohort females employed in this study were 
always carrying one mutant allele of the Catnb gene (Catnbwt/lox(ex3)). 
To investigate if deletion of Runx1 and Runx2 impinged on Wnt/β-catenin driven 
mammary tumourigenesis, Runx1fl/fl and Runx2fl/fl mice were crossed onto BLG-
Cre;Catnbwt/lox(ex3) mice to generate two separate conditional knock-out colonies: 
the BLG-Cre;Catnbwt/lox(ex3);Runx1fl/fl and BLG-Cre;Catnbwt/lox(ex3);Runx2fl/fl 
cohorts of mice. The Runx1fl/fl line, previously discussed in Chapter 1, was 
generated in the lab of Professor Nancy Speck (Growney et al., 2005) and kindly 
given to us by Marella De Bruijn (Oxford). The Runx2fl/fl line was created by 
Theresa Higgins and Ian Rosewell in the lab of Professor Mike Owen (ICRF labs, 
London) and characterized by Ferrari et al. (2015). Similarly to Runx1, by placing 
the loxP sites flanking exon 3 of the gene, recombination of Runx2 excises the 
DNA binding domain, leading to the formation of a non-functional protein. Of 
note, all GEMM lines, and therefore all mouse cohorts described in the following 
chapters, were maintained on a mixed background. Furthermore, in view of the 
pattern of BLG-Cre expression, low in pubertal and virgin mice, while high during 
lactation, all females from the BLG-Cre;Catnbwt/lox(ex3);Runx1wt/wt;Runx2wt/wt  and 
single BLG-Cre;Catnbwt/lox(ex3);Runx1fl/fl and BLG-Cre;Catnbwt/lox(ex3);Runx2fl/fl 
conditional knock-out colonies were mated at the age of 12 weeks in order to 
undergo two rounds of parities. By doing so, expression of BLG-Cre, and 
therefore recombination of the Catnbwt/lox(ex3) and either Runx1fl/fl or Runx2fl/fl 
alleles, could be maximized. All pups were standardly culled at day 0 due to 
lactation deficits in the β-catenin positive glands. After the second round of 
parity, females were monitored weekly for the formation of mammary tumours. 
Once a palpable lesion was noticed in any of the five pairs of murine mammary 
glands, this was recorded and measured twice a week with the use of calipers. 
When a lesion reached clinical end point, the animal was humanely sacrificed. 
This experimental procedure allowed the evaluation of three different 
parameters: the time from birth to tumour notice, the time from birth to clinical 
end point and the time from tumour notice to end point. 
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4.3 Results 
4.3.1 Deletion of Runx1, and Runx2, accelerates Wnt/β-catenin 
mammary tumourigenesis without affecting survival of mice 
When the Runx1wt/wt, Runx1wt/fl and Runx1fl/fl multiparous (MP) cohorts of BLG-
Cre;Catnbwt/lox(ex3) mice were monitored for tumour formation (Figure 4. 1A), 
homozygous deletion of Runx1 resulted in a significant acceleration of palpable 
tumour formation (258 average days) in respect to control mice (341 average 
days). The same scenario did not hold true when only one copy of the gene was 
excised, as heterozygous (Runx1wt/fl) mice displayed an average palpable tumour 
formation at 282 days (Figure 4. 1B). In view of the recent NGS findings 
reporting the presence of RUNX1 somatic mutations in human breast biopsies 
(Banerji et al., 2012; Cancer Genome Atlas, 2012; Cornen et al., 2014; Ellis et 
al., 2012), this result was indicative of a tumour suppressive role exerted by the 
gene in a GEMM of mammary tumourigenesis. Nonetheless, no differences were 
observed in terms of overall survival, as both Runx1wt/fl and Runx1fl/fl mice 
showed an average time from birth to clinical end point of 335 and 347 days, 
respectively, which closely approached the average 370 days displayed by 
controls (Figure 4. 1C). Accordingly, when the time from tumour notice to 
clinical end point was assessed, the absence of both copies of Runx1 resulted in 
a significantly extended survival (90 average days from tumour notice), 
compared to Runx1wt/fl and Runx1wt/wt mice (56 and average 53 days, 
respectively) (Figure 4. 1D). Two different hypotheses could be proposed to 
explain the intriguing pattern of Wnt/β-catenin-driven tumourigenesis upon loss 
of Runx1. According to the first one, the gene might have a dualistic role during 
mammary tumourigenesis, acting as a tumour suppressor at early stages, yet as 
an oncogene at later stages. This is synonymous with reports showing a 
chameleon-like role for RUNX1 in different tissues, as well as in different tissue-
contexts (sees Chapter 1). Alternatively, the delay of established Wnt/β-catenin-
driven lesions could be instead ascribed to the presence of RUNX2. On multiple 
occasions, in fact, the two genes have been shown to compensate for each other 
(Chuang et al., 2013), thus envisioning a scenario whereby Runx2, in the absence 
of Runx1, might exert a tumour suppressive role. 
                                                                                                                    134 
 
 
 
Figure 4. 1 Runx1 deletion accelerates Wnt/β-catenin-driven mammary tumourigenesis, yet 
it does not affect survival of the mice. 
(A) Schematic of the three parameters used to assess the impact of Runx1 deletion upon Wnt/β-
catenin-driven mammary tumourigenesis. 12 week old females were mated to undergo two 
rounds of parities in order to maximize the expression of the BLG-Cre driver. Mice were 
monitored twice a week for tumour formation and sacrificed once a mammary tumour lesion 
reached clinical end point. (B, C, D) Kaplan-Meier curves of MP BLG-Cre;Catnbwt/lox(ex3) mice, in 
the absence of one copy (Runx1wt/fl) or both copies (Runx1fl/fl) of the Runx1 allele. (B) Time from 
birth to tumour notice of Runx1wt/wt (n=11), Runx1wt/fl (n=6) and Runx1fl/fl (n=12) mice. (C) Time 
from birth to clinical end point of Runx1wt/wt (n=10), Runx1wt/fl (n=6) and Runx1fl/fl (n=12) mice. 
(D) Time from tumour notice to end point of Runx1wt/wt (n=7), Runx1wt/fl (n=5) and Runx1fl/fl (n=9) 
mice. Statistical analysis was performed using the Log-rank (Mantel-Cox) test in GraphPad Prism. 
**P<0.01. MP, multiparous. 
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In view of the previously described role for RUNX2 in regulating mammary 
stemness (Ferrari et al., 2015), the same experimental pipeline was utilized to 
assess the impact of Runx2 deletion upon Wnt/β-catenin driven mammary 
tumourigenesis (Figure 4. 2A). In doing so, only mice carrying one deleted copy 
of the Runx2 gene (Runx2wt/fl) displayed a significant acceleration of palpable 
tumour formation (231 average days), whereas excision of both copies of the 
gene (Runx2fl/fl) showed no difference compared to Runx2wt/wt control mice (367 
and 341 average days, respectively) (Figure 4. 2B). On the contrary, a 
significantly improved overall survivalwas found in Runx2fl/fl mice (451 average 
days) when compared to both the Runx2wt/fl and the Runx2wt/wt cohorts (338 and 
370 average days, respectively) (Figure 4. 2C). Lastly, whilst the time from 
tumour notice to clinical end point appeared prolonged in the absence of Runx2, 
this parameter was not statistically significant among cohorts, probably due to 
the low number of mice (Figure 4. 2D).  
To fully understand the above results, it is important to mention that the 
Runx2fl/fl transgenic line of mice was found to be affected by the presence of an 
hypomorphic allele. Thus, upon systemic reduction of RUNX2 levels, the majority 
of mice belonging to the BLG-Cre;Catnbwt/lox(ex3);Runx2fl/fl cohort generally 
appeared skinnier, lighter in weight and often characterized by breathing 
difficulties. For the same reason, many animals had to be censored out of the 
survival analysis due to tumour-unrelated reasons. Nonetheless, based on the 
results obtained from the Runx2wt/fl cohort of mice, Runx2 appeared to act as a 
tumour suppressor gene in the early stage of Wnt/β-catenin mammary 
tumourigenesis. If so, this could have explained the prolonged time from tumour 
notice to end point displayed by Runx1fl/fl mice (Figure 4. 1D). Equally, the trend 
towards delayed tumour progression shown by both cohorts of Runx2-deficient 
mice could then be ascribed to the suppressive role of RUNX1. Altogether, these 
observations supported the notion of a high degree of homology displayed by the 
Runx genes, able to compensate for each other at least in the context of 
aberrant Wnt/β-catenin signalling pathway. 
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Figure 4. 2 Heterozygous deletion of Runx2 accelerates Wnt/β-catenin-driven mammary 
tumourigenesis, yet it does not affect survival of the mice. 
(A) Schematic of the three parameters used to assess the impact of Runx2 deletion upon Wnt/β-
catenin-driven mammary tumourigenesis. 12 week old females were mated to undergo two 
rounds of parities in order to maximize the expression of the BLG-Cre driver. Mice were 
monitored twice a week for tumour formation and sacrificed once a mammary tumour lesion 
reached clinical end point (i.e. 15 mm per width or length). (B, C, D) Kaplan-Meier curves of MP 
BLG-Cre;Catnbwt/lox(ex3) mice, in the absence of one copy (Runx2wt/fl) or both copies (Runx2fl/fl) of 
the Runx2 allele. (B) Time from birth to tumour notice of Runx2wt/wt (n=11), Runx2wt/fl (n=7) and 
Runx2fl/fl (n=11) mice. (C) Time from birth to clinical end point of Runx2wt/wt (n=10), Runx2wt/fl 
(n=8) and Runx2fl/fl (n=11) mice. (D) Time from tumour notice to end point of Runx2wt/wt (n=7), 
Runx2wt/fl (n=4) and Runx2fl/fl (n=3) mice. Statistical analysis was performed using the Log-rank 
(Mantel-Cox) test in GraphPad Prism. *P<0.05; ***P<0.001. MP, multiparous. 
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It is important to mention that, regardless of the Runx status of the mice, all MP 
cohorts of BLG-Cre;Catnbwt/lox(ex3) mice displayed a long tumour latency, 
comprised between 350 and 450 days. Of note, whilst maximizing the expression 
of the BLG-Cre driver, the use of parity is concomitantly characterized by the 
increased chance of incipient pre-neoplastic cells to be lost during involution. As 
such, to investigate the effect of parity upon Wnt/β-catenin-mediated mammary 
tumourigenesis, corresponding nulliparous (NP) cohorts of BLG-Cre;Catnbwt/lox(ex3) 
mice were generated. Interestingly, only three out of thirteen (23%) mice from 
the NP Runx1wt/wt;Runx2wt/wt group developed mammary lesions around 493 days 
on average. Nonetheless, whilst two of them reached clinical end point (590 
average days), the remaining tumour-bearing mouse and the rest of the animal 
cohort had to be sacrificed for unrelated reasons at an average time of 390 days. 
In regards to the latter, perhaps due to the leakiness of BLG-Cre expression in 
the liver (data not shown) and the crucial role exerted by Wnt/β-catenin in the 
organ (Behari, 2010), the majority of animals appeared to suffer from gross 
hepatomegaly. Differently, when the Runx1fl/fl MP and NP cohorts of BLG-
Cre;Catnbwt/lox(ex3) mice were compared with each other, no major differences 
were found among them, yet only in respect to MP Runx1wt/wt control mice 
(Figure 4. 3). If on one hand this result ruled out the possibility of Runx1-
deficient pre-neoplastic MMECs being lost during involution, on the other the 
absence for parity requirements highlighted the effect of deleting Runx1 in the 
context of Wnt/β-catenin-driven mammary tumourigenesis. Being the luminal 
layer predominantly remodelled during mammary gland reproductive 
development, these observations also hinted at the possibility of Wnt/β-catenin-
driven pre-neoplastic transformation occurring in the basal epithelial 
compartment of the organ. On the contrary, a significant delay in the time from 
birth to tumour notice was seen with NP Runx2fl/fl mice (504 days on average), 
as compared to both MP Runx2fl/fl and Runx2wt/wt cohorts (367 and 341 average 
days, respectively) (Figure 4. 4B). No difference was instead found in regards to 
the other two parameters when comparing the NP and MP Runx2fl/fl cohorts 
(Figure 4. 4C and D). In conclusion, albeit the inception of Runx2-deleted Wnt/β-
catenin driven mammary lesions resulted significantly accelerated in the MP 
cohort, the dependency of parity shown by Runx2fl/fl mice could have just been a 
reflection of the hypomorphic allele affecting this transgenic line. 
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Figure 4. 3 Wnt/β-catenin-driven mammary tumourigenesis, in the absence of Runx1, is not 
influenced by parity. 
(A) Schematic of the three parameters used to assess the impact of Runx1 deletion upon Wnt/β-
catenin-driven mammary tumourigenesis. Both MP and NP mice were monitored twice a week for 
tumour formation and sacrificed once a mammary tumour lesion reached end point. (B, C, D) 
Kaplan-Meier curves of BLG-Cre;Catnbwt/lox(ex3) mice from the MP Runx1wt/wt, MP Runx1fl/fl and NP 
Runx1fl/fl cohorts of mice. (B) Time from birth to tumour notice of MP Runx1wt/wt (n=11), MP 
Runx1fl/fl (n=12) and NP Runx1fl/fl (n=12) mice. (C) Time from birth to clinical end point of MP 
Runx1wt/wt (n=10), MP Runx1fl/fl (n=12) and NP Runx1fl/fl (n=13) mice. (D) Time from tumour 
notice to end point of MP Runx1wt/wt (n=7), MP Runx1fl/fl (n=9) and NP Runx1fl/fl (n=10) mice. 
Statistical analysis was performed using the Log-rank (Mantel-Cox) test in GraphPad Prism. 
*P<0.05; **P<0.01. MP, multiparous; NP, nulliparous. 
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Figure 4. 4 Deletion of Runx2, in the absence of parity, delays the appearance of BLG-Cre 
driven Wnt/β-catenin-activated mammary lesions. 
(A) Schematic of the three parameters used to assess the impact of Runx2 deletion upon Wnt/β-
catenin-driven mammary tumourigenesis. Both MP and NP mice were monitored twice a week for 
tumour formation and sacrificed once a mammary lesion reached end point. (B, C, D) Kaplan-
Meier curves of BLG-Cre;Catnbwt/lox(ex3) mice from the MP Runx2wt/wt, MP Runx2fl/fl and NP 
Runx2fl/fl cohorts of mice. (B) Time from birth to tumour notice of MP Runx1wt/wt (n=11), MP 
Runx2fl/fl (n=11) and NP Runx2fl/fl (n=6) mice. (C) Time from birth to clinical end point of MP 
Runx2wt/wt (n=10), MP Runx2fl/fl (n=11) and NP Runx2fl/fl (n=6) mice. (D) Time from tumour notice 
to end point of MP Runx2wt/wt (n=7), MP Runx2fl/fl (n=3) and NP Runx2fl/fl (n=3) mice. Statistical 
analysis was performed using the Log-rank (Mantel-Cox) test in GraphPad Prism. *P<0.05; 
**P<0.01. MP, multiparous; NP, nulliparous. 
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4.3.2 Combined deletion of Runx1 and Runx2 results in a 
remarkable acceleration of Wnt/β-catenin-driven mammary 
tumourigenesis 
In view of the effects on tumour progression displayed by the Runx1fl/fl and 
Runx2fl/fl cohorts of mice, the high degree of homology existing between the two 
genes and the possibility of compensating for each other (Chuang et al., 2013), 
the combinatorial effect of Runx1 and Runx2 deletion upon Wnt/β-catenin-
driven mammary tumourigenesis was also evaluated. To this end, BLG-
Cre;Catnbwt/lox(ex3) mice were crossed onto Runx1fl/fl and Runx2fl/fl mice to 
generate a new cohort of BLG-Cre;Catnbwt/lox(ex3);Runx1fl/fl;Runx2fl/fl mice. Given 
the presence of the Runx2fl/fl hypomorphic allele, the main aim of this analysis 
was to assess the contribution of deleting one or both copies of Runx2 on a 
Runx1-null Wnt/β-catenin activated background. Accordingly, deletion of one 
allele of the Runx2 gene resulted in a remarkable acceleration of Wnt/β-catenin 
driven mammary tumourigenesis (Figure 4. 5). On one hand, this was 
corroborated by the significant decreased timeframe from birth to tumour notice 
displayed by the Runx1fl/fl;Runx2wt/fl cohort (131 average days), as compared to 
both Runx1fl/fl;Runx2wt/wt (258 average days) and Runx1wt/wt;Runx2wt/wt control 
mice (341 average days) (Figure 4. 5B). It was further supported by a 
significantly reduced overall survival shown by Runx1fl/fl;Runx2wt/fl animals (235 
average days), as opposed to the Runx1fl/fl;Runx2wt/wt and Runx1wt/wt;Runx2wt/wt 
cohorts (347 and 370 average days, respectively) (Figure 4. 5C). On the contrary, 
progression of established Runx1-deficient Wnt/β-catenin-activated tumour 
lesions, intended as the timeframe from tumour notice to clinical end point, 
remained unchanged both in the presence or absence of Runx2. Nonetheless, 
whilst the delayed tumour progression shown by Runx1fl/fl;Runx2wt/wt mice (90 
average days) proved to be significantly different when compared to controls (53 
average days), this was not the case  for the Runx1fl/fl;Runx2wt/fl cohort, wherein 
progression of established lesions occurred at an average time of 103 average 
days (Figure 4. 5D). Whilst emphasizing the tumour suppressive activity played 
by Runx2 in the context of Runx1 loss, these findings also highlighted the 
survival advantage displayed by recombined MMECs to survive upon activation of 
Wnt/β-catenin, homozygous loss of Runx1 and heterozygous deletion of Runx2.  
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Figure 4. 5 Heterozygous deletion of Runx2 significantly accelerates Wnt/β-catenin-driven 
mammary tumourigenesis in a Runx1-null background. 
(A) Schematic of the three parameters used to assess the impact of heterozygous Runx2 deletion 
upon Wnt/β-catenin-driven mammary tumourigenesis in a Runx1-null background. (B, C, D) 
Kaplan-Meier curves of BLG-Cre;Catnbwt/lox(ex3) mice, in the presence (Runx1fl/fl;Runx2wt/wt)  or 
absence of one copy (Runx1fl/fl;Runx2wt/fl) of the Runx2 gene. (B) Time from birth to tumour 
notice of Runx1wt/wt;Runx2wt/wt (n=11), Runx1fl/fl;Runx2wt/wt (n=12) and Runx1fl/fl;Runx2wt/fl (n=6) 
mice. (C) Time from birth to clinical end point of Runx1wt/wt;Runx2wt/wt (n=10), 
Runx1fl/fl;Runx2wt/wt (n=12) and Runx1fl/fl;Runx2wt/fl (n=5) mice. (D) Time from tumour notice to 
end point of Runx1wt/wt;Runx2wt/wt (n=7), Runx1fl/fl;Runx2wt/wt (n=9) and Runx1fl/fl;Runx2wt/fl (n=5) 
mice. All mice underwent two parities. Statistical analysis was performed using the Log-rank 
(Mantel-Cox) test in GraphPad Prism. **P<0.01; ****P<0.0001.  
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To investigate how parity could affect the tumourigenesis displayed by BLG-
Cre;Catnbwt/lox(ex3);Runx1fl/fl;Runx2wt/fl animals, a corresponding NP cohort of 
mice was generated and monitored over time for the formation of mammary 
lesions (Figure 4. 6). In doing so, NP Runx1fl/fl;Runx2wt/fl mice were found to 
display a significant delay in the formation of palpable Wnt/β-catenin-activated 
mammary tumours as compared to the corresponding MP cohort (181 and 131 
average days, respectively). Nonetheless, this timeframe remained overall 
accelerated as compared to both MP cohorts of Runx1fl/fl;Runx2wt/wt and 
Runx1wt/wt;Runx2wt/wt mice (258 and 341 average days, respectively) (Figure 4. 
6B). In view of its hormone responsiveness, this result reinforced the seminal 
role played by parity in potentiating the expression of BLG-Cre. When the overall 
survival of the mice was evaluated, no difference could be observed between 
the MP and NP cohorts of Runx1fl/fl;Runx2wt/fl mice, which had to be sacrificed at 
an average time of 235 and 234 days, respectively. Nonetheless, the timeframe 
from birth to clinical end point displayed by NP Runx1fl/fl;Runx2wt/fl mice 
resulted to be significantly different in relation to both MP Runx1fl/fl;Runx2wt/wt 
and MP Runx1wt/wt;Runx2wt/wt control mice (347 and 370 average days, 
respectively) (Figure 4. 6C). The delayed appearance of Wnt/β-catenin driven 
palpable lesions displayed by NP Runx1fl/fl;Runx2wt/fl mice, yet the absence of 
any difference in terms of overall survival as compared to the corresponding MP 
cohort could be explained by an accelerated tumour progression (Figure 4. 6D). 
Albeit not statistically significant to any of the other MP cohorts of BLG-
Cre;Catnbwt/lox(ex3) mice, probably due to small numbers, this result highlighted a 
controversial role for parity. If on one hand it accelerated the appearance of 
Wnt/β-catenin-driven mammary lesions upon homozygous loss of Runx1 and 
heterozygous loss of Runx2, on the other it also lessened their growth. 
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Figure 4. 6 The effect of parity on heterozygous loss of Runx2 upon Wnt/β-catenin-driven 
mammary tumourigenesis in a Runx1-null background. 
(A) Schematic of the three parameters used to assess the impact of parity on heterozygous Runx2 
deletion upon Wnt/β-catenin-driven mammary tumourigenesis in a Runx1-null background. (B, C, 
D) Kaplan-Meier curves of BLG-Cre;Catnbwt/lox(ex3) mice from the MP Runx1fl/fl;Runx2wt/wt, MP 
Runx1fl/fl;Runx2wt/fl and NP Runx1fl/fl;Runx2wt/fl cohorts. (B) Time from birth to tumour notice of 
Runx1wt/wt;Runx2wt/wt (n=11), Runx1fl/fl;Runx2wt/wt (n=12), MP Runx1fl/fl;Runx2wt/fl (n=6) and NP 
Runx1fl/fl;Runx2wt/fl (n=9) mice. (C) Time from birth to clinical end point of Runx1wt/wt;Runx2wt/wt 
(n=10), Runx1fl/fl;Runx2wt/wt (n=12), MP Runx1fl/fl;Runx2wt/fl (n=5) and NP Runx1fl/fl;Runx2wt/fl 
(n=9) mice. (D) Time from tumour notice to end point of Runx1wt/wt;Runx2wt/wt (n=7), 
Runx1fl/fl;Runx2wt/wt (n=9), MP Runx1fl/fl;Runx2wt/fl (n=5) and NP Runx1fl/fl;Runx2wt/fl (n=7) mice. 
Statistical analysis was performed using the Log-rank (Mantel-Cox) test in GraphPad Prism. 
**P<0.01; ***P<0.001 ****P<0.0001. MP, multiparous; NP, nulliparous. 
                                                                                                                    144 
 
Collectively, these results encouraged further investigation of the effect that 
deletion of both copies of Runx2 might have had upon Wnt/β-catenin-driven 
mammary tumourigenesis on a Runx1-null background. Thus, a cohort of 
Runx1fl/fl;Runx2fl/fl mice was generated. As mentioned above, all females 
employed in this study were usually divided in two categories, a MP and NP ones, 
with the former comprising mice that have undergone two rounds of parities. 
The latter experimental approach, however, could not be achieved in this case, 
as co-deletion of both copies of Runx2 on a Runx1-null background resulted in a 
highly significant acceleration of Wnt/β-catenin-driven mammary 
tumourigenesis. This translated in the appearance of palpable mammary lesions 
at an average time of 56 days (Figure 4. 7B), as well as in a significantly 
decreased overall survival around 99 days (Figure 4. 7C). For the above reasons, 
these results remarkably distinguished the NP cohort of Runx1fl/fl;Runx2fl/fl mice 
from all other MP cohorts of BLG-Cre;Catnbwt/lox(ex3) animals. Nonetheless, when 
the time from palpable lesions to end point was assessed, the growth of 
established Runx1fl/fl;Runx2fl/fl-deficient mammary lesions appeared to overlap 
to the one characterizing Runx1wt/wt;Runx2wt/wt control tumours. On the contrary 
and as already discussed above, Runx1-null lesions, both in the presence 
(Runx1fl/fl;Runx2wt/wt) or absence of only one copy of Runx2 
(Runx1fl/fl;Runx2wt/fl), were significantly delayed in their tumour growth at this 
stage of disease progression (Figure 4. 7D). A definitive proof of the tumour 
suppressive role exerted by RUNX2 in halting the formation of Runx1-null Wnt/β-
catenin-driven mammary lesions was obtained. Altogether, these results 
confirmed the presence of a tantalizing interplay between the Runx genes and 
canonical Wnt signalling, whereby both RUNX1 and RUNX2 appear to act as 
“sentinels” of β-catenin. As such, only upon combined deletion of both genes the 
Wnt/β-catenin pathway is fully unleashed resulting in a remarkable oncogenic 
transformation of the mammary epithelium. For an overview of MP 
Runx1wt/wt;Runx2wt/wt, Runx1fl/fl;Runx2wt/wt, Runx1wt/wt;Runx2fl/fl and NP 
Runx1fl/fl;Runx2fl/fl cohorts of BLG-Cre;Catnbwt/lox(ex3) mice, refer to Figure 4. 8; 
for an overview of MP Runx1wt/wt;Runx2wt/wt and NP Runx1fl/fl;Runx2wt/wt, 
Runx1wt/wt;Runx2fl/fl and Runx1fl/fl;Runx2fl/fl cohorts of BLG-Cre;Catnbwt/lox(ex3) 
mice, refer to Figure 4. 9. 
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Figure 4. 7 Co-deletion of Runx1 and Runx2 significantly accelerates Wnt/β-catenin-driven 
oncogenic transformation of the mammary epithelium. 
(A) Schematic of the three parameters used to assess the impact of Runx1 and Runx2 co-deletion 
upon Wnt/β-catenin-driven mammary tumourigenesis. (B, C, D) Kaplan-Meier curves of BLG-
Cre;Catnbwt/lox(ex3) mice from the MP Runx1fl/fl;Runx2wt/wt, MP Runx1fl/fl;Runx2wt/fl and NP 
Runx1fl/fl;Runx2fl/fl cohorts. (B) Time from birth to tumour notice of Runx1wt/wt;Runx2wt/wt (n=11), 
Runx1fl/fl;Runx2wt/wt (n=12), Runx1fl/fl;Runx2wt/fl (n=6) and Runx1fl/fl;Runx2fl/fl (n=18) mice. (C) 
Time from birth to clinical end point of Runx1wt/wt;Runx2wt/wt (n=10), Runx1fl/fl;Runx2wt/wt (n=12), 
Runx1fl/fl;Runx2wt/fl (n=5) and Runx1fl/fl;Runx2fl/fl (n=18) mice. (D) Time from tumour notice to 
end point of Runx1wt/wt;Runx2wt/wt (n=7), Runx1fl/fl;Runx2wt/wt (n=9), Runx1fl/fl;Runx2wt/fl (n=5) and 
Runx1fl/fl;Runx2fl/fl (n=13) mice. Statistical analysis was performed using the Log-rank (Mantel-
Cox) test in GraphPad Prism. *P<0.05; ***P<0.001 ****P<0.0001. MP, multiparous; NP, nulliparous. 
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Figure 4. 8 Survival analysis of Runx-deficient cohorts of multiparous mice carrying an 
activated mutation of β-catenin. 
Overview of the time from birth to tumour notice (A), from birth to end point (B) and from 
tumour notice to end point (C) of all MP Runx-deficient and NP Runx1fl/fl;Runx2fl/fl cohorts of 
BLG-Cre;Catnbwt/lox(ex3) cohorts. MP, multiparous; NP, nulliparous. 
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Figure 4. 9 Survival analysis of Runx-deficient cohorts of nulliparous mice carrying an 
activated mutation of β-catenin. 
Overview of the time from birth to tumour notice (A), from birth to end point (B) and from 
tumour notice to end point (C) of all NP Runx-deficient and MP Runx1wt/wt;Runx2wt/wt cohorts of 
BLG-Cre;Catnbwt/lox(ex3) cohorts.   MP, multiparous; NP, nulliparous. 
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4.3.3 Characterization of Runx-deficient breast cancer cohorts of 
mice carrying an activating mutation of β-catenin 
When mice from all BLG-Cre;Catnbwt/lox(ex3) cohorts reached clinical end point, 
these were sacrificed and both the body weight and the total weight of all ten 
tumour-bearing and non-tumour bearing mammary glands were recorded. 
Through the combination of these two parameters the tumour burden of the 
mouse was then calculated and expressed as the total weight of all mammary 
glands divided by the body weight of the mouse. In addition, the number of 
tumour burdened mammary glands was also noted. All cohorts of Runx-deficient 
BLG-Cre;Catnbwt/lox(ex3) mice were characterized and compared with each other. 
Analysis of Runx1-deficient mice, comprising MP Runx1wt/fl;Runx2wt/wt and both 
MP and NP Runx1fl/fl;Runx2wt/wt cohorts, showed no difference in terms of body 
weight (Figure 4. 10A). Nonetheless, albeit not significant, all three Runx1-
deleted cohorts displayed a trend towards higher tumour burden (Figure 4. 10B) 
and higher number of tumour burdened mammary glands (Figure 4. 10C), in 
respect to Runx1wt/wt;Runx2wt/wt control mice. In line with pathological 
examination, these results suggested that deletion of Runx1 favoured the 
appearance of multiple Wnt/β-catenin-driven mammary lesions affecting more 
than one murine gland (n=3 on average). Loss of Runx1 appeared to predispose a 
higher number of MMECs to Wnt/β-catenin-driven oncogenic transformation. 
When the same analysis was performed on Runx2-deficient cohorts of BLG-
Cre;Catnbwt/lox(ex3) mice, both the MP and NP groups of Runx1wt/wt;Runx2fl/fl mice 
displayed lighter body weights as compared to MP cohorts of 
Runx1wt/wt;Runx2wt/fl and control Runx1wt/wt;Runx2wt/wt animals (Figure 4. 11A). 
Albeit not significant, probably due to low number of animals, these findings 
reflected the previously discussed hypomorphic allele affecting the Runx2fl/fl 
transgenic line. A significant increase of tumour burden was found to be 
displayed by Runx1wt/wt;Runx2wt/flmice, yet not from animals carrying 
homozygous deletion of Runx2, in respect to controls (Figure 4. 11B). No major 
differences were instead observed in relation to the number of mammary glands 
affected by Wnt/β-catenin-driven mammary lesions (Figure 4. 11C). 
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Figure 4. 10 Effect of Runx1 loss on body weight, tumour burden and number of tumour 
burdened mammary glands in Wnt/β-catenin activated mutant mice at clinical end point. 
Scatter dot plots of body weight (A), tumour burden (B) and number of tumour burdened 
mammary glands (C) from clinical end point BLG-Cre;Catnbwt/lox(ex3) mice of the MP 
Runx1wt/wt;Runx2wt/wt, MP Runx1wt/fl;Runx2wt/wt, MP Runx1fl/fl;Runx2wt/wt and NP 
Runx1fl/fl;Runx2wt/wt cohorts of mice. Females from the MP cohorts were mated at the age of 12 
week to undergo two rounds of parities. Both MP and NP cohorts (represented with full and 
empty symbols, respectively) were monitored twice a week for the presence of tumours. Once a 
lesion was noticed, its size was recorded and monitored over time. Mice were sacrificed when 
the first tumour lesion reached clinical end point. The number of tumour burden mammary 
glands represents the number of tumour bearing mammary glands over the total number of ten 
murine mammary glands. Statistical analysis was performed by the Kruskal-Wallis test with 
Dunn’s multiple comparisons in GraphPad Prism. Error bars represent mean with SD (n≥5 per 
each cohort). No significant differences were found among cohorts. MP, multiparous; NP, 
nulliparous. 
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Figure 4. 11 Effect of Runx2 loss on body weight, tumour burden and number of tumour 
burdened mammary glands in Wnt/β-catenin activated mutant mice at clinical end point. 
Scatter dot plots of body weight (A), tumour burden (B) and number of tumour burdened 
mammary glands (C) from clinical end point BLG-Cre;Catnbwt/lox(ex3) mice of the MP 
Runx1wt/wt;Runx2wt/wt, MP Runx1wt/wt;Runx2wt/fl, MP Runx1wt/wt;Runx2fl/fl and NP 
Runx1wt/wt;Runx2fl/fl cohorts of mice. Females from the MP cohorts were mated at the age of 12 
week to undergo two rounds of parities. Both MP and NP cohorts (represented with full and 
empty symbols, respectively) were monitored twice a week for the presence of tumours. Once a 
lesion was noticed, its size was recorded and monitored over time. Mice were sacrificed when 
the first tumour lesion reached clinical end point. The number of tumour burden mammary 
glands represents the number of tumour bearing mammary glands over the total number of ten 
murine mammary glands. Statistical analysis was performed by the Kruskal-Wallis test with 
Dunn’s multiple comparisons in GraphPad Prism. Error bars represent mean with SD (n≥3 per 
each cohort, but for the tumour burden of MP Runx1wt/wt;Runx2fl/fl with n=1). *P<0.05. MP, 
multiparous; NP, nulliparous. 
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When characterization of clinical end point BLG-Cre;Catnbwt/lox(ex3) mice carrying 
co-deletion of both Runx1 and Runx2 alleles was performed, the NP 
Runx1fl/fl;Runx2fl/fl group displayed a significantly lower body weight in respect 
to both MP Runx1fl/fl;Runx2wt/fl and control Runx1wt/wt;Runx2wt/wt cohorts (Figure 
4. 12A). This result was in line with the previously discussed reduced overall 
survival of NP Runx1fl/fl;Runx2fl/fl occurring at a much younger age (average time 
of 99 days) (Figure 4. 7). Regardless, a significantly increased tumour burden as 
compared to controls was found in NP Runx1-null mice carrying either 
heterozygous or homozygous deletion of Runx2 (Figure 4. 12B). The same could 
not be said for MP Runx1fl/fl;Runx2wt/fl mice, even though the latter cohort 
showed an acceleration of tumourigenesis in respect to the NP counterpart 
(Figure 4. 6). This finding highlighted again the putative impact played by 
pregnancy, and subsequent involution stage, in the clearance of pre-neoplastic 
Wnt/β-catenin driven tumour cells. Importantly, the increased tumour burden 
shown by NP Runx1fl/fl;Runx2fl/fl mice was also reflected by a significantly 
increased number of tumour burdened mammary glands (n=8 on average), when 
compared with the Runx1wt/wt;Runx2wt/wt group (n=1 on average). Although the 
same scenario did not apply to the MP and NP cohorts of Runx1fl/fl;Runx2wt/fl 
mice, these also showed a higher trend towards increase tumour burdened 
glands in respect to controls (Figure 4. 12C). The distinctive features 
characterizing NP Runx1fl/fl;Runx2fl/fl mice became even more striking when this 
group of mice was compared to all Runx-deficient MP (Figure 4. 13) and NP 
(Figure 4. 14) cohorts of BLG-Cre;Catnbwt/lox(ex3) mice. Indeed, despite being the 
only group characterized by the lowest body weight, NP Runx1fl/fl;Runx2fl/fl mice 
were always found to show the highest tumour burden, as well as the highest 
number of tumour burdened mammary glands among all cohorts. Thus, if Runx1 
deletion was already able to partly increase the percentage of MMECs 
susceptible to Wnt/β-catenin oncogenic transformation (Figure 4. 10), deletion 
of Runx2 on a Runx1-null background resulted in a complete exacerbation of this 
phenotype. Whilst reiterating the compensatory effect exerted by both genes, 
these findings highlighted once again the deleterious consequences of combined 
Runx1 and Runx2 deletion on a mammary-specific Wnt/β-catenin activated 
background. Representative pictures of the gross pathology of clinical end point 
of Runx-deficient MP and NP cohorts of BLG-Cre;Catnbwt/lox(ex3) mice are shown in 
Figure 4. 15. 
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Figure 4. 12 Effect of combined Runx1 and Runx2 loss on body weight, tumour burden and 
number of tumour burdened mammary glands in Wnt/β-catenin activated mutant mice at 
clinical end point. 
Scatter dot plots of body weight (A), tumour burden (B) and number of tumour burdened 
mammary glands (C) from clinical end point BLG-Cre;Catnbwt/lox(ex3) mice of the MP 
Runx1wt/wt;Runx2wt/wt, MP Runx1fl/fl;Runx2wt/fl, NP Runx1fl/fl;Runx2wt/fl and NP Runx1fl/fl;Runx2fl/fl 
cohorts of mice. Females from the MP cohorts were mated at the age of 12 week to undergo two 
rounds of parities. Both MP and NP cohorts (represented with full and empty symbols, 
respectively) were monitored twice a week for the presence of tumours. Once a lesion was 
noticed, its size was recorded and monitored over time. Mice were sacrificed when the first 
tumour lesion reached clinical end point (i.e. 15 mm per width or length). The number of tumour 
burden mammary glands represents the number of tumour bearing mammary glands over the 
total number of ten murine mammary glands. Statistical analysis was performed by the Kruskal-
Wallis test with Dunn’s multiple comparisons in GraphPad Prism. Error bars represent mean with 
SD (n≥4 per each cohort). *P<0.05, ***P<0.001, ****P<0.0001. MP, multiparous; NP, nulliparous. 
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Figure 4. 13 Characterization of Runx-deficient multiparous cohorts of mice carrying a 
mammary-specific activating mutation of β-catenin. 
Scatter dot plots of body weight (A), tumour burden (B) and number of tumour burdened 
mammary glands (C) from clinical end point BLG-Cre;Catnbwt/lox(ex3) mice, upon loss of Runx1 (MP 
Runx1wt/fl;Runx2wt/wt and MP Runx1fl/fl;Runx2wt/wt), Runx2 (MP Runx1wt/wt;Runx2wt/fl and MP 
Runx1wt/wt;Runx2fl/fl), or combined deletion of both genes (MP Runx1fl/fl;Runx2wt/fl and NP 
Runx1fl/fl;Runx2fl/fl). All females, except those from the NP Runx1fl/fl;Runx2fl/fl cohort, were 
mated at the age of 12 week to undergo two rounds of parities. Both MP and NP cohorts 
(represented with full and empty symbols, respectively) were monitored twice a week for the 
presence of tumours and sacrificed when the first lesion reached clinical end point. The number 
of tumour burden mammary glands represents the number of tumour bearing mammary glands 
over the total number of ten murine mammary glands. Statistical analysis was performed by the 
Kruskal-Wallis test with Dunn’s multiple comparisons in GraphPad Prism. Error bars represent 
mean with SD (n≥3 per each cohort, except for the tumour burden of MP Runx1wt/wt;Runx2fl/fl 
with n=1). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. MP, multiparous; NP, nulliparous. 
                                                                                                                    154 
 
 
 
Figure 4. 14 Characterization of Runx-deficient nulliparous cohorts of mice carrying a 
mammary-specific activating mutation of β-catenin. 
Scatter dot plots of body weight (A), tumour burden (B) and number of tumour burdened 
mammary glands (C) from clinical end point BLG-Cre;Catnbwt/lox(ex3) mice, upon loss of Runx1 (NP 
Runx1fl/fl;Runx2wt/wt), Runx2 (NP Runx1wt/wt;Runx2fl/fl), or combined deletion of both genes (NP 
Runx1fl/fl;Runx2wt/fl and NP Runx1fl/fl;Runx2fl/fl). All MP females were mated at the age of 12 
week to undergo two rounds of parities. Both MP and NP cohorts (represented with full and 
empty symbols, respectively) were monitored twice a week for the presence of tumours and 
sacrificed when a lesion reached clinical end point. The number of tumour burden mammary 
glands represents the number of tumour bearing mammary glands over the total number of ten 
murine mammary glands. Statistical analysis was performed by the Kruskal-Wallis test with 
Dunn’s multiple comparisons in GraphPad Prism. Error bars represent mean with SD (n≥3 per 
each cohort). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. MP, multiparous; NP, nulliparous. 
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Figure 4. 15 Gross appearance of the phenotypical changes affecting the mammary glands of 
Wnt/β-catenin-activated mutant mice upon loss of the Runx genes.  
Pictures of BLG-Cre;Catnbwt/lox(ex3) Runx-deficient mice. MP, multiparous; NP, nulliparous.  
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4.3.4 Activation of the Wnt/β-catenin signalling pathway leads to 
the formation of adenosquamous mammary lesions 
When mice from all Runx-deficient BLG-Cre;Catnbwt/lox(ex3) cohorts reached 
clinical end point, their mammary tumours were dissected out and formalin-
fixed paraffin-embedded in order to preserve tissue architecture. Tissue blocks 
were then sectioned to generate corresponding blanks, which were used for H&E 
staining and IHC analysis. Examination of H&E stained tumour sections from BLG-
Cre;Catnbwt/lox(ex3) mice revealed the presence of a highly disorganized mammary 
structure, characterized by the formation of adenosquamous lesions reminiscent 
of metaplastic human breast cancer (Figure 4. 16). These highly differentiated 
and heterogenous elements were found to be composed of two main epithelial 
compartments, i.e. dense glandular regions and enlarged keratin pearls, 
surrounded by extensive areas of connective tissue. In an attempt to dissect the 
composition of the lesions, both basal (CK5, CK14 and p63) and luminal (CK8/18) 
epithelial markers were used. As such, if dense epithelial glandular elements 
displayed a higher amount of CK8/18 positivity, CK5 and CK14 positive cells 
appeared to be restricted to the external layer of keratin nodules. αSMA, a 
marker of myoepithelial cells, was found to surround both types of 
adenosquamous lesions. Importantly, whilst being predominantly localized at the 
plasma membrane in wild type mice, strong nuclear β-catenin staining was 
reported in both tumourigenic elements, which also displayed a modest amount 
of Ki67 positive cells (Figure 4. 16). This result aligned with the constitutive 
activation of canonical Wnt signalling characterizing BLG-Cre;Catnbwt/lox(ex3) mice 
and highlighted a causative role for β-catenin in the conversion of a normal 
mammary epithelium into a tumourigenic one. In addition, macroscopic and 
microscopic examination of lungs, and other organs, revealed no evidence of 
metastasis shown by Wnt/β-catenin activated GEMM of breast cancer. Of note, 
when the same analysis was applied to all cohorts of BLG-Cre;Catnbwt/lox(ex3) 
mice, histopathological examination revealed no major differences depending on 
the Runx status of the mice (data not shown). 
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Figure 4. 16 Histopathological analysis of Wnt/β-catenin driven adenosquamous lesions. 
H&E and IHC staining of basal (CK5, CK14, p63), luminal (CK8/18), myoepithelial (α-SMA), 
proliferative (Ki67) and β-catenin makers on adenosquamous sections from clinical end point 
Wnt/β-catenin-activated mutant mice. Scale bar, 500 µm. 
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4.3.5 Investigating the tumourigenic potential of Wnt/β-catenin-
driven mammary lesions upon loss of the Runx genes 
The significant acceleration of Wnt/β-catenin-driven tumourigenesis, coupled 
with the increased tumour burden and number of tumour-burdened mammary 
glands displayed by NP Runx1fl/fl;Runx2fl/fl mice may represent the expansion of 
a stem/progenitor mammary subpopulation. This hypothesis elicited an 
investigation of the stem-like properties characterizing Wnt/β-catenin activated 
mammary tumours, in the context of Runx1, Runx2 or Runx1 and Runx2 loss. 
Transplantation has for long been considered the gold standard assay to test the 
regenerative and tumourigenic potential of normal or transformed mammary 
tissues and/or MMECs. In view of this, two experimental approaches could have 
been employed: the first one refers to the injection of dissociated mammary 
tumour cells, either at fixed or limiting dilutions; the second one to the 
transplantation of mammary tumour-derived fragments. Due to the peculiar 
histopathology characterizing BLG-Cre;Catnbwt/lox(ex3) mice, mechanical and 
enzymatic dissociation of Wnt/β-catenin-driven adenosquamous lesions turned 
out to be extremely challenging. Therefore, to overcome these technical 
difficulties, the second approach was adopted. In addition, this choice allowed 
maintaining the intact structural architecture of Wnt/β-catenin-driven tumours, 
so that interactions between cells of different compartments (epithelial and 
stromal) and of different potentials (stem, progenitor and differentiated) could 
be preserved.  
As such, BLG-Cre;Catnbwt/lox(ex3) mice of the MP Runx1wt/wt;Runx2wt/wt, MP 
Runx1fl/fl;Runx2wt/wt, MP Runx1wt/wt;Runx2fl/fl and NP Runx1fl/fl;Runx2fl/fl groups 
were sacrificed at clinical end point and their biggest tumour lesion dissected 
out. Each tumour was then sectioned into five tumour fragments, hereafter 
referred to as mouse-derived tumour fragments (MDTFs), which were 
independently transplanted into immunodeficient mice (Figure 4. 17). The 
growth of MDTFs generated from different Runx-deficient BLG-Cre;Catnbwt/lox(ex3) 
cohorts was monitored over time and recipient mice were sacrificed when 
clinical end point was reached (Figure 4. 18). Based on the obtained results, 25% 
of MDTFs derived from the MP Runx1wt/wt;Runx2wt/wt control cohort displayed the 
ability to transplant (Figure 4. 19A). Whilst an increased take rate was reported 
in the absence of Runx1 (35%) (Figure 4. 19B) and combined deletion of Runx1 
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and Runx2 (40%) (Figure 4. 19D), these differences did not appear to be 
statistically significant in respect to controls. Of note, examination of H&E 
stained tumour sections from all three cohorts of BLG-Cre;Catnbwt/lox(ex3) mice 
revealed not only similarity among each other, yet also maintenance of the 
histopathology characterizing donor tumours (data not shown). A different 
scenario applied instead to the MP Runx1wt/wt;Runx2fl/fl cohort, whose MDTFs 
failed to grow out in recipient mice (Figure 4. 19C), albeit this could be due to 
the low number of transplant experiments performed. Nonetheless, one ways to 
circumvent this issue could be to test the tumourigenic potential of MDTFs 
derived from the MP Runx1wt/wt;Runx2wt/fl cohort of mice. The long tumour 
latency displayed by the majority of BLG-Cre;Catnbwt/lox(ex3) cohorts, their mixed 
background and the expensive use of immunocompromised recipient, hindered 
the possibility to carry out serial transplantation analysis. In the near future, 
backcrossing of the BLG-Cre, Catnbwt/lox(ex3), Runx1fl/fl and Runx2fl/fl alleles onto 
a pure FVB background will enable the use of syngeneic recipient mice, wherein 
MDTFs could be transplanted either subcutaneously or orthotopically. Thus, 
implementation of the transplantation technique may allow clarification of how 
deletion of Runx1, Runx2 or both genes impact upon the tumourigenic potential 
of Wnt/β-catenin driven mammary tumours. 
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Figure 4. 17 Overview of the transplantation assay. 
Workflow depicting the steps required to test the regenerative potential of Wnt/β-catenin-driven 
mammary tumours upon loss of Runx1, Runx2 or both genes through the use of the 
transplantation assay. BLG-Cre;Catnbwt/lox(ex3) from all Runx-deficient cohorts mice were 
sacrificed at clinical end point and their biggest tumour lesion was dissected out. Each tumour 
was divided into five MDTFs (3 mm x 3 mm), which were independently transplanted into the 
right flank of five immunodeficient (athymic and CD1 nude) mice. The growth of MDTFs was 
monitored over time and recipient mice were sacrificed when clinical end point was reached. 
MDTF, mouse-derived tumour fragment.  
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Figure 4. 18 Investigating the tumourigenic potential of Wnt/β-catenin driven mammary 
tumours in the absence of the Runx genes. 
Growth curves of MDTFs derived from BLG-Cre;Catnbwt/lox(ex3) mice of the (A) MP 
Runx1wt/wt;Runx2wt/wt (n=4 donor mice), (B) MP Runx1fl/fl;Runx2wt/wt (n=4 donor mice), (C) MP 
Runx1wt/wt;Runx2fl/fl (n=2 donor mice) and (D) NP Runx1fl/fl;Runx2fl/fl (n=5 donor mice) cohorts. 
Donor mice from each BLG-Cre;Catnbwt/lox(ex3) cohort are shown below each graph and are 
characterized by a different symbol. Donor mice were sacrificed at clinical end point, when their 
biggest tumour lesion was dissected out. Each tumour was sectioned into five independent 
MDTFs. Each MDTF was subcutaneously transplanted into an immunodeficient (recipient) mouse. 
The growth of each MDTF was monitored over time by measuring its volume (mm3) via the 
formula [(L x W x W)/2, with L>W] through the use of calipers. Recipient mice were euthanized 
when clinical end point was reached, that is when L or W of the tumour equalled 15 mm or if the 
lesion ulcerated. The growth of all five MDTFs derived from each donor mouse is displayed on 
the graph by five separate lines characterized by the same symbol. L, length; MDTF, mouse 
derived tumour fragment; MP, multiparous; NP, nulliparous; W, width. 
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Figure 4. 19 Summary of the tumourigenic potential of Wnt/β-catenin driven mammary 
tumours in the absence of the Runx genes. 
Pie charts of the take rate displayed by the transplantation of MDTFs derived from BLG-
Cre;Catnbwt/lox(ex3) mice of the MP Runx1wt/wt;Runx2wt/wt (n=4), MP Runx1fl/fl;Runx2wt/wt (n=4), MP 
Runx1wt/wt;Runx2fl/fl (n=2) and NP Runx1fl/fl;Runx2fl/fl (n=5) cohorts. Donor mice were sacrificed 
at clinical end point and their biggest tumour lesion dissected out. Each tumour was divided into 
five MDTFs, which were independently transplanted into immunodeficient mice. Each pie chart 
represents the take rate of all five MDTFs derived from each donor GEMM. Underneath each pie 
chart, the percentage of MDTFs growth and/or rejection is displayed from that donor. Asterisk in 
the NP Runx1fl/fl;Runx2fl/fl cohort of mice indicate the use of CD1 recipient mice. For all other 
transplants experiments, athymic nude mice were used. GEMM, genetically engineered mouse 
model; MDTF, mouse-derived tumour fragment; MP, multiparous; NP, nulliparous. 
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4.4 Discussion 
It is now broadly accepted that Wnt signalling plays a major role in the 
mammary gland, wherein it exerts a tight control upon the self-renewal 
potential and proliferative capacity of mammary stem/progenitor cells. In 
addition, the pathway has been involved in the aetiology of many epithelial 
cancers, including breast cancer, raising the possibility that these two processes 
might be linked. Indeed, aberrant Wnt signalling was shown to override the 
aforementioned mechanisms, culminating in uncontrolled cycling and expansion 
of the MaSCs pool (Reya and Clevers, 2005). This appears to be particularly true 
for breast cancer, as corroborated by Wnt1-driven GEMMs whose mammary 
tumours displayed an accumulation of neoplastic cells with stem/progenitor-like 
features (Liu et al., 2004; Teissedre et al., 2009). In many cases, Wnt-driven 
tumourigenesis was shown to occur through dysregulation of the canonical 
pathway. This process could result from activation of Wnt receptors, inactivation 
of any member of the β-catenin destruction complex, such as deletion of APC, or 
from direct mutations of the CTNNB1 gene (Polakis, 1999). In all cases, the net 
result is the stabilization of cytosolic β-catenin through prevention of its 
proteosomal degradation, whilst promotion of its translocation to the nucleus. 
This event can in turn lead to the persistent activation and/or repression of a 
multitude of downstream proto-oncogenes and tumour suppressors, resulting in 
aberrant cell growth and oncogenic transformation (Polakis, 2000). In line with 
the fact of taking part in the same signalling cascade, the majority of these 
genetic alterations were found to be mutually exclusive. In this regards, whilst 
APC inactivating mutations were predominantly linked to sporadic and inherited 
forms of colon cancers (Miyoshi et al., 1992), activating mutations of β-catenin 
were found in human hepatocellular (Miyoshi et al., 1998), uterine (Fukuki et 
al., 1998) and ovarian (Palacios and Gamallo, 1998) cancers. Albeit generally 
uncommon in human breast cancer (Lin et al., 2000) and often displayed only by 
benign fibromas (Abraham et al., 2002), genetic alterations of β-catenin were 
documented in a rare subtype of the disease referred to as metaplastic breast 
cancer (Hayes et al., 2008). Nonetheless, up to 40% of human breast cancer 
appears to be characterized by increased cytoplasmic and nuclear β-catenin and 
correlates with poor or worse patient prognosis (Lin et al., 2000). Altogether, 
these findings highlight that deregulation of upstream β-catenin elements are 
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likely to be the cause of aberrant Wnt signalling in breast cancer (Incassati et 
al., 2010). 
Notwithstanding the paucity of β-catenin activating mutations, several breast 
cancer GEMMs have thus far relied on the use of β-catenin mutant alleles, 
including N-terminally truncated ∆N57, ∆N89, ∆N90 and Catnbwt/lox(ex3) ones, to 
mimic constitutive activation of canonical Wnt signalling. Interestingly, despite 
all aiming at removal of the amino acid residuals critical for β-catenin 
degradation, the use of different Wnt/β-catenin-driven GEMMs has led over time 
to very disparate results (Incassati et al., 2010). On one hand, the K5-∆N57β-
catenin mouse model showed the development of invasive basal-type carcinomas 
(Teuliere et al., 2004). On the other, MMTV- or whey acidic protein-Cre-
Catnbwt/lox(ex3) GEMMs displayed squamous metaplasia (Miyoshi et al., 2002). In 
addition, when the MMTV promoter was used to drive recombination of the ∆N89 
or ∆N90 β-catenin alleles, the formation of adenocarcinomas was observed 
(Imbert et al., 2001; Michaelson and Leder, 2001). This wide phenotypic 
variability was indicative of a highly context-dependent role played by β-
catenin, depending on different epithelial compartments of the mammary gland, 
yet also on the specific targeted cell type within the latter (Incassati et al., 
2010). In case the event that the same promoter driver was used to guide 
recombination, phenotypic differences were instead attributed to changes in β-
catenin cellular levels, stemming perhaps from the use of different transgenic 
lines of mice (Miyoshi et al., 2002).  
Despite not mimicking the genetic aberrations found in the majority of human 
breast cancer, the use of Wnt/β-catenin-activated GEMMs has certainly 
reinforced the causative role played by canonical Wnt in the aetiology of the 
disease. Notwithstanding the potent oncogenic effect exerted by β-catenin, it is 
now widely accepted that cancer is characterized by a “multihit” nature, as it 
requires more than one genetic event to arise (Vogelstein, 1983). This notion 
was corroborated by the absence of gross adenosquamous lesions in the NP 
cohort of BLG-Cre;Catnbwt/lox(ex3) control mice. In view of the hormone-
responsiveness shown by the BLG-Cre driver, it was only after two rounds of 
parities that mammary tumours started to appear, albeit occurring at an average 
time of 341 days and affecting only a few mammary glands. Therefore, the long 
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tumour latency and the low penetrance of tumour formation supported the idea 
that BLG-Cre-mediated activation of β-catenin was not fully sufficient to drive 
breast tumourigenesis. In an effort to unveil new putative breast cancer players 
whose genetic aberrations were able to unleash aberrant activation of the 
Wnt/β-catenin pathway in the mammary gland, attention was focused on the 
Runx family of genes. Highly expressed in the basal epithelial compartment 
(McDonald et al., 2014; van Bragt et al., 2014) and shown to play a role in the 
regulation of mammary stemness (Ferrari et al., 2015), an interplay between the 
Wnt signalling pathway and Runx genes was hypothesized. Accordingly, deletion 
of Runx1 and heterozygous deletion of Runx2 resulted in a significant 
acceleration of palpable tumour formation in respect to control mice, providing 
for the first time a compelling evidence for a tumour suppressive function 
exerted by these genes in a breast cancer GEMM. More importantly, whilst 
generally potentiated in the presence of multiple parities, the same BLG-Cre 
driven phenotype could also be observed in nulliparous mice, thus strengthening 
the effect of Runx1 or Runx2 deletion in the context of activated Wnt/β-catenin 
signalling. What was particularly fascinating was the ability of Runx1 and Runx2 
to seemingly compensate for the other deleted gene, as evidenced by the 
delayed tumour progression in Runx1- and Runx2-deficient cohorts. Further 
proof of this hypothesis was seen through combined deletion of both genes, 
which resulted in the appearance of Wnt/β-catenin-driven lesions at around 56 
days and in the overall survival of the mice at 99 days. If on one hand these 
results showed the potent tumour suppressive effects exerted by Runx1 and 
Runx2, on the other these emphasized the remarkable survival advantage 
displayed by Wnt/β-catenin-activated MMECs upon homozygous loss of Runx1 and 
Runx2. In addition, what emerged from the analysis was also the long latency, 
yet fast tumour progression characterizing the Runx1wt/wt;Runx2wt/wt control 
cohort of mice. Of note, this intriguing pattern of BLG-Cre-mediated Wnt/β-
catenin-driven mammary tumourigenesis appeared indicative of the presence of 
secondary hits. Considering the similar tumour progression displayed by 
Runx1wt/wt;Runx2wt/wt and Runx1fl/fl;Runx2fl/fl mice, it is tempting to speculate 
that these secondary hits might refer to Runx1 and Runx2. 
If acceleration of tumourigenesis denoted a tumour suppressive role played by 
the Runx genes, the increased tumour burden and number of tumour burdened 
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mammary glands upon combined Runx1 and Runx2 deletion hinted towards the 
expansion of a stem/progenitor subpopulation susceptible to Wnt/β-catenin-
driven transformation. Interestingly, a trend towards increased tumour burden 
and higher number of tumour-burdened mammary glands was also observed upon 
deletion of Runx1, yet not Runx2. Therefore, the extent to which these genes 
act and perhaps the context wherein they function may be different. 
Nonetheless, when the tumourigenic potential of Runx-deficient lesions was 
assessed using an in vivo transplantation assay, deletion of Runx1 or combined 
deletion of Runx1 and Runx2 resulted in higher take rates as compared to 
controls (albeit numbers were too low to show significant differences). In 
addition, despite the lack of outgrowth displayed by the Runx2-deficient group 
of mice, no conclusion could be drawn in view of the low number of transplants 
performed. If first passage tumours displayed equal transplantability, perhaps 
the future use of serial transplants on syngeneic mice might help unravel how 
deletion of Runx1, Runx2 or both genes impinges upon the long-termn 
tumourigenic potential of Wnt/β-catenin-driven mammary lesions. 
Finally, upon histopathological examination, all cohorts of BLG-
Cre;Catnbwt/lox(ex3) mice, regardless of their Runx status, were found to be 
characterized by the presence of adenosquamous lesions. Nonetheless, this is 
not the first time this phenotype was reported among Catnbwt/lox(ex3)–driven 
breast cancer GEMMs. In fact, due to its prominent role as a major determinant 
of epidermal epithelium, stabilization of β-catenin was already shown to induce 
trans-differentiation of the mammary epithelium into an epidermal once 
(Miyoshi et al., 2002). As such, one could then imagine that the identity and 
differentiation of mammary gland can only be achieved through tight regulation 
of the Wnt/β-catenin signalling pathway. In view of the suppressive role shown 
by the Runx genes in the context of activated Wnt/β-catenin signalling, it is then 
tempting to speculate that RUNX1 and RUNX2 might act as “sentinels” of 
mammary epithelial cell fate and identity. 
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5 Dissecting the role played by Runx1 and Runx2 in 
the early stages of Wnt/β-catenin driven breast 
tumourigenesis 
 
5.1 Introduction  
In contrast to the majority of genetic diseases, cancer arises from the sequential 
accumulation of several somatic mutations hitting one or a few cells-of-origin. In 
line with the multi-hit nature of tumourigenesis is also the fact that cancer 
incidence dramatically increases with age (Vogelstein et al., 1983). Although the 
steps of this gradual evolution are well-documented for some types of cancer, 
yet not so much for others, common traits can be defined. It is proposed in fact 
that cancers grow through a process of clonal expansion, whereby, upon the 
acquisition of sequential mutations, targeted cells would proliferate, leading to 
the abnormal expansion of their progeny. In this way, oncogenic transformation 
of normal tissues would give rise to benign lesions. Acquisition of further hits 
will allow growth of benign tumours. Over time, cells within incipient pre-
neoplastic lesions will keep acquiring different somatic mutations giving rise to 
distinct subclones. Lastly, through a process of Darwinian evolution or “selective 
sweep”, fittest sub-clones will dominate over others, thus converting benign 
tumours into malignant ones (Nowell, 1976). In view of above, the significant 
acceleration of tumourigenesis, the decrease in overall survival and increase in 
tumour burden displayed by BLG-Cre;Catnbwt/lox(ex3);Runx1fl/fl;Runx2fl/fl mice (see 
Chapter 3) were all indicative hints of a precocious Wnt/β-catenin-driven 
transformation of the mammary epithelium. As ‘in solving a problem of this 
sort, the grand thing is to be able to reason backwards’ (Sherlock Holmes - Sir 
Arthur Conan Doyle), a thorough investigation of the early effects of MMECs 
transformation following activation of the Wnt/β-catenin signalling pathway was 
next performed. 
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5.2 Results 
5.2.1 Activation of Wnt/β-catenin signalling alters mammary 
development in the absence of Runx1 and Runx2 
One of the main advantages of the murine mammary gland relates to the fact 
that its development takes place predominantly after birth (Medina et al., 
1996). To investigate if BLG-Cre-driven activation of the Wnt/β-catenin 
signalling pathway in the context of Runx gene deletion was impinging on an 
established mammary epithelium, or rather on an incipient one, a thorough 
characterization of all cohorts of BLG-Cre;Catnbwt/lox(ex3) mice was carried out. In 
parallel, to discriminate between the role exerted by RUNX1 and RUNX2 in a 
Wnt/β-catenin-activated context or in a physiological background, the 
corresponding cohorts of BLG-Cre;Catnbwt/wt virgin mice were also analysed.  
5.2.1.1  Analysis of mammary gland pubertal development in 9 week old 
virgin female mice 
As the majority of BLG-Cre;Catnbwt/lox(ex3);Runx1fl/fl;Runx2fl/fl mice developed palpable 
mammary tumour lesions around 56 days on average, it was reckoned that the 9 week 
developmental time-point might capture the conversion of the normal mammary epithelium 
into a pre-neoplastic one. Of note, all 9 week old Runx deficient mice displayed lighter body 
weights compared to BLG-Cre;Catnbwt/lox(ex3) control mice, but results were found to be 
statistically significant only in the absence of Runx2 (Figure 5. 1A). However, no differences 
were observed among groups in relation to cumulative mammary gland weight (Figure 5. 1B). 
Differently, whilst 9 week old BLG-Cre;Catnbwt/wt mice showed generally comparable body 
weights, regardless of their Runx status (Figure 5. 1C), a decrease in cumulative mammary 
gland weight was found in the Runx1fl/fl cohort of mice (Figure 5. 1D). When #4 mammary 
glands from BLG-Cre;Catnbwt/lox(ex3) mice were analysed by whole-mount examination, these 
showed thickened epithelial ducts across all genotypes, in line with the presence of 
mammary pre-neoplastic lesions observed by H&E stains (Figure 5. 2; compare to  
Figure 5. 3). This phenotype, however, appeared exacerbated in the Runx1fl/fl;Runx2fl/fl 
cohort of mice, whose mammary glands displayed lack of normal tissue architecture (Figure 
5. 2D). On the other hand, BLG-Cre combined excision of Runx1 and/or Runx2 in the 
mammary epithelium of wild type mice did not appear to affect mammary gland morphology 
at this stage ( 
Figure 5. 3). Indeed, all cohorts of 9 week old BLG-Cre;Catnbwt/wt mice were characterized 
by ramified mammary trees, with elongated epithelial ducts extending throughout the 
mammary fat pad. These results suggested a peculiar function exerted by RUNX1 and RUNX2 
particularly in the context of activated Wnt/β-catenin signalling pathway (Figure 5. 2;  
Figure 5. 3).  
To investigate the extent to which the presence of thickened epithelial ducts 
reported by control, Runx1fl/fl and Runx2fl/fl mice, and the disrupted tissue 
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architecture of Runx1fl/fl;Runx2fl/fl animals have impinged on ductal 
morphogenesis, quantification of the ductal elongation of #4 mammary glands 
was carried out. This was achieved by measuring the distance of the three 
longest TEBs to/from the lymph node, taken as a reference point. In doing so, 
whilst no differences were found depending on the Runx status of the mice, a 
severe delay in ductal elongation was reported by all cohorts of BLG-
Cre;Catnbwt/lox(ex3) when compared to BLG-Cre;Catnbwt/wt females (Figure 5. 4). 
It should be noted, however, that a high degree of variability was evident in all 
Wnt/β-catenin activated mice, perhaps due to the mixed background or to 
differences in the level of BLG-Cre-mediated recombination (Figure 5. 4A).  
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Figure 5. 1 Effect of mammary specific Runx1 and Runx2 loss on body weight and cumulative 
mammary gland weight in 9 week old Wnt/β-catenin mutant and wild type mice. 
Scatter dot plots of body weight and cumulative mammary gland weight of 9 week old BLG-
Cre;Catnbwt/lox(ex3) (A, B) and BLG-Cre;Catnbwt/wt (C, D) female mice upon loss of Runx1, Runx2 or 
both genes. Cumulative mammary gland weight was expressed as a percentage of total mammary 
gland weight divided by the body weight of the animal. Statistical analysis was performed by the 
Kruskal-Wallis test with Dunn’s multiple comparisons in GraphPad Prism. Error bars represent 
mean with SD (n≥4 per each cohort). *P<0.05, **P<0.01.  
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Figure 5. 2 Combined loss of Runx1 and Runx2 results in a dramatic impairment of ductal 
morphogenesis upon activation of the Wnt/β-catenin signalling in late puberty. 
Whole-mounts of #4 MGs (first two left columns) and corresponding H&Es (right column) from 9 
week old BLG-Cre;Catnbwt/lox(ex3) female mice of the Runx1wt/wt;Runx2wt/wt (A), 
Runx1fl/fl;Runx2wt/wt (B), Runx1wt/wt;Runx2fl/fl  (C) and Runx1fl/fl;Runx2fl/fl  (D) cohorts. Two 
representative whole-mount pictures of n≥ 4 are shown per genotype to highlight the variability 
within each cohort. One representative H&E image of n≥ 4 is shown per genotype. Arrows 
indicate the presence of thickened epithelial ducts. Scale bar of whole-mounts, 1000 µm. Scale 
of H&Es, 500 µm. H&E, haematoxylin eosin stain; MG, mammary gland. 
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Figure 5. 3 Mammary-specific deletion of Runx1 and Runx2 does not affect ductal 
morphogenesis of Wnt/β-catenin wild type mice in late puberty. 
Whole-mounts of  #4 MGs (left column) and corresponding H&E (right column) from 9 week old 
BLG-Cre;Catnbwt/wt female mice (A), upon loss of Runx1 (Runx1fl/fl;Runx2wt/wt) (B), Runx2 
(Runx1wt/wt;Runx2fl/fl) (C), or both genes (Runx1fl/fl;Runx2fl/f)  (D). One representative whole-
mount and H&E image of n≥ 4 is shown per cohort. Scale bar of whole-mounts, 1000 µm. Scale of 
H&Es, 500 µm. H&E, haematoxylin eosin stain; MG, mammary gland. 
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Figure 5. 4 Effect of Runx1 and Runx2 loss on mammary ductal elongation in 9 weeks old 
Wnt/β-catenin activated mutant and wild type mice.  
Scatter dot plot showing the ductal elongation of #4 MGs from 9 weeks old BLG-
Cre;Catnbwt/lox(ex3) (A) and BLG-Cre;Catnbwt/wt (B) female mice upon loss of Runx1, Runx2 or both 
genes. Ductal elongation was assessed by measuring the length of the epithelial tree to and from 
the LN. Arrows represent the direction of epithelial growth through the mammary fat pad. 
Statistical analysis was performed by the Kruskal-Wallis test with Dunn’s multiple comparisons in 
GraphPad Prism. Error bars represent mean with SD (n=4 per each BLG-Cre;Catnbwt/lox(ex3) and 
BLG-Cre;Catnbwt/wt cohort). No significance was found. LN, lymph node; MG, mammary gland. 
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5.2.1.2  Analysis of mammary gland pubertal development in 6 week old 
virgin female mice 
The presence of gross morphological differences observed in the whole-mounts 
and H&Es of 9 week old BLG-Cre;Catnbwt/lox(ex3) mice suggested a more 
precocious transformation of the mammary epithelium upon activation of the 
Wnt/β-catenin signalling pathway. This prompted an analysis at earlier stages of 
pubertal mammary gland development. When the 6 week developmental time-
point was analysed, both single knock-out Runx1fl/fl and Runx2fl/fl cohorts of BLG-
Cre;Catnbwt/lox(ex3) mice displayed a significantly lighter body weights compared 
to wild type controls (Figure 5. 5A). The same phenotype could also be observed 
upon combined deletion of Runx1 and Runx2, albeit the difference was not 
significant. Nonetheless, only Runx1fl/fl animals presented with a significantly 
reduced cumulative mammary gland weight, whereas the other cohorts of 
Runx2fl/fl and Runx1fl/fl;Runx2fl/fl behaved like control mice (Figure 5. 5B). 
Lighter body weights were also observed among the BLG-Cre;Catnbwt/wt groups 
of mice, yet only upon loss of Runx2 or combined excision of Runx1 and Runx2 
(Figure 5. 5C). No changes, however, were found in relation to cumulative 
mammary gland weight of the latter groups of mice (Figure 5. 5D). When #4 
mammary glands were examined, both whole-mounts and H&E stains from all 
groups of BLG-Cre;Catnbwt/lox(ex3) mice displayed altered mammary trees 
characterized by the presence of Wnt/β-catenin-driven mammary pre-neoplastic 
lesions (Figure 5. 6; compare to Figure 5. 7). Nonetheless, whilst an epithelial 
ramified structure could still be visible in the control and single knock-out 
cohorts of mice, this appeared lost upon combined deletion of Runx1 and Runx2 
(Figure 5. 6D). As in the case of the 9 week developmental stage, mammary-
specific combined excision of Runx1 and Runx2 did not appear to influence 
ductal morphogenesis of wild type mice (Figure 5. 7), indicating the specificity 
of the aforementioned phenotype to the context of an activated Wnt/β-catenin 
signalling pathway. Quantification of the ductal elongation characterizing #4 
mammary glands revealed a significant delay of epithelial growth only for the 
double knock-out cohorts of BLG-Cre;Catnbwt/lox(ex3) mice as compared to control 
(Figure 5. 8A). Albeit the same trend was noticed in the corresponding BLG-
Cre;Catnbwt/wt group of mice, no significant differences emerged in this case 
(Figure 5. 8B). Nonetheless, all BLG-Cre;Catnbwt/wt displayed more elongated 
ductal trees as compared to BLG-Cre;Catnbwt/lox(ex3) mice. 
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Figure 5. 5 Effect of mammary specific Runx1 and Runx2 loss on body weight and cumulative 
mammary gland weight in 6 week old Wnt/β-catenin mutant and wild type mice. 
Scatter dot plots of body weight and cumulative mammary gland weight of 6 week old BLG-
Cre;Catnbwt/lox(ex3) (A, B) and BLG-Cre;Catnbwt/wt (C, D) female mice upon loss of Runx1, Runx2 or 
both genes.  Cumulative mammary gland weight was expressed as a percentage of total 
mammary gland weight divided by the body weight of the animal. Statistical analysis was 
performed by the Kruskal-Wallis test with Dunn’s multiple comparisons in GraphPad Prism. Error 
bars represent mean with SD (n≥4 per each cohort). *P<0.05, **P<0.01. 
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Figure 5. 6 Combined loss of Runx1 and Runx2 results in a dramatic impairment of ductal 
morphogenesis upon activation of the Wnt/β-catenin signalling pathway in mid puberty. 
Whole-mounts of #4 MGs (left column) and corresponding H&Es (right column) from 6 weeks old 
BLG-Cre;Catnbwt/lox(ex3) female mice of the Runx1wt/wt;Runx2wt/wt (A), Runx1fl/fl;Runx2wt/wt (B), 
Runx1wt/wt;Runx2fl/fl  (C) and Runx1fl/fl;Runx2fl/fl  (D) cohorts. One representative whole-mount 
and H&E image of n≥5 is shown per genotype. Arrows indicate the presence of thickened 
epithelial ducts. Scale bar of whole-mounts, 1000 µm. Scale of H&Es, 500 µm. H&E, 
haematoxylin eosin stain; MG, mammary gland. 
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Figure 5. 7 Mammary-specific deletion of Runx1 and Runx2 does not affect ductal 
morphogenesis of Wnt/β-catenin wild type mice in mid puberty. 
Whole-mounts of #4 MGs (left column) and corresponding H&E (right column) from 6 week old 
BLG-Cre;Catnbwt/wt female mice of the Runx1wt/wt;Runx2wt/wt (A), Runx1fl/fl;Runx2wt/wt (B), 
Runx1wt/wt;Runx2fl/fl  (C) and Runx1fl/fl;Runx2fl/fl  (D) cohorts. One representative whole-mount 
and H&E image of n≥4 is shown per cohort. Scale bar of whole-mounts, 1000 µm. Scale of H&Es, 
500 µm. H&E, haematoxylin eosin stain; MG, mammary gland. 
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Figure 5. 8 Effect of Runx1 and Runx2 loss on mammary ductal elongation in 6 week old 
Wnt/β-catenin activated mutant and wild type mice. 
Scatter dot plots showing the ductal elongation of #4 MGs from 6 weeks old BLG-
Cre;Catnbwt/lox(ex3) (A) and BLG-Cre;Catnbwt/wt (B) female mice upon loss of Runx1, Runx2 or both 
genes. Ductal elongation was assessed by measuring the length of the epithelial tree to and from 
LN. Arrows represent the direction of epithelial growth through the mammary fat pad. Statistical 
analysis was performed by the Kruskal-Wallis test with Dunnet’s multiple comparisons in 
GraphPad Prism. Error bars represent mean with SD (n=4 per each BLG-Cre;Catnbwt/lox(ex3) and 
BLG-Cre;Catnbwt/wt cohort). *P<0.05. LN, lymph node; MG, mammary gland.  
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5.2.1.3  Analysis of mammary gland pre-pubertal development in 3 week old 
virgin female mice 
The evidently altered mammary epithelium observed in all cohorts of 6 week old 
BLG-Cre;Catnbwt/lox(ex3) female mice led to the hypothesis that perhaps 
activation of the Wnt/β-catenin pathway was impinging on the pre-pubertal 
formation of mammary glands. Therefore, the status of the glands was assessed 
at the 3 week developmental time-point. Here, all single and double Runx 
knock-out cohorts of BLG-Cre;Catnbwt/lox(ex3) and BLG-Cre;Catnbwt/wt mice 
displayed lighter body weights and reduced cumulative mammary gland weight 
compared to wild type controls (Figure 5. 9). However, these differences did not 
appear to be statistically significant, possibly due to the small number of 
animals assessed or the high inter-mouse variation. When whole-mount analysis 
of #1 and #4 mammary glands were performed, no morphological differences 
could be discerned among the single and double knock-out cohorts of BLG-
Cre;Catnbwt/lox(ex3) mice. In fact, in contrast to the 6 and 9 week developmental 
time-points, all three Runx deficient groups of animals displayed a dramatically 
distorted mammary anlage compared to control mice (Figure 5. 10, left and mid 
panels). Importantly, this phenotype displayed 100% penetrance, as it was found 
to equally affect all five pairs of murine mammary glands. In addition, 
considering the high abundancy of TEBs present at this developmental stage, it 
was not surprising to find the presence of Wnt/β-catenin pre-neoplastic 
mammary lesions affecting the latter, as shown by H&E stains (Figure 5. 10, right 
panel). The same scenario did not hold true for BLG-Cre;Catnbwt/wt mice, which 
displayed normal-looking mammary anlages, regardless of their Runx status 
(Figure 5. 11). As directional growth of the mammary epithelial rudiment starts 
with ovary maturation and hormone release, quantification of ductal elongation 
was not carried out at this hormone-independent developmental stage. 
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Figure 5. 9 Effect of mammary specific Runx1 and Runx2 loss on body weight and cumulative 
mammary gland weight in 3 week old Wnt/β-catenin mutant and wild type mice. 
Scatter dot plots of body weight and cumulative mammary gland weight of 3 week old BLG-
Cre;Catnbwt/lox(ex3) (A, B) and BLG-Cre;Catnbwt/wt (C, D) female mice upon loss of Runx1, Runx2 or 
both genes. Cumulative mammary gland weight was expressed as a percentage of total mammary 
gland weight divided by the body weight of the animal. Statistical analysis was performed by the 
Kruskal-Wallis test with Dunn’s multiple comparisons in GraphPad Prism. Error bars represent 
mean with SD (n≥3 per each cohort, except for BLG-Cre;Catnbwt/wt;Runx1wt/wt;Runx2wt/wt with 
n=1). No significance was found among groups. No statistical test could be run for the BLG-
Cre;Catnbwt/wt cohort, as only was mouse was present in the Runx1wt/wt;Runx2wt/wt group. 
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Figure 5. 10 Individual or combined loss of Runx1 and Runx2 severely compromise the 
morphology of the mammary anlage in the presence of activated Wnt/β-catenin signalling. 
Whole-mounts of cervical (#1) and abdominal (#4) MGs (left and mid columns) and representative 
H&Es (right column) from 3 week old BLG-Cre;Catnbwt/lox(ex3) female mice of the 
Runx1wt/wt;Runx2wt/wt (A), Runx1fl/fl;Runx2wt/wt (B), Runx1wt/wt;Runx2fl/fl  (C) and 
Runx1fl/fl;Runx2fl/fl  (D) cohorts. One representative whole-mount and H&E image of n≥3 is shown 
per genotype. Scale bar of whole-mounts, 500 µm. Scale of H&Es, 500 µm. H&E, haematoxylin 
eosin; MG, mammary gland. 
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Figure 5. 11 Mammary-specific deletion of Runx1 and Runx2 does not affect the morphology 
of the anlage of Wnt/β-catenin wild type mice. 
Whole-mounts of cervical (#1) and abdominal (#4) MGs (left and mid columns) and representative 
H&Es (right column) from 3 week old BLG-Cre;Catnbwt/wt female mice of the Runx1wt/wt;Runx2wt/wt 
(A), Runx1fl/fl;Runx2wt/wt (B), Runx1wt/wt;Runx2fl/fl  (C) and Runx1fl/fl;Runx2fl/fl  (D) cohorts. One 
representative whole-mount and H&E image of n≥4 is shown per genotype, but for 
Runx1wt/wt;Runx2wt/wt with n=1. Scale bar of whole-mounts, 500 µm. Scale of H&Es, 500 µm. H&E, 
haematoxylin eosin; MG, mammary gland. 
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5.2.2 Investigating the tumour suppressive mechanisms exerted 
by RUNX1 and RUNX2  
To investigate how deletion of Runx1 and/or Runx2 affected the proliferative 
signals conveyed by mammary-specific activation of the Wnt/β-catenin signalling 
pathway, an analysis of the growth of pre-neoplastic mammary lesions was 
performed. To this end, 6 week old BLG-Cre;Catnbwt/lox(ex3) pubertal mice were 
injected with BrdU and their mammary glands harvested two hours after 
injection. Tissues from all animal cohorts were formalin-fixed paraffin-
embedded and stained with an anti-BrdU antibody to assess the presence of 
cycling (BrdU+) cells within incipient mammary lesions. Being the mammary 
gland a heterogeneous organ composed of both epithelial and stromal 
compartments, it was first necessary to determine the amount of total 
epithelium (TE) present per each slide analysed, across all different genotypes.  
Quantification of TE revealed a moderate increase of epithelial tissue only upon 
combined loss of Runx1 and Runx2, yet not in the absence of each individual 
gene (Figure 5. 12A). A significant difference, however, was found between 
Runx1fl/fl;Runx2fl/fl and Runx1fl/fl mice, in line with the enlarged mammary 
structure displayed by the whole-mounts of double floxed mice, versus the 
thinner and smaller mammary trees observed upon loss of Runx1 (Figure 5. 6). In 
view of the use of a conditional GEMM wherein BLG-Cre-driven activation would 
have occurred only in a subset of MMECs, it was important to further distinguish 
between the amount of normal and abnormal epithelium (NE and AE, 
respectively) present per slide. By doing so, results of the analysis revealed a 
trend towards increased NE displayed by both single knock-out cohorts of mice 
(Figure 5. 12B), counterbalanced by a higher amount of AE observed in both 
control and Runx1fl/fl;Runx2fl/fl animals (Figure 5. 12C). In both cases, significant 
differences emerged specifically between the Runx2fl/fl and Runx1fl/fl;Runx2fl/fl 
groups of mice (Figure 5. 12).  
Interestingly, when the proliferative index displayed by each epithelial layer 
(i.e. TE, NE and AE) was quantified, no significant differences emerged between 
Runx1fl/fl;Runx2fl/fl mice and the other cohorts of BLG-Cre;Catnbwt/lox(ex3) animals 
(Figure 5. 13). What emerged, instead, was a trend to increased TE proliferation 
displayed by Runx1fl/fl animals (Figure 5. 13A). Of note, this increase appeared 
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to be due to moderate levels of proliferation occurring in both NE (Figure 5. 13B) 
and AE (Figure 5. 13C). Albeit not significant, these results were perhaps 
indicative of a compensatory mechanism occurring in the absence of Runx1.  
Nonetheless, when TE, NE and AE proliferative indices were multiplied by the 
percentage occupied by each layer within the analysed mammary gland tissue, 
Runx1fl/fl;Runx2fl/fl mice displayed significantly higher levels of TE proliferation 
compared to Runx1fl/fl mice, yet not to wild type BLG-Cre;Catnbwt/lox(ex3) animals 
(Figure 5. 14A). Of note, this increase appeared to relate to the high cell 
turnover characterizing AE (Figure 5. 14C), but not NE (Figure 5. 14B). 
Representative histological sections of anti-BrdU staining of pre-neoplastic 
mammary lesions from all cohorts BLG-Cre;Catnbwt/lox(ex3) mice are shown in 
Figure 5. 15. 
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Figure 5. 12 Perturbation of pubertal mammary epithelium upon activation of the Wnt/β-
catenin pathway in the absence of Runx1 and Runx2. 
Scatter dot plots showing the distribution of TE (A), NE (B) and AE (C) displayed by 6 week old 
BLG-Cre;Catnbwt/lox(ex3) female mice in the absence of Runx1, Runx2 or both genes. (A) TE was 
calculated as a percentage of total mammary gland area. (B) NE and (C) AE were calculated as 
percentages of TE area. Statistical analysis was performed by the Kruskal-Wallis test with Dunn’s 
multiple comparisons in GraphPad Prism. Error bars represent mean with SD (n≥3 per each 
cohort). *P<0.05. AE, abnormal epithelium; NE, normal epithelium; TE, total epithelium. 
 
                                                                                                                    186 
 
 
 
Figure 5. 13 Quantification of the proliferative density of pubertal mammary epithelium 
upon activation of the Wnt/β-catenin pathway in the absence of Runx1 and Runx2. 
Scatter dot plots of TE (A), NE (B) and AE (C) proliferative density displayed by 6 week old BLG-
Cre;Catnbwt/lox(ex3) female mice in the absence of Runx1, Runx2 or both genes. Mice were injected 
with BrdU, their mammary glands harvested after 2 hours, and the tissues stained with anti-
BrdU. (A) TE proliferative density was calculated dividing the number of BrdU+ cells within TE by 
TE area. (B) NE proliferative density was calculated dividing the number of BrdU+ cells within NE 
by NE area. (C) AE proliferative density was calculated dividing the total number of BrdU+ cells 
with AE by AE area. Statistical analysis was performed by the Kruskal-Wallis test with Dunn’s 
multiple comparisons in GraphPad Prism. Error bars represent mean with SD (n≥3 per each 
cohort). No significant differences were found among groups. AE, abnormal epithelium; BrdU, 
bromodeoxyuridine; NE, normal epithelium; TE, total epithelium. 
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Figure 5. 14 Normalized proliferative density of pubertal mammary epithelium upon 
activation of the Wnt/β-catenin pathway in the absence of Runx1 and Runx2. 
Scatter dot plots of normalized TE (A), NE (B) and AE (C) proliferative density displayed by MGs 
of 6 week old BLG-Cre;Catnbwt/lox(ex3) female mice in the absence of Runx1, Runx2 or both genes. 
Mice were injected with BrdU, their mammary glands harvested after 2 hours, and the tissues 
stained with anti-BrdU. (A) TE proliferative density was normalized by dividing it by the % TE 
area. (B) NE proliferative density was normalized by dividing it by the % NE area. (C) AE 
proliferative density was normalized by dividing it by the % AE area. Statistical analysis was 
performed by the Kruskal-Wallis test with Dunn’s multiple comparisons in GraphPad Prism. Error 
bars represent mean with SD (n≥3 per each cohort). *P<0.05. AE, abnormal epithelium; BrdU, 
bromodeoxyuridine; NE, normal epithelium; TE, total epithelium. 
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Figure 5. 15 Immunohistochemistry for BrdU on pre-neoplastic Wnt/β-catenin mammary 
lesions upon loss of Runx1 and Runx2. 
Histological sections of anti-BrdU stained mammary glands from 6 week old BLG-
Cre;Catnbwt/lox(ex3) mice of the Runx1wt/wt;Runx2wt/wt (A), Runx1fl/fl;Runx2wt/wt (B), 
Runx1wt/wt;Runx2fl/fl  (C) and Runx1fl/fl;Runx2fl/fl  (D) cohorts. One representative image of n=3, 
but for the Runx1fl/fl;Runx2wt/wt group with n=6, is shown per genotype. Images were captured 
via the HALO software, using the 2X (left column) and 10X (right column) lenses. 
                                                                                                                    189 
 
5.2.3 Histopathological characterization of Wnt/β-catenin 
preneoplastic lesions in the absence of the Runx genes 
In an attempt to perform a thorough characterization of the histopathological 
features displayed by pre-neoplastic Wnt/β-catenin-driven mammary lesions, 6 
week old BLG-Cre;Catnbwt/lox(ex3) mice were euthanized and their mammary 
glands formalin-fixed paraffin-embedded for H&E and IHC analysis. Upon H&E 
examination, Runx1wt/wt;Runx2wt/wt animals displayed a distorted mammary 
tissue architecture with presence of adenosquamous lesions (Figure 5. 16). In 
line with the causative tumourigenic role played by canonical Wnt signalling, 
strong nuclear β-catenin could be observed in specific foci of the mammary 
gland. In the rest of the organ, the protein was instead found to be mainly 
located at the cell membrane, exerting its function as a cell-adhesion molecule. 
IHC analysis of CK5 and CK8/18 staining indicated the simultaneous presence of 
abnormally expanded basal and luminal MMECs, respectively. In addition, CK10 
positive cells could also be detected within the centre of most lesions, 
confirming trans-differentiation of MMECs into epidermal cells upon Wnt/β-
catenin-driven oncogenic transformation. Lastly, strong α-SMA staining was 
found to delineate the majority of pre-neoplastic lesions, which also showed 
levels of ERα and PR positivity. Interestingly, whilst the pattern of hormone 
receptors expression is reported to be evenly scattered across normal mammary 
ducts, the presence of contiguous HR+ cells was often observed in Wnt/β-
catenin-driven mammary lesions (Figure 5. 16). The same histopathological 
features were visible in Runx1fl/fl;Runx2wt/wt animals, albeit to a smaller extent 
of control mice due to the low amount of epithelial mammary tissue displayed 
upon loss of Runx1 (Figure 5. 17). In addition, correct interpretation of IHC 
staining in this cohort of mice was often confounded by the unknown presence of 
infiltrating melanocytes, which appeared brown in colour as with all IHC positive 
MMECs. Regardless, strong nuclear β-catenin staining was also evident in the 
mammary glands of Runx1fl/fl;Runx2wt/wt mice, yet this time in a fewer 
percentage of MMECs. As in the case of control mice, Runx1-deleted pre-
neoplastic lesions appeared to be composed of both basal (CK5+) and luminal 
(CK8/18+) cells, surrounded by a layer of myoepithelial (α-SMA) MMECs. On the 
contrary, only non-specific CK10 staining could be observed, suggesting a lower 
degree of epithelial trans-differentiation upon loss of Runx1. As in the case of 
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control mice, ERα and PR positive cells were found to be highly abundant within 
Wnt/β-catenin-driven mammary lesions, suggesting perhaps a dependency on 
hormonal cues, at least at the developmental stage analysed (Figure 5. 17). 
When the same analysis was applied to Runx1wt/wt;Runx2fl/fl mice, a high degree 
of mammary epithelial transformation was visible by H&Es (Figure 5. 18). Like in 
the case of controls, several foci of strong nuclear β-catenin staining were 
interspersed with disorganized mammary ducts, wherein the protein remained 
located at the plasma membrane. In line with both Runx1wt/wt;Runx2wt/wt and 
Runx1fl/fl;Runx2wt/wt mice, Runx2-deleted pre-neoplastic lesions appeared 
characterized by the presence of basal (CK5 and α-SMA) and luminal (CK8/18) 
markers, again indicative of an abnormal expansion of both epithelial lineages. 
No staining could instead be observed for the epidermal marker CK10. 
Interestingly, however, when the hormonal status of incipient lesions was 
assessed, these displayed very strong ERα staining, with positive cells often 
found adjacent to each other (Figure 5. 19). In line with whole-mount 
examinations, Wnt/β-catenin pre-neoplastic lesions appeared to dominate the 
mammary gland landscape of Runx1fl/fl;Runx2fl/fl mice, displaying a more 
widespread β-catenin expression as compared to all other cohorts of BLG-
Cre;Catnbwt/lox(ex3) mice (Figure 5. 19). Akin to the other groups, Runx1- and 
Runx2-deleted mammary lesions were characterized by the presence of both CK5 
and CK8/18 positive cells. Nonetheless, a reduction of α-SMA, as well as ERα and 
PR staining, was seen in this cohort. On the contrary, the highest levels of CK10 
positivity appeared to distinguish Runx1fl/fl;Runx2fl/fl animals, suggesting a 
prominent Wnt/β-catenin mediated trans-differentiation of the mammary 
epithelium upon loss of Runx genes (Figure 5. 19). IHC analysis for RUNX1 and 
RUNX2, as displayed by all cohorts of BLG-Cre;Catnbwt/lox(ex3) mice, is shown in 
Figure 5. 20. In line with previous analysis done in our lab (McDonald et al., 
2014), RUNX1 epithelial expression appeared stronger than RUNX2, which instead 
was occasionally found in the stroma surrounding pre-neoplastic lesions of 
Runx1wt/wt;Runx2wt/wt animals. Albeit Runx1fl/fl;Runx2fl/fl mice showed the lowest 
levels of expression for both genes, correlating RUNX1 and RUNX2 expression 
with the genotype of Runx-deficient BLG-Cre;Catnbwt/lox(ex3) mice revealed to be 
a challenging task, probably due to the high prevalence of BLG-Cre negative, 
Runx-proficient MMECs. 
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Figure 5. 16 Histopathological analysis of Wnt/β-catenin driven pre-neoplastic lesions. 
H&E and IHC staining of β-catenin, basal (CK5), luminal (CK8/18), epidermal (CK10), 
myoepithelial (α-SMA) and hormonal (ERα, PR) makers on pre-neoplastic mammary tumour 
lesions from 6 week old BLG-Cre;Catnbwt/lox(ex3);Runx1wt/wt;Runx2wt/wt  mice. Representative 
pictures of n=3 mice. Scale bar, 500 µm. H&E, haematoxylin eosin; IHC, immunohistochemistry. 
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Figure 5. 17 Histopathological analysis of Wnt/β-catenin driven lesions upon Runx1 loss. 
H&E and IHC staining of β-catenin, basal (CK5), luminal (CK8/18), epidermal (CK10), 
myoepithelial (α-SMA) and hormonal (ERα, PR) makers on pre-neoplastic mammary tumour 
lesions from 6 week old BLG-Cre;Catnbwt/lox(ex3);Runx1fl/fl;Runx2wt/wt  mice. Representative 
pictures of n=3 mice. Scale bar, 500 µm. H&E, haematoxylin eosin; IHC, immunohistochemistry. 
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Figure 5. 18 Histopathological analysis of Wnt/β-catenin driven lesions upon Runx2 loss. 
H&E and IHC staining of β-catenin, basal (CK5), luminal (CK8/18), epidermal (CK10), 
myoepithelial (α-SMA) and hormonal (ERα, PR) makers on pre-neoplastic mammary tumour 
lesions from 6 week old BLG-Cre;Catnbwt/lox(ex3);Runx1wt/wt;Runx2fl/fl  mice. Representative 
pictures of n=3 mice Scale bar, 500 µm. H&E, haematoxylin eosin; IHC, immunohistochemistry. 
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Figure 5. 19 Histopathological analysis of Wnt/β-catenin lesions upon loss of Runx genes. 
H&E and IHC staining of β-catenin, basal (CK5), luminal (CK8/18), epidermal (CK10), 
myoepithelial (α-SMA) and hormonal (ERα, PR) makers on pre-neoplastic mammary tumour 
lesions from 6 week old BLG-Cre;Catnbwt/lox(ex3);Runx1fl/fl;Runx2fl/fl  mice. Representative pictures 
of n=3 mice Scale bar, 500 µm. H&E, haematoxylin eosin; IHC, immunohistochemistry. 
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Figure 5. 20 RUNX1 and RUNX2 analysis of Wnt/β-catenin driven adenosquamous lesions. 
Representative IHC images of RUNX1 and RUNX2 staining from 6 week old BLG-Cre;Catnbwt/lox(ex3) 
mice of the Runx1wt/wt;Runx2wt/wt (A), Runx1fl/fl;Runx2wt/wt (B), Runx1wt/wt;Runx2fl/fl (C) and 
Runx1fl/fl;Runx2fl/fl (D) cohorts. One representative image of n=3 is shown per cohort. IHC. 
Immunohistochemistry. 
                                                                                                                    196 
 
5.2.4 Expression analysis of Wnt/β-catenin target genes upon loss 
of Runx genes 
In view of the presence of strong nuclear β-catenin foci found within the vast 
majority of pre-neoplastic lesions displayed by BLG-Cre;Catnbwt/lox(ex3) animals, a 
preliminary analysis of Wnt/β-catenin target genes was performed. In this 
regards, Runx1wt/wt;Runx2wt/wt,  Runx1fl/fl;Runx2wt/wt, Runx1wt/wt;Runx2fl/fl and 
Runx1fl/fl;Runx2fl/fl mice were euthanized at the age of 6 weeks and all ten 
mammary glands dissected out for collection. Organs were then processed as 
previously described (Chapter 3), in order to obtain a single cell suspension 
enriched in MMECs. Following RNA extraction and cDNA synthesis, qPCR analysis 
for a restricted panel of Wnt/ β-catenin target genes was carried out. As already 
discussed in Chapter 4, nuclear translocation of unphosphorylated β-catenin 
leads to the formation of a bipartite transcription factor complex composed by 
members of the TCF/LEF family (Eastman et al., 1999). This result in a 
transient, yet potent, activation of gene transcription affecting a wide range of 
β-catenin targeted genes (Daniels et al., 2005). Albeit the identity of the 
majority of them is still elusive, some others have well-been documented. 
Among the latter category, Ccnd1 and Myc represent major drivers of β-catenin-
induced cell proliferation (Lin et al., 2000), whereas Lgr5, Cd44 and Ascl2 genes 
are crucial mediators of the role played by canonical Wnt signalling in the 
regulation of mammary stemness (Zeng et al., 2010). Accordingly, whilst high 
Ccnd1 levels were consistently shown for Runx1wt/wt;Runx2fl/fl mice, all three 
Runx-deficient cohorts showed a reduction of Myc expression as compared to 
controls (Figure 5. 21). Nonetheless, a significant difference in Myc levels was 
only found upon combined deletion of Runx1 and Runx2 (P=0.00384). Thus, it 
could be speculated that Myc might represent a downstream target of the Runx 
genes. When analysis of Wnt/β-catenin stem-like genes was  performed, a 
modest increase in Lgr5 levels was displayed by all Runx-deficient cohorts of 
mice, as compared to Runx1wt/wt;Runx2wt/wt animals, albeit a significant 
difference was only reported upon deletion of Runx2 (P=0.00638). Whilst some 
variability was found in relation to Cd44, both within and across cohorts, an 
intriguing pattern of expression was observed in the case of the Ascl2 gene, 
which showed a trend towards increased levels in both Runx1fl/fl;Runx2wt/wt and 
Runx1fl/fl;Runx2fl/fl cohorts of BLG-Cre;Catnbwt/lox(ex3) mice (Figure 5. 21). 
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Figure 5. 21 Expression analysis of Wnt/β-catenin target genes upon loss of Runx1 and 
Runx2. 
Bar chart showing mRNA expression levels of five Wnt/β-catenin target genes in 
Runx1wt/wt;Runx2wt/wt,  Runx1fl/fl;Runx2wt/wt, Runx1wt/wt;Runx2fl/fl and Runx1fl/fl;Runx2fl/fl cohort 
of BLG-Cre;Catnbwt/lox(ex3) mice. Animals were euthanized at 6 weeks of age and their mammary 
glands dissected out for collection. Organs were mechanically and enzymatically digested in 
order to obtain a single cell suspension enriched in MMECs. Samples were then processed for RNA 
extraction, cDNA synthesis and qPCR analysis. Three replicates per cohort are shown individually 
to highlight the variability within each group. Each replicate contains mammary glands from 
more than one animal. Data analysis was performed using the CFX Manager software, version 3.1 
(BioRad) and the GenEx Standard software, version 6.1 (MultiD Analyses). Data were first 
normalized to Actin and Fbxo38 reference genes and then expressed as fold change of 
Runx1wt/wt;Runx2wt/wt control mice. The x axis indicates five different Wnt/β-catenin target 
genes (Ccnd1, Myc, Lgr5, Cd44 and Ascl2); the y axis shows expression values after log2 
transformation, where 0 represents the base value. Anything above 0 is up-regulated, whilst 
anything below 0 is downregulated in respect to Runx1wt/wt;Runx2wt/wt mice. Statistical analysis 
(shown in the text) was performed by the multiple comparisons t-test with the Dunn-Bonferroni 
correction method, comparing each cohort to the Runx1wt/wt;Runx2wt/wt group. Cut off value of 
this analysis is 0.006379. RNA extraction, cDNA synthesis and qPCR analysis was done by Dimitris 
Athineos. 
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5.3 Discussion 
Overall, this analysis revealed a precocious transformation of the mammary 
epithelium in response to BLG-Cre-driven activation of the Wnt/β-catenin 
signalling pathway. Proof of oncogenic changes relate to the presence of 
thickened epithelial ducts in mammary whole-mounts and H&E pre-neoplastic 
lesions at both pre-pubertal (3 weeks) and pubertal (6 and 9 weeks) time-points. 
Nonetheless, the mammary anlage and the subsequent elongation of the 
incipient ductal tree characterizing Runx wild type BLG-Cre;Catnbwt/lox(ex3) 
control mice did not appear to be severely compromised. In net contrast, 
individual or combined deletion of Runx1 and Runx2 resulted in the formation of 
enlarged mammary rudiments at 3 weeks of age. By 6 weeks, this phenotype 
dramatically impinged on the subsequent elongation of pubertal mammary 
glands, whereby growth of ductal trees appeared halted in the absence of Runx1 
and Runx2, yet augmented upon combined loss of both genes. At the end of 
puberty (9 weeks), whilst ductal elongation and mammary gland morphogenesis 
were partly restored in the vast majority of both Runx1fl/fl and Runx2fl/fl mice, a 
similar rescue of the phenotype was not observed in the absence of both genes. 
Thus, it could be speculated that activation of the Wnt/β-catenin signalling 
pathway might target a population of stem/progenitor cells present in the TEBs 
of pre-pubertal mice. Whilst expansion of this pre-neoplastic subset of cells 
would occur upon individual and combined loss of Runx1 and Runx2, its survival 
would appear to be enhanced in the absence of both genes. Altogether, this 
hints towards a potent tumour suppressive role played by Runx1 and Runx2 in 
the early stages of Wnt/β-catenin-mediated mammary tumourigenesis. 
Of note, one of the most common mechanisms by which activated Wnt/β-catenin 
signalling drives tumourigenesis is via an increase in cell proliferation (Zeng et 
al., 2010). However, on the basis of the results explained above, the enlarged 
mammary tree arising from combined loss of Runx1 and Runx2 cannot be solely 
justified by the moderate rate of TE proliferative density. Moreover, in line with 
the high predominance of pre-neoplastic lesions evident by IHC, proliferation 
appears to be tightly linked to the subsequent differentiation of the incipient 
mammary epithelium. Due to the experimental procedure used, which involves 
the incorporation of BrdU by proliferating cells and its gradual decrease over cell 
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division, it might be possible that fast cycling cells could not be captured by this 
technique. Alternatively, the enlarged epithelial structure seen upon loss of 
Runx1 and Runx2 might stem from either a decrease in cell death or from 
changes in MaSC behaviour. MaSCs would use the balance between ACD and SCD 
in order to self-renew and differentiate (ACD) or to expand the SC pool (SCD) 
(Ballard et al., 2015). It is also known that, while committed progenitors arising 
via ACD display a high proliferative rate, MaSCs are generally believed to be slow 
cycling cells (Welm et al., 2002; Visvader et al., 2016). As such, it could be 
speculated that BLG-Cre-driven activation of the Wnt/β-catenin signalling 
pathway switches the balance from ACD to SCD in the absence of Runx1 and 
Runx2. Due to their intrinsic differences in cell proliferation, the use of a label-
retaining approach might help discriminate between the presence of an 
expanded MaSC pool (the result of SCD) versus the presence of transient 
amplifying cells (the result of ACD). Albeit the same phenotype was not observed 
in Runx1fl/fl mice, the latter displayed the highest levels of TE proliferative 
density. However, if TE proliferation of Runx1fl/fl mice did not lead to a 
corresponding increase in the amount of total TE, compensatory processes have 
to exist. This could point towards an increased cell death, a reduced cell 
survival, or to the presence of a tumour suppressive mechanism able to halt 
Wnt/β-catenin driven pre-neoplastic transformation in the absence of Runx1. 
Due to the phenotype displayed with the concomitant absence of Runx2, there is 
a high chance these two genes might compensate for each other’s absence. 
Following histopathological characterization of pre-neoplastic Wnt/β-catenin-
driven mammary lesions, foci of strong nuclear β-catenin staining could be 
observed across all cohorts of pubertal (6 week old) mice. These data reiterated 
the causative tumourigenic role played by canonical Wnt signalling, able to 
cause a precocious transformation of the mammary epithelium. As suggested by 
IHC analysis, signs of this transformation were displayed by distorted mammary 
ducts composed by abnormally expanded basal and luminal epithelial cells, 
surrounded by an almost intact MYO layer. Culmination of this phenotype was 
represented by the presence of epidermal cells found within the centre of pre-
neoplastic lesions, particularly upon combined deletion of both Runx1 and 
Runx2. Interestingly, high levels of HRs were also found across all mouse 
cohorts, with ERα positive cells often located in close proximity to each other. 
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These observations suggested a link between canonical Wnt and hormone 
signalling and hinted towards the possibility of a targeted HR positive cell-of-
origin. Preliminary analysis of Wnt/β-catenin target genes showed an increase of 
Lgr5 expression displayed by all three cohorts of Runx-deficient mice. In 
addition, a modest increase of the Ascl2 transcription factor was specifically 
found upon deletion of Runx1, both in the presence or absence of Runx2. In view 
of its well-known function as a stem cell identity gene in the colon (Schuijers  et 
al., 2015), these findings might point towards the expansion of a stem-like 
population of MMECs in the absence of Runx1 or combined loss of both Runx 
genes. Nonetheless, a considerable amount of variability was found within each 
group of mice. These discrepancies could be ascribed to the peculiar 
developmental time point chosen, characterized by the presence of both normal 
and pre-neoplastic mammary tissue. In addition, being all cohorts on a mixed 
background, strain-related differences cannot be ruled out. Future directives 
might be focused on increasing not only the panel of Wnt/β-catenin target 
genes, but also the number of experimental animals per each cohort. Lastly, 
given the multitude of signalling pathways the Wnt/β-catenin signalling interact 
with, an unbiased analysis of RNA-sequencing might help unveil the contribution 
played by Runx genes loss upon Wnt/β-catenin-driven mammary tumourigenesis. 
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6 Characterization of Wnt/β-catenin activated 
mammary epithelial cells upon Runx deletion 
 
6.1 Introduction 
Mammary-specific activation of the Wnt/β-catenin signalling pathway showed a 
remarkable disruption of postnatal mammary gland development in the absence 
of Runx1 and Runx2 (see Chapter 5). In order to capture the early stages of 
oncogenic transformation, responsible for converting a normal mammary 
epithelium into an incipient pre-neoplastic one, an experimental ex vivo-based 
approach was exploited. This consisted in the extraction and characterization of 
the functional and phenotypic features displayed by Wnt/β-catenin-activated 
MMECs, in the attempt to better understand the mechanism(s) underpinning the 
tumour suppressive function exerted by RUNX1 and RUNX2 in the context of Wnt 
siganlling. 
6.2 Experimental procedures 
In view of the phenotypic variability visible by whole-mounts affecting all 
cohorts of BLG-Cre;Catnbwt/lox(ex3) mice and the low amount of epithelial tissue 
correlated with some genotypes, MMEC extraction was performed by harvesting 
mammary glands from 7 to 8 week old females. Considering the subtle molecular 
differences reported between different pairs of mammary glands (Veltmaat et 
al., 2013), all ten murine glands were harvested at any time, with removal of 
the inguinal lymph nodes. In addition, although some experiments were 
performed with one mouse per group, some others were carried out pulling 
together mammary glands from more than one animal per genotype. As for any 
fractionation studies, one of the main hurdles of this technique consisted in 
obtaining a single cell suspension from solid mammary gland tissues. Indeed, the 
ramified ductal structure of the mammary gland lays its foundation on the 
properties of MMECs, which appear to be tightly connected to each other, as 
well as to the extracellular matrix. In brief, mammary glands were firstly 
mechanically dissociated with the use of a tissue chopper and secondly 
enzymatically digested via a mixture of collagenase and hyaluronidase. Following 
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a series of washes to remove all cell debris and the majority of non-epithelial 
cells, the digested tissue was subjected to red blood cell lysis. Lastly, after two 
sequential steps of trypsinization and filtration, a single-cell suspension could be 
obtained and used for different ex vivo experimental assays (Figure 6. 1). 
 
 
 
Figure 6. 1 Pipeline for the extraction and characterization of mammary epithelial cells. 
Workflow of the eight steps required to extract and characterize the properties of MMECs. (1) All 
five pairs of mammary glands are dissected out and (2) placed in a 50 ml tube with PBS. (3) 
Mammary glands are mechanically disrupted with a tissue chopper until a fine tissue paste is 
obtained. (4) Chopped tissue is enzymatically digested at 37°C for 1.5 hours in medium 
containing collagenase and hyaluronidase. (5) Digested tissue is treated with NHCl4 for 5 minutes 
at room temperature to lyse red blood cells. (6) The lysate is trypsinized for 10 minutes at 37°C 
and filtered through 70 µm pores. (7) A single cell suspension enriched in MMECs is obtained. (8) 
The properties of MMECs can be tested via different ex vivo functional assays tumoursphere 
assay. MMEC, mouse mammary epithelial cell; PBS, phosphate buffered saline.  
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6.3 Results 
6.3.1 Investigating how loss of Runx1 and Runx2 impinges on 
Wnt/β-catenin-driven mammary stemness 
The Wnt/β-catenin signalling pathway plays a major role in regulating self-
renewal potential and proliferative ability of stem/progenitor cells. Not 
surprisingly, aberrant Wnt/β-catenin signalling has also been shown to exploit 
the latter mechanisms to drive malignant transformation of several tissues, 
including the breast (Reya and Clevers, 2005). In an attempt to investigate if 
individual or combined deletion of Runx1 and Runx2 impinged on the stemness 
properties exhibited by Wnt/β-catenin-activated MMECs, the tumoursphere assay 
was employed. Following optimization of the appropriate culture conditions, 
freshly extracted MMECs from all cohorts of BLG-Cre;Catnbwt/lox(ex3) mice were 
plated in non-adherent conditions at a density of 10,000 live cells per well. After 
6 days, spheres were manually counted and photographed to assess their 
morphology. Nonetheless, as the accurate number of spheres was confounded by 
the presence of aggregates and cell debris, sphere size was used as a surrogate 
measure of stem/progenitor activity. Accordingly, whilst all BLG-
Cre;Catnbwt/lox(ex3) derived MMECs demonstrated the ability to grow in suspension 
(Figure 6. 2A), a significant reduction in the frequency of small size spheres was 
found in the absence of Runx2 as compared to Runx-wild type controls (Figure 6. 
2B). However, when all groups were compared with each other, 
Runx1fl/fl;Runx2fl/fl cultures displayed a significantly higher frequency of small 
tumourspheres in respect to both Runx1fl/fl and Runx2fl/fl-derived MMECs.  
When primary tumoursphere-derived cells were re-plated at a density of 5,000 
live cells per well under the same non-adherent conditions, genotypes showed 
the ability to form secondary tumourspheres (Figure 6. 3A). These appeared to 
be significantly bigger upon loss of Runx2 (Figure 6. 3B). Albeit combined 
deletion of Runx1 and Runx2 did not seem to affect the size of secondary 
tumourspheres in relation to Runx-wild type cohorts (Figure 6. 3), these were 
found to be significantly smaller in relation to Runx2fl/fl-derived MMECs. In 
addition, Runx1fl/fl;Runx2fl/fl-derived secondary tumourspheres generally 
appeared to be lower in number compared to all other groups of BLG-
Cre;Catnbwt/lox(ex3) mice (data not shown). 
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Figure 6. 2 Primary tumoursphere growth of Wnt/β-catenin activated mammary epithelial 
cells in the absence of Runx1 and/or Runx2. 
Representative pictures (A) and scatter dot plot of the area (B) of primary tumourspheres 
derived from the extraction of MMECs from 7 to 8 week old BLG-Cre;Catnbwt/lox(ex3) female mice, 
in the absence of Runx1 (Runx1fl/fl;Runx2wt/wt), Runx2 (Runx1wt/wt;Runx2fl/fl), or both genes 
(Runx1fl/fl;Runx2fl/fl). Images were captured with the 4X (left and mid columns) and 10X (right 
column) objective lens of the Olympus CKX41 microscope. One representative picture of n≥3 is 
shown per genotype. Spheres area (µm) was calculated via ImageJ and grouped into three 
ranges: 1500-4500, 4500-7500, 7500-15000. The graph shows the frequency (%) of measured 
spheres according to each range across all genotypes. Statistical analysis was performed by the 
two-way ANOVA test in GraphPad Prism. The Dunnet’s multiple comparisons test was used to 
compare all genotypes to the Runx1wt/wt;Runx2wt/wt control cohort; the Tukey’s multiple 
comparisons test was used to compare all genotypes with each other. Error bars represent mean 
with SD (n≥3 for Runx1wt/wt;Runx2wt/wt, n≥4 for the other cohorts). *P<0.05; **P<0.01. MMEC, 
mouse mammary epithelial cells. 
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Figure 6. 3 Secondary tumoursphere growth of Wnt/β-catenin activated mammary epithelial 
cells in the absence of Runx1 and/or Runx2. 
Representative pictures (A) and scatter dot plot of the area (B) of secondary tumourspheres 
derived from the extraction of MMECs from 7 to 8 week old BLG-Cre;Catnbwt/lox(ex3) female mice, 
in the absence of Runx1 (Runx1fl/fl;Runx2wt/wt), Runx2 (Runx1wt/wt;Runx2fl/fl), or both genes 
(Runx1fl/fl;Runx2fl/fl). Images were captured with the 4X objective lens of the Olympus CKX41 
microscope. One representative image of n≥3 is shown per genotype. Spheres area (µm) was 
calculated via ImageJ and grouped into three ranges: 1500-3500, 3500-5500, 5500-7500. The 
graph shows the frequency (%) of measured spheres according to each range across all 
genotypes. Statistical analysis was performed by the two-way ANOVA test in GraphPad Prism. 
The Dunnet’s multiple comparisons test was used to compare all genotypes to the 
Runx1wt/wt;Runx2wt/wt control cohort; the Tukey’s multiple comparisons test was used to compare 
all genotypes with each other. Error bars represent mean with SD (n≥3 for Runx1wt/wt;Runx2wt/wt, 
n≥4 for the other cohorts). **P<0.001. MMEC, mouse mammary epithelial cells. 
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6.3.2 Loss of Runx1 favours the expansion of a basal subpopulation 
of mammary cells upon activated Wnt/β-catenin signalling 
To investigate if Wnt/β-catenin pre-neoplastic transformation of the mammary 
epithelium was due to the expansion of a progenitor subpopulation of MMECs in 
the absence of the Runx genes, the CFC assay was employed. By embedding 
freshly extracted MMECs from 7 to 8 week old BLG-Cre;Catnbwt/lox(ex3) mice in 
matrigel in the presence of GFs-enriched medium, the activity of different 
progenitor populations could be inferred via the formation of discrete colonies. 
However, due to the high degree of cellular heterogeneity present in the MG and 
the low reliability of epithelial versus non-epithelial cell count, the number of 
generated colonies per cohort could not be taken into account. Nonetheless, 
whilst the latter is a general reflection of progenitor cell’ activity, colony 
morphology is indicative of the different types of active progenitors present in 
the original cell mixture. It is in fact believed that cells enriched in the Lin-
CD24+CD49flow subgroup, containing LPs, would mainly give rise to acinar-like 
colonies, whereas cells enriched in the Lin-CD24+CD49fhigh subpopulation, 
comprising BPs/MRUs, would form solid-like colonies (Stingl et al., 2006; Joshi et 
al., 2010).  
When the ratio of solid versus acinar colonies was calculated, it was found that 
BLG-Cre;Catnbwt/lox(ex3)-derived MMECs predominantly formed solid colonies in 
the absence of Runx1 (Figure 6. 4). Interestingly, this phenotype appeared to be 
independent of the Runx2 status, as Runx1fl/fl;Runx2fl/fl-derived MMECs also 
showed a similar behaviour. On the contrary, MMECs extracted from 
Runx1wt/wt;Runx2wt/wt and Runx2fl/fl mice displayed a ratio equal to one, 
indicating comparable levels of solid versus acinar colonies. Whilst the size of 
acinar colonies was found to be unchanged between groups, MMECs extracted 
from Runx1fl/fl and Runx1fl/fl;Runx2fl/fl mice generated a significantly lower 
frequency of 0-100 µm and higher frequency of 100-200 µm solid spheres as 
compared to controls (Figure 6. 5). This result perhaps suggested an increased 
proliferative activity displayed by BPs in the absence of Runx1. It is important to 
point out, however, that none of MMECs extracted from each cohort of BLG-
Cre;Catnbwt/lox(ex3) mice managed to form any discrete colonies in the absence of 
GFs (EGF, FGF2 and Insulin), indicating an equal dependency of Wnt/β-catenin 
driven MMECs towards external cues (data not shown). 
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Figure 6. 4 Deletion of Runx1 favours the formation of basal colonies on a Wnt/β-catenin 
activated background. 
(A) Scatter dot plot of the ratio of solid versus acinar colonies generated by MMECs extracted 
from 7 to 8 week old BLG-Cre;Catnbwt/lox(ex3) female mice, in the absence of Runx1 
(Runx1fl/fl;Runx2wt/wt), Runx2 (Runx1wt/wt;Runx2fl/fl), or both genes (Runx1fl/fl;Runx2fl/fl). 5,000 
live MMECs were plated per well in a 20 µl drop of matrigel, covered with medium supplemented 
with GFs. Cells were fed after 3 days with the addition of fresh medium and cultured for up to 6 
days. For each genotype, the ratio between solid and acinar colonies was calculated per well and 
averaged among all 12 technical replicates. Each dot represents an independent biological 
replicate. (B) One representative picture of n=5 displaying solid and acinar colonies is shown per 
each cohort. Images were taken with the 4X objective lens of the Olympus CKX41 microscope. 
Statistical analysis was performed by the two-way ANOVA test with Dunnet’s multiple 
comparisons in GraphPad Prism. Error bars represent mean with SD (n=5 per each cohort). 
****P<0.0001. MMEC, mouse mammary epithelial cell. 
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Figure 6. 5 Size of acinar and solid colonies formed by Wnt/β-catenin activated mammary 
epithelial cells upon loss of Runx1 and Runx2. 
 
Analysis of the diameter displayed by acinar (A) and solid (B) colonies formed by MMECs 
extracted from 7 to 8 week old BLG-Cre;Catnbwt/lox(ex3) female mice, in the absence of Runx1 
(Runx1fl/fl;Runx2wt/wt), Runx2 (Runx1wt/wt;Runx2fl/fl), or both genes (Runx1fl/fl;Runx2fl/fl). 5,000 
live MMECs were plated per well in a 20 µl drop of matrigel, covered with medium supplemented 
with GFs. Cells were fed after 3 days with the addition of fresh medium and cultured for up to 6 
days. Pictures of each of the 12 technical replicates were taken at day 6 with the 4X objective 
lens of the Olympus CKX41 microscope. The diameter of both acinar and solid colonies was 
analysed via the use of ImageJ. Statistical analysis was performed by the two-way ANOVA test 
with Dunnet’s multiple comparisons in GraphPad Prism. Error bars represent mean with SD (n≥3 
per each cohort). *P<0.05. MMEC, mouse mammary epithelial cell. 
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Perhaps as a reflection of the cellular heterogeneity displayed by the basal 
compartment of the mammary gland, three different morphological types of 
solid colonies could be distinguished among all BLG-Cre;Catnbwt/lox(ex3) cohorts of 
mice: regularly-shaped, branched-shaped and irregularly-shaped. On the basis of 
evidence reported by the literature (Petersen et al., 1992; Stingl et al., 2006), 
regularly-shaped colonies could be due to the presence of BPs, whereas the 
other two types of colonies to the activity of MRUs. However, while branched-
shaped colonies might arise from the activity of normal MRUs (N-MRUs), 
irregularly-shaped colonies could arise from abnormal MRUs (A-MRUs) (Figure 6. 
6A). Interestingly, the morphological appearance of basal colonies appeared to 
correlate with the Runx status of BLG-Cre;Catnbwt/lox(ex3) mice, as the majority of 
Runx1-deficient MMECs, both in the presence or absence of Runx2, generated a 
significantly lower frequency of regularly-shaped colonies versus a higher 
frequency of irregularly-shaped ones. On the contrary, both control and Runx2-
floxed MMECs predominantly formed regularly-shaped colonies, albeit a trend 
towards increased irregular-colonies was also found upon deletion of Runx2 
(Figure 6. 6B). Of note, albeit diestrus-staged animals have been shown to give 
rise to more solid- versus acinar-like colonies due to the high levels of 
progesterone (Joshi et al., 2010), no correlation was found between colony 
morphology and the oestrous cycle of the mice in this study (data not shown). 
Collectively, these data suggested that, in the absence of Runx1, activation of 
the Wnt/β-catenin signalling pathway might lead to the expansion of a 
transformed subpopulation of stem/progenitor cells contained within the basal 
compartment of the mammary gland and display a moderate rate of proliferative 
ability in 3D culture. Nonetheless, as in the case of the tumoursphere assay, it 
remains to be seen whether the heterogeneity displayed by solid colonies can be 
truly ascribed to activation of the Wnt/β-catenin pathway or is rather a 
reflection of the different proportions of normal and abnormal MMECs present in 
mammary glands. Lastly, despite the cellular heterogeneity of the luminal 
epithelial compartment of the mammary gland discussed in the introduction, no 
morphological differences were observed among acinar colonies across all 
different cohorts of BLG-Cre;Catnbwt/lox(ex3) mice. This finding supported the idea 
that perhaps BLG-Cre mediated activation of the Wnt/β-catenin signalling 
pathway might target a subpopulation of MMECs lying within the basal epithelial 
lineage. 
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Figure 6. 6 Morphological heterogeneity displayed by Wnt/β-catenin activated solid colonies 
upon loss of Runx1 and Runx2. 
(A) Two representative pictures showing three different morphological types of solid colonies, 
such as branched-shaped, irregularly-shaped and regularly-shaped, arising from N-MRUs, A-MRUs 
and BPs, respectively. (B) Scatter dot plot of three types of solid colonies generated by 
extracted MMECs from 7 to 8 week old BLG-Cre;Catnbwt/lox(ex3) female mice, in the absence of 
Runx1 (Runx1fl/fl;Runx2wt/wt), Runx2 (Runx1wt/wt;Runx2fl/fl), or both genes (Runx1fl/fl;Runx2fl/fl). 
5,000 live MMECs were plated per well in a 20 µl drop of matrigel, covered with medium 
supplemented with GFs. Cells were fed with fresh medium after 3 days and cultured for up to 6 
days. Pictures of each of the 12 replicates were taken at day 6 with the 10X objective lens of the 
Olympus CKX41 microscope. Statistical analysis was performed by the two-way ANOVA test with 
Dunnet’s multiple comparisons in GraphPad Prism. Error bars represent mean with SD (n≥3 per 
each cohort). ****P<0.0001. A-MRU, abnormal mammary repopulating unit; BP, basal progenitor; 
N-MRU, normal mammary repopulating unit; MMEC, mouse mammary epithelial cells. 
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6.3.3 Phenotypic characterization of Wnt/β-catenin-driven 
mammary epithelial cells  
Based on the ex vivo functional analysis reported above, Runx genes deletion 
was shown to significantly alter the properties of Wnt/β-catenin-activated pre-
neoplastic MMECs, perhaps by interfering with the basal stem/progenitor subset 
of the latter. Thus, in the attempt to capture the molecular changes displayed 
by the mammary epithelium of all cohorts of BLG-Cre;Catnbwt/lox(ex3) mice, an 
experimental flow cytometry-based approach was exploited. As for previous 
analysis, the same experimental procedure was also applied to all corresponding 
groups of BLG-Cre;Catnbwt/wt mice, so that the different contribution of Runx 
genes deletion occurring in a tumourigenic (Wnt/β-catenin activated) and non-
tumourigenic (Wnt/β-catenin wild type) setting could be discerned. While doing 
so, it was felt important to avoid any in vitro culture step in order to minimize 
the presence of putative molecular mechanisms of cell adaptation to non-
physiological conditions. As such, freshly extracted MMECs from all cohorts of 7 
to 8 week old BLG-Cre mice were analysed by flow cytometry within the same 
day to preserve cell viability. In view of the high degree of cellular 
heterogeneity displayed by the mammary gland, a panel of different 
fluorochrome-conjugated antibodies had to be used in the first place to 
eliminate the majority of contaminating haematopoietic and endothelial cells 
from the original mixture (see Materials and Methods). Afterwards, MMEC 
enrichment was achieved via the combinatorial use of two main cell surface 
markers, i.e. CD24 and CD49f. CD24 (heat stable antigen) is a protein detected 
in the apical membrane and cytoplasm of human luminal cells (Jones et al., 
2004), whereas in mice its expression appears to be more widespread, being 
present in epithelial, as well as endothelial and adipocyte cells (Stingl et al., 
2006). CD49f (α6-integrin), instead, seems to be located in the basal layer of the 
human skin (Carter et al., 1990) and in the basal compartment of the murine 
mammary epithelium (Stingl et al., 2006). By following this pipeline, three 
different subpopulations of Lin- mammary cells could be resolved: stromal (CD24-
CD49f-), luminal (CD24+CD49flow) and basal (CD24+CD49fhigh) (Stingl et al., 2006; 
Asselin-Labat et al., 2010) (Figure 6. 1). 
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6.3.3.1  Epithelial versus stromal cells 
As discussed in Chapter 1, murine mammary gland postnatal development 
undergoes two distinct phases: a hormone-independent one, when the mammary 
anlage grows isometrically with the rest of the body; and a hormone-dependent 
one, during which the mammary epithelial tree proliferates and elongates 
throughout the stromal fat pad in response to external hormonal cues. As such, 
one could then imagine that the morphological appearance displayed by the 
mammary gland in late puberty stems from the subsequent contribution of these 
two interconnected processes, as well as from the interaction between the 
epithelial and stromal compartment. In view of the remarkable phenotypes 
observed in the whole-mounts of all virgin BLG-Cre;Catnbwt/lox(ex3) mice (see 
Chapter 5), it was first investigated whether mammary specific deletion of 
Runx1, Runx2 or both genes, caused an unbalance between the percentage of 
epithelial and stromal cells expressed over total Lin- MMECs.  
As perhaps expected from the developmental time-point analysed (i.e. 7 to 8 
weeks), the percentage of stromal cells generally appeared to be greater than 
the epithelial counterpart, in both tumourigenic and non-tumourigenic settings 
across all different genotypes (Figure 6. 7). The only exception occurred within 
the Runx1fl/fl;Runx2fl/fl cohort of BLG-Cre;Catnbwt/lox(ex3) mice, wherein epithelial 
and stromal cells equalled each other (Figure 6. 7A). Albeit no significant 
differences were found when comparing each Runx-deficient cohort to its 
corresponding BLG-Cre;Catnbwt/lox(ex3) and BLG-Cre;Catnbwt/wt control group, 
deletion of Runx1 resulted in a significant decrease of epithelial and increase of 
stromal cells when compared to Runx1fl/fl;Runx2fl/fl mice of the BLG-
Cre;Catnbwt/lox(ex3) cohort (Figure 6. 7A). Of note, this result tided up not only 
with findings from the 6 and 9 weeks whole-mount analysis, whereby a small 
Runx1-deficient tree contrasted the presence of an enlarged mammary structure 
in the absence of both genes, but also to the previously shown quantification of 
TE, which appeared decreased upon deletion of Runx1 yet increased with 
combined excision of both genes (see Chapter 5). Altogether, these data might 
suggest that the restricted proliferative ability of Wnt/β-catenin-driven Runx1-
deificient MMECs might only be unleashed in the absence of Runx2. 
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Figure 6. 7 Effects of Runx1 and Runx2 deletion on mammary epithelial and stromal cells in a 
Wnt/β-catenin activated and wild type setting.  
Scatter dot plots showing the proportion of epithelial and stromal cells from (A) BLG-
Cre;Catnbwt/lox(ex3) and (B) BLG-Cre;Catnbwt/wt mice, upon deletion of Runx1 
(Runx1fl/fl;Runx2wt/wt), Runx2 (Runx1wt/wt;Runx2fl/fl) or both genes (Runx1fl/fl;Runx2fl/fl). Cells 
were extracted from all five pairs of mammary glands of 7 to 8 weeks old female mice and are 
expressed as a percentage of total Lin- cells. Statistical analysis was performed by the two-way 
ANOVA with the Tukey’s multiple comparisons test in GraphPad Prism. Error bars represent mean 
with SD (n≥3 for each cohort). *P<0.05. Lin-, lineage negative. 
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6.3.3.2  Luminal versus basal cells 
To accomplish its milk-producing function, the epithelial compartment of the 
mammary gland is composed of two main cell lineages: luminal cells, devoted to 
the production and secretion of milk into the ductal lumen of the gland, and 
basal/MYO cells, allowing the former in the process of milk ejection during 
lactation. As such, a balance between the two populations is fundamental to 
both mammary gland pubertal development, as well as homeostasis during 
adulthood. To investigate if activation of the Wnt/β-catenin signalling pathway 
altered the equilibrium between the luminal and basal layers of the mammary 
gland in the context of Runx genes deletion, the proportion of each subset of 
MMECs was analysed and expressed as a percentage of total Lin- cells. In doing 
so, deletion of Runx1 resulted in a significant decrease of the percentage of 
luminal cells compared to Runx1 wild type BLG-Cre;Catnbwt/lox(ex3) control mice. 
Whilst deletion of Runx2 displayed a similar, yet not significant, trend, 
combined loss of both genes was found to significantly restore both Runx1- and 
Runx2-deficient luminal population to slightly higher level than controls (Figure 
6. 8A). Thus, the decreased epithelial subset showed by Runx1-deficient BLG-
Cre;Catnbwt/lox(ex3) glands (Figure 6. 7A) might be attributed to changes affecting 
the luminal compartment of the mammary gland. A similar pattern was also 
observed in a Wnt/β-catenin wild type setting, whereby mammary specific 
deletion of Runx1 or Runx2 resulted in a moderate (yet not significant) reduction 
of luminal cells, which was rescued to the levels of BLG-Cre;Catnbwt/wt control 
glands upon combined excision of both genes (Figure 6. 8B). However, in 
contrast to the tumourigenic context, even the basal subset of MMECs appeared 
perturbed upon Runx genes loss. In particular, the latter showed a reduction in 
both Runx1fl/fl and Runx1fl/fl;Runx2fl/fl mice, whilst a significant increase in the 
absence of Runx2 (Figure 6. 8). Altogether, these results are indicative of a 
context-dependent interplay existing between RUNX1 and RUNX2, which seems 
to depend not only on the epithelial compartment of the mammary gland, but 
also on the presence of a tumourigenic or non-tumourigenic setting affecting the 
latter. Representative density plots of the luminal and basal expression profiles 
displayed by each cohort of BLG-Cre;Catnbwt/lox(ex3) and BLG-Cre;Catnbwt/wt mice 
are shown in Figure 6. 9 and Figure 6. 10, respectively. 
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Figure 6. 8 Effects of Runx1 and Runx2 deletion on luminal and basal mammary epithelial 
cells in a Wnt/β-catenin activated and wild type setting. 
Scatter dot plots of luminal and basal MMECs from (A) BLG-Cre;Catnbwt/lox(ex3) and (B) BLG-
Cre;Catnbwt/wt mice, upon deletion of Runx1 (Runx1fl/fl;Runx2wt/wt), Runx2 (Runx1wt/wt;Runx2fl/fl) 
or both genes (Runx1fl/fl;Runx2fl/fl). Cells were extracted from all five pairs of mammary glands 
of 7 to 8 weeks old female mice and are expressed as a percentage of total Lin- cells. Error bars 
represent mean with SD (n≥3 for each cohort). Statistical analysis was performed by the two-way 
ANOVA with the Tukey’s multiple comparisons test in GraphPad Prism. *P<0.05, *** P<0.001. Lin-, 
lineage negative; MMEC, mouse mammary epithelial cell. 
                                                                                                                    216 
 
 
 
Figure 6. 9 Expression profiles of luminal and basal mammary epithelial cells upon deletion 
of Runx1 and Runx2 in a Wnt/β-catenin activated mutant background. 
Representative density plots showing the distribution of the luminal (LUM) and basal (BAS) 
subpopulations of MMECs extracted from BLG-Cre;Catnbwt/lox(ex3) mice (A), upon deletion of Runx1 
(Runx1fl/fl;Runx2wt/wt) (B), Runx2 (Runx1wt/wt;Runx2fl/fl) (C), or both genes (Runx1fl/fl;Runx2fl/fl) 
(D). Five pairs of mammary glands, extracted from 7 to 8 week old females, were mechanically 
chopped and enzymatically digested to obtain a single cell suspension. This was labelled with a 
panel of fluorochrome-conjugated antibodies in order to enrich for MMECs. Luminal and basal 
cells were resolved with the combinatorial use of the CD24 and CD49f cell surface markers and 
expressed as a percentage of total Lin- cells. Luminal cells are enriched in the Lin-CD24+CD49flow 
subset, whilst basal cells are enriched in the Lin-CD24+CD49fhigh one. One representative graph of 
n≥6 is shown per genotype. BAS, basal; Lin-, lineage negative; LUM, luminal; MMEC, mouse 
mammary epithelial cell.  
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Figure 6. 10 Expression profiles of luminal and basal mammary epithelial cells upon deletion 
of Runx1 and Runx2 in a Wnt/β-catenin wild type background. 
Representative density plots showing the distribution of the luminal (LUM) and basal (BAS) 
subpopulations of MMECs extracted from BLG-Cre;Catnbwtwt) mice (A), upon deletion of Runx1 
(Runx1fl/fl;Runx2wt/wt) (B), Runx2 (Runx1wt/wt;Runx2fl/fl) (C), or both genes (Runx1fl/fl;Runx2fl/fl) 
(D). Five pair of mammary glands, extracted from 7 to 8 week old females, were mechanically 
chopped and enzymatically digested to obtain a single cell suspension. This was labelled with a 
panel of fluorochrome-conjugated antibodies in order to enrich for MMECs. Luminal and basal 
cells were resolved with the combinatorial use of the CD24 and CD49f cell surface markers and 
expressed as a percentage of total Lin- cells. Luminal cells are enriched in the Lin-CD24+CD49flow 
subset, whilst basal cells are enriched in the Lin-CD24+CD49fhigh one. One representative graph of 
n≥3 is shown per genotype. BAS, basal; Lin-, lineage negative; LUM, luminal; MMEC, mouse 
mammary epithelial cell. 
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6.3.3.3  Sca-1 expression in the luminal compartment 
The decrease of luminal MMECs displayed by Runx1fl/fl or Runx2fl/fl mice, whilst 
its rescue seen in the Runx1fl/fl;Runx2fl/fl cohort, unleashed the question as to 
whether deletion of one or both genes had a preferential effect on specific 
subsets of luminal cells. As mentioned in Chapter 1, the luminal compartment of 
the mammary gland is characterized by a high degree of heterogeneity, being 
composed of different types of LPs and differentiated MMECs, including ER+/PR+ 
(sensor) and ER-/PR- (effector) cells of the ductal and alveolar subtypes, 
respectively (Clarke et al., 1997). In an attempt to capture such variability, 
different cell surface markers have been employed over time, one of them being 
Sca-1. Early studies looking at Sca-1 expression in the mammary gland found 
positive cells mainly scattered in the luminal epithelium, being more expressed 
in TEBs as opposed to terminal ducts (Welm et al., 2002). Long-term labelling 
experiments also showed that Sca-1+ MMECs contained a slow cycling population 
and displayed a higher outgrowth potential compared to the negative 
counterpart upon transplants. Thus, Sca-1 was proposed as a marker to enrich 
for a quiescent population of stem/progenitors thought to reside in the luminal 
epithelium (Welm et al., 2002). However, as transplant experiments were 
performed on total Sca-1+ and Sca-1- MMECs without prior sorting for the luminal 
or basal subpopulations, proper identification of Sca-1+ cells was hampered. 
Furthermore, although Sca-1-enriched MMECs showed an increased ability to 
generate an outgrowth in cleared fat pads, their self-renewal potential was not 
tested in subsequent transplants. Lastly, Sca-1 expression in the mammary gland 
was assessed without the use of any markers for the basal or luminal lineage, 
thus hindering the exact location of Sca-1+ cells. According to later studies, Sca-
1 expression was found to be restricted to a specific subset of luminal cells 
displaying high levels of hormone-related genes (e.g. Esr-1, Pr, Prlr), thus being 
recognized as a marker for ERα+ LPs and mature cells (Sleeman et al., 2007; 
Shehata et al., 2012). When the proportion of Sca-1+ and Sca-1- luminal cells was 
examined, no significant differences were found among all BLG-
Cre;Catnbwt/lox(ex3) cohorts of mice (Figure 6. 11A). What emerged, instead, was 
a significant increase of Sca-1+ luminal cells showed by Runx1fl/fl mice in respect 
to BLG-Cre;Catnbwt/wt controls (Figure 6. 11B). Interestingly, very preliminary 
data revealed an opposite trend for Runx2, whereby deletion of the gene would 
result in a decrease of Sca-1+ cells. However, extremely caution is noted as this 
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result is only based on one mouse. On the other hand, combined loss of both 
genes appeared to rescue the phenotype of both Runx1fl/fl and Runx2fl/fl mice to 
the levels of controls (Figure 6. 11B).  
6.3.3.4  Sca-1 expression in the basal compartment 
When the basal subset of MMECs was analysed for Sca-1 expression, results 
showed a significant increase in the percentage of Sca-1+ cells in the 
Runx1fl/fl;Runx2fl/fl cohort of BLG-Cre;Catnbwt/lox(ex3) mice as compared to 
controls (Figure 6. 12 and Figure 6. 13). In addition, when all groups of animals 
were compared with each other, such increase resulted to be significant even in 
relation to both Runx1fl/fl and Runx2fl/fl mice (data not shown). Instead, no 
differences were found among the corresponding cohorts of BLG-Cre;Catnbwt/wt 
mice, wherein the proportion of Sca-1- cells always exceeded the positive 
counterpart (Figure 6. 12B). If the role played by Sca-1 in the luminal epithelium 
has been better elucidated, the picture does not seem to be so clear for the 
basal compartment of the mammary gland. As discussed in the introduction, 
cumulative evidences have argued against the regenerative potential displayed 
by Sca-1+ basal cells, claiming that the marker cannot be used to enrich for 
MaSCs (Shackleton et al., 2006; Stingl et al., 2006). Albeit in agreement with the 
latter, Dall et al. (2017) have recently found the Lin-CD24+CD49fhighSca-1+ subset 
of cells particularly abundant in young mice as compared to old mice. In the 
former, Sca-1+ basal cells were shown to be an actively cycling population, 
mainly located in TEBs versus terminal ducts, and displaying both basal as well 
as luminal markers (e.g. ERα and PR). Thus, it was hypothesized that Sca-1+ 
basal cells may represent a subset of hormone-responsive pubertal MaSCs, 
particularly committed to ductal morphogenesis. Their decrease occurring with 
age could be indicative of a negative regulation exerted by E2, whereby the 
hormone might prompt CD24+CD49fhighSca-1+ cells proliferation, as well as 
differentiation into the negative subset. In view of their hormone responsiveness 
and the carcinogen sensitivity shown by TEBs (Russo et al., 1983), Sca-1+ basal 
cells might represent a transient, yet vulnerable target for oncogenic 
transformation (Dall et al., 2017). 
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Figure 6. 11 Effects of Runx1 and Runx2 deletion on the expression profile of Sca-1 luminal 
mammary cells in a Wnt/β-catenin activated mutant and wild type setting. 
 
Scatter dot plots of Sca-1+ and Sca-1- luminal MMECs from BLG-Cre;Catnbwt/lox(ex3) (A) and BLG-
Cre;Catnbw/wt (B) mice, upon deletion of Runx1 (Runx1fl/fl;Runx2wt/wt), Runx2 
(Runx1wt/wt;Runx2fl/fl) or both genes (Runx1fl/fl;Runx2fl/fl). Cells were extracted from mammary 
glands of 7 to 8 week old female mice, resolved with the combinatorial use of CD24 and CD49f 
and expressed as a percentage of total luminal (Lin-CD24+CD49flow) MMECs. Error bars represent 
mean with SD (n≥4 for each cohort, but for the Runx2fl/fl group of BLG-Cre;Catnbw/wt mice with 
n=1). Statistical analysis was performed by the two-way ANOVA with the Dunnett’s multiple 
comparisons test in GraphPad Prism. *P<0.05. MMEC, mouse mammary epithelial cells. 
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Figure 6. 12 Effects of Runx1 and Runx2 deletion on the expression profile of Sca-1 basal 
mammary cells in a Wnt/β-catenin activated mutant and wild type setting. 
Scatter dot plots of Sca-1+ and Sca-1- basal MMECs from BLG-Cre;Catnbwt/lox(ex3) (A) and BLG-
Cre;Catnbw/wt (B) mice, upon deletion of Runx1 (Runx1fl/fl;Runx2wt/wt), Runx2 
(Runx1wt/wt;Runx2fl/fl) or both genes (Runx1fl/fl;Runx2fl/fl). Cells were extracted from mammary 
glands of 7 to 8 week old female mice, resolved with the combinatorial use of CD24 and CD49f 
and expressed as a percentage of total luminal (Lin-CD24+CD49fhigh) MMECs. Error bars represent 
mean with SD (n≥4 for each cohort, but for BLG-Cre;Catnbw/wt;Runx2fl/fl mice with n=1). 
Statistical analysis was performed by the two-way ANOVA with the Dunnett’s multiple 
comparisons test in GraphPad Prism. *P<0.05. MMEC, mouse mammary epithelial cells. 
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Figure 6. 13 Sca-1 expression profile of basal mouse mammary epithelial cells upon loss of 
Runx1 and Runx2 deletion in a Wnt/β-catenin activated background. 
Representative density plots showing the distribution of Sca-1+ and Sca-1- basal MMEC from BLG-
Cre;Catnbwt/lox(ex3) mice (A), upon deletion of Runx1 (Runx1fl/fl;Runx2wt/wt) (B), Runx2 
(Runx1wt/wt;Runx2fl/fl) (C), or both genes (Runx1fl/fl;Runx2fl/fl) (D). Mammary glands, extracted 
from 7 to 8 week old females, were mechanically chopped and enzymatically digested to obtain 
a single cell suspension. This was labelled with a panel of fluorochrome-based antibodies in 
order to enrich for MMECs. Basal cells were resolved with the combinatorial use of the CD24 and 
CD49f cell surface markers and found to be enriched in the Lin-CD24+CD49fhigh subset. Sca-1+ and 
Sca-1- basal cells are expressed as a percentage of total basal (Lin-CD24+CD49fhigh) MMECs. One 
representative graph of n≥4 is shown per genotype. MMEC, mouse mammary epithelial cell; Lin-, 
lineage negative. 
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6.4 Discussion  
As mentioned in Chapter 1, the results obtained with transplantation studies 
have revealed the existence of a “growth-regulating system” within the 
mammary gland (Faulkin et al., 1960). This has been ascribed to the presence 
and peculiar properties owned by MaSCs, able to govern both mammary pubertal 
development and homeostasis during adulthood through the formation of a 
highly organized hierarchical structure of cells. Of note, “the ability to override 
this growth-regulating system appears to be the principal characteristic of 
neoplastic tissue” (Faulkin et al., 1960). In this regard, the presence of overtly 
disrupted mammary tissues upon activation of the Wnt/β-catenin pathway in the 
absence of Runx1 and Runx2 leads to the hypothesis that this dysregulation 
might originate from changes affecting the mammary epithelial cell hierarchy. 
However, in view of the high degree of cellular heterogeneity characterizing the 
latter (see Chapter 1), this is not an inconsequential premise to dissect. As such, 
it was reckoned that only through the combinatorial use of multiple techniques 
it would have been possible to characterize the functional and phenotypic 
characteristics displayed by Wnt/β-catenin-activated MMECs in the context of 
Runx genes deletion. To begin, as the significant acceleration of tumourigenesis 
and high penetrance of tumour burden displayed by BLG-
Cre;Catnbwt/lox(ex3);Runx1fl/fl;Runx2fl/fl mice (observed in Chapter 4) hinted at the 
presence of an altered stem/progenitor subpopulation,  the tumoursphere and 
CFC assays were employed. 
Correct interpretation of the sphere assay has so far been hindered by the 
presence of confounding results reported by the literature. One of the main 
arguments concerns the rapidity of sphere formation, which could not be 
inferred solely to the clonal expansion of MaSCs. As such, spheres would rather 
appear to be formed by a mixture of stem and progenitor (or transient 
amplifying) cells (Clarke et al., 2006). If that holds true, sphere formation could 
be considered the result of a combination of both SCD and ACD. In addition, 
whilst the size of spheres would be an indirect measure of the proliferative 
ability of stem/progenitor cells (via ACD and SCD), the number of secondary 
spheres would mainly reflect MaSCs’ self-renewal potential. In this regards, the 
bigger size of primary and secondary spheres shown by Runx2fl/fl-derived MMECs 
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of the BLG-Cre;Catnbwt/lox(ex3) cohort might be indicative of an increased 
proliferative ability owned by stem/progenitor cells in the absence of the gene. 
Nonetheless, with concomitant loss of Runx1, Runx2-deficient MMECs appeared 
to give rise to fewer and smaller spheres, with reduced self-renewal potential. It 
should be noted, however, that at the 7 to 8 week developmental time-point, 
both control and single knock-out Runx1fl/fl and Runx2fl/fl cohorts of BLG-
Cre;Catnbwt/lox(ex3) mice displayed a higher percentage of normal epithelium, in 
contrast to Runx1fl/fl;Runx2fl/fl animals, characterized by a higher amount of 
abnormal epithelium (see Chapter 5). Therefore, only results obtained from the 
latter cohort of mice could be more confidently ascribed to the predominant 
presence of Wnt/β-catenin transformed MMECs, and not to remaining normal 
MMECs. If that is the case, then BLG-Cre driven constitutive activation of the 
Wnt/β-catenin signalling pathway is able to reduce the proliferative and self-
renewal potential of stem/progenitor cells in the absence of both Runx1 and 
Runx2. But if this hypothesis holds true, how can the enlarged mammary 
structure displayed by Runx1fl/fl;Runx2fl/fl whole-mounts be explained? Perhaps 
by envisioning a Wnt/β-catenin-driven switch from ACD to SCD which might 
foster the expansion of slow-cycling cells. The reduced self-renewal potential 
shown by secondary tumourspheres might in turn arise from the sudden terminal 
differentiation route taken by the latter population. Whilst the previously 
discussed use of the transplantation technique was employed in the attempt to 
test this hypothesis (see Chapter 4), this has only been carried out with primary 
transplants to date and requires serial passaging of MDTFs in vivo. Through 
backcrossing of the BLG-Cre;Catnbwt/lox(ex3) line in a pure FVB background, it will 
be possible to explore the in vivo regenerative potential of Wnt/β-catenin-
activated Runx1fl/fl;Runx2fl/fl-deficient mammary lesions upon serial 
transplantations. In addition, considering the precocious transformation of the 
mammary epithelium, it would be worthwhile applying the same experimental 
pipeline to pre-neoplastic MMECs extracted from all virgin cohorts of BLG-
Cre;Catnbwt/lox(ex3) mice. 
If the different types of discrete colonies formed by MMECs when challenged in 
CFC assays can be truly ascribed to the presence of specific subpopulations of 
stem/progenitor cells, then activation of the Wnt/β-catenin signalling pathway 
upon loss of Runx1 might favour the expansion of a transformed subset of cells 
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lying within the basal lineage. Importantly, this phenotype appears to be 
independent of the Runx2 status carried by Runx1-deficient MMECs, as a 
predominance of solid colonies was also observed in the Runx1fl/fl;Runx2fl/fl 
cohort of BLG-Cre;Catnbwt/lox(ex3) mice. In agreement with the notion that ‘all 
pathological changes are merely physiological modified ones’ (Beatson, 1896), 
preliminary results showed that extraction of MMECs from BLG-Cre;Catnbwt/wt 
cohorts of mice also led to a higher predominance of solid colonies upon loss of 
Runx1 or combined deletion of Runx1 and Runx2. On the contrary, Runx2-
deficient and control-derived MMECs displayed a ratio equal to one, indicating 
the absence of any preferential addiction towards basal or acinar colony 
formation (data not shown). These pieces of evidence suggest a different role 
played by RUNX1 and RUNX2 in regulating mammary epithelial cell fates. In view 
of the role shown by progesterone in driving the expansion of MaSCs (Joshi et 
al., 2010), it was surprising not to find a correlation between the oestrous cycle 
of the animals and the type of morphological colonies generated by matrigel-
embedded MMECs. Three main hypotheses have been put forward to explain this 
discrepancy. Firstly, in view of the changes in oestrous cycle dynamics displayed 
by different strains of mice (Barkley and Bradford, 1981), the lack of correlation 
might stem from the fact that both cohorts of BLG-Cre;Catnbwt/lox(ex3) and BLG-
Cre;Catnbwt/wt mice are on a mixed background. Secondly, it might be that 
mammary-specific activation of the Wnt/β-catenin signalling pathway can 
override the effects that ovarian hormones have on the mammary epithelial cell 
hierarchy. However, the fact that no correlation was found among all groups of 
BLG-Cre;Catnbwt/wt mice would argue against this hypothesis. Thirdly, the peak 
of progesterone at each diestrus cycle might indeed favour the expansion of a 
Wnt/β-catenin-activated subset of basal stem/progenitor cells, which could then 
expand upon loss of Runx1 and persist across all stages of the oestrous cycle.  
Whilst hinting towards the basal compartment as the putative primary source of 
the aberrant mammary structures displayed by Wnt/β-catenin-activated Runx1-
deficient mice, these ex vivo assays could not explain the different timeframes 
of palpable tumour formation and overall survival displayed by Runx1fl/fl and 
Runx1fl/fl;Runx2fl/fl mice. Thus, to gain a better insight into how deletion of 
Runx1 or combined excision of both Runx1 and Runx2 could differently affect 
Wnt/β-catenin-driven tumourigenesis, the phenotypic profile of extracted 
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MMECs was assessed. What emerged from the analysis was a significant decrease 
of epithelial cells displayed by Runx1fl/fl mice, which might stem from a 
reduction of the luminal rather than the basal compartment. Importantly, whilst 
no similar observations could be found upon combined loss of Runx1 and Runx2, 
a significant increase of Sca-1+ basal cells seemed to exclusively characterize the 
Runx1fl/fl;Runx2fl/fl cohort of mice as compared to all other BLG-
Cre;Catnbwt/lox(ex3) groups. In view of its high abundance in young mice and its 
preferential location in TEBs (Dall et al., 2017), it is tempting to speculate that 
the Lin-CD24+CD49fhighSca-1+ subset might represent the “cell-of-origin” of BLG-
Cre mediated Wnt/β-catenin driven breast tumourigenesis (Figure 6. 14). 
Proposed as a hormone-responsive MaSC subpopulation particularly devoted to 
ductal morphogenesis (Dall et al., 2017), it could be assumed that the 
physiological role of the Lin-CD24+CD49fhighSca-1+ subset would be to feed into 
both the basal and luminal layers of incipient pubertal ducts. Thus, one could 
envision the possibility of a Wnt/β-catenin driven Runx1- and Runx2-deficient 
subpopulation of Sca-1+ basal cells, entering the cell cycle in response to E2, 
expanding abnormally within TEBs and disseminating its pre-neoplastic progeny 
along subtending ducts (Figure 6. 14). In this regards, the absence of a similar 
increase in Runx1fl/fl mice might be indicative of either a decreased survival 
capability of Sca-1+ basal cells in the absence of the gene or the presence of a 
compensatory tumour suppressive mechanism, perhaps exerted by RUNX2. This 
could explain why there is a delay in ductal elongation and the presence of 
fewer epithelia in 6 week whole-mounts, but also a partial disappearance of pre-
neoplastic lesions in 9 week old Runx1fl/fl mice. What needs to be addressed next 
is how deletion of Runx1, Runx2 or both genes, impinges on the tumourigenic 
potential of Wnt/β-catenin-activated Sca-1+ basal cells. One way to test this 
hypothesis would be to isolate the cells via FACS and carry out a thorough 
molecular and functional characterization of the population. If an active Wnt/β-
catenin signalling pathway and deletion of Runx can be validates in these Sca-1+ 
cells, these could then be challenged in serial transplantation assays. 
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Figure 6. 14 Working model. 
 
Schematic diagram illustrating the putative “cell-of-origin” of BLG-Cre driven Wnt/βcatenin 
mammary tumours upon combinatorial loss of Runx1 and Runx2. Deletion of both genes may 
favour the abnormal expansion of a stem/progenitor subpopulation of Sca-1+ cells residing in the 
basal layer of the mammary gland. Particularly abundant in terminal end buds, Sca-1+ basal cells 
are believed to drive the ductal elongation of the epithelial tree upon release of hormonal cues 
occurring at the onset of puberty. An abnormal expansion and increased survival of this peculiar 
subpopulation may negatively impact on the highly organized structure of the mammary 
epithelial cell hierarchy, eventually resulting in the formation of Wnt/ βcatenin mammary 
lesions.  
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Interestingly, a trend towards decreased epithelium characterizing Runx1fl/fl 
mice was also observed on a Wnt/β-catenin wild type background in relation to 
Runx1wt/wt animals (29% and 45%, respectively) (Table 6. 1). This time, however, 
the reduction appeared to stem from a lower percentage displayed by both 
luminal (13%) and basal cells (16%) in respect to controls (19% and 26%, 
respectively). Differently, BLG-Cre mediated deletion of Runx2 appeared to 
cause a reduction of the luminal subpopulation (10%), yet an increase of the 
basal one (33%) compared to controls. Combined deletion of both genes was 
instead able to partly restore both the luminal (16%) and basal (16%) 
subpopulations (Table 6. 1). These results are indicative of a context-dependent 
interplay between RUNX1 and RUNX2, which might exert similar effects within 
the luminal compartment, while opposite functions in the basal one. In regards 
to the luminal compartment, three different scenarios might be proposed. 
According to the first one, RUNX1 and RUNX2 might have tumour suppressive 
effects. As such, deletion of Runx1 or Runx2 would result in a decreased luminal 
population in view of the suppressive function of the remaining gene, whereas 
deletion of both genes would rescue the phenotype. What remains puzzling, 
however, is how the presence or absence of both Runx1 and Runx2 leads to a 
similar percentage of luminal cells. Perhaps, one could presume that in a 
physiological context RUNX1 and RUNX2 would be responsible for keeping the 
luminal population under control (making sure the percentage does not go over 
19%), whereas in their absence compensatory mechanism would take their place 
to avoid any increase of luminal cells. According to the second scenario, both 
RUNX1 and RUNX2 might have promoting effects. This would explain why 
deletion of Runx1 or Runx2 causes a decrease of the luminal population, 
although it does not justify how the absence of both genes restores the luminal 
subset to the level of control mice. Furthermore, this hypothesis would not take 
into account the possibility of the remaining gene to compensate for the missing 
one. According to the third one, the genes might have dualist effect exerted on 
different subsets of luminal cells. In support of the latter, several lines of 
evidence have suggested a role for RUNX1 as a master regulator of luminal cell 
fate decisions, by promoting the ER program whilst inhibiting the alveolar one 
(van Bragt et al., 2014). In addition, as corroborated by the reduction of ER+ 
cells upon MMTV-Cre mediated excision of Runx1, the gene appears to be 
required for the survival of the latter population. Nonetheless, results obtained 
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from the BLG-Cre driven mouse model led to opposite findings, as deletion of 
the gene resulted in a significant increase of Sca-1+ (ER+) luminal cells. 
Interestingly, deletion of Runx2 had the opposite effect, whereas the absence of 
both genes restored the Sca-1+ subset to the levels of control mice. This result is 
of particular interest in view of the previously discussed tumour suppressive role 
played by RUNX1 in ER+ cells (see Chapter 1). As such, it could be envisioned 
that, whilst loss of Runx1 leads to a moderate decrease of the luminal 
compartment, the latter experiences an increase of ER+Sca-1+ and decrease of 
ER-Sca-1- cells. In view of the fundamental role exerted by hormonal paracrine 
circuits between ER+Sca-1+ (sensor) and ER-Sca-1- (effector) cells, it would be 
interesting to see if upon loss of Runx1, ER+Sca-1+ sensor cells might expand, 
whilst losing their ability to “feed” the effector cellular counterpart through 
release of paracrine molecules. Although expression of both genes does not 
appear to be very high in extracted luminal cells as compared to basal MMECs 
(McDonald et al., 2014; van Bragt et al., 2014), this data is indicative of an 
important role played by RUNX1 and RUNX2 in the luminal layer of the mammary 
gland. Nonetheless, owing to the heterogeneity of the luminal lineage, it would 
be necessary to dissect the specific function played by each gene by 
characterizing their expression in different luminal subpopulations, including 
ER+ and ER- cells. This, for instance, could be achieved by performing co-
immunofluorescence for ER and RUNX1 or RUNX2 or by isolating different subsets 
of luminal cells by FACS. A different, yet more straightforward, scenario might 
hold true for the basal compartment, wherein both Runx1 and Runx2 appear to 
be more expressed (McDonald et al., 2014; van Bragt et al., 2014). Within the 
latter, RUNX1 seems to exert a positive effect (as its deletion leads to a 
decrease of basal cells), whereas RUNX2 appears to have a negative function 
(since its excision yields to an expansion of the population). By counterbalancing 
each other, deletion of both genes results in the rescue of basal cells to the 
level of control mice. In line with this hypothesis, cumulative evidence has 
labelled RUNX1 as a master regulator of MaSCs differentiation, as its deletion 
was shown to block stem/progenitor cells in a bipotent/undifferentiated state 
susceptible to oncogenic transformation (Sokol et al., 2015). Accordingly, an 
increase in the basal population has been observed in the Runx1fl/fl cohort of 
BLG-Cre;Catnbwt/lox(ex3) mice, further corroborating the role of the latter 
compartment as the primary source of Wnt/β-catenin transformation. 
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At the bottom of all the aforementioned questions lies the uncertainty of the 
“cell-of-origin” of Wnt/β-catenin mammary lesions. Indeed, while trying to 
understand the phenotype of any conditional mouse model, it is imperative to 
consider not only the genetic aberrations carried by the latter, but also the 
driver of those recombination events (Holen et al., 2017). As mentioned in 
chapter 3, the novelty of the BLG-Cre;Catnbwt/lox(ex3) breast cancer mouse model 
allowed the possibility to study for the first time the effects of Runx genes 
deletion in the context of activated Wnt/β-catenin, yet also the fact that both 
genetic events are driven by the BLG-Cre. As for any other conditional model, if 
the in vivo phenotype is assumed to stem from a cell-autonomous effect, then 
one way to unveil its cell-of-origin is by guiding the expression of a reporter 
gene under the control of the same driver. In this regards, the absence of a 
reporter gene within the BLG-Cre;Catnbwt/lox(ex3) cohorts of mice hampered the 
possibility to specifically ascribe the changes observed within each MMEC 
subpopulation to activation of Wnt/β-catenin and deletion of Runx1, Runx2 or 
both genes. Nonetheless, characterization of BLG-Cre expression in a Wnt/β-
catenin wild type setting was previously performed by N. Ferrari (unpublished; 
PhD thesis) through the use of the Z/EG (lacZ/EGFP) reporter line of mice 
(Novak et al., 2000). Due to the presence of a lox-stop-lox cassette preceding 
the enhanced green fluorescent protein (EGFP) transgene, visualization of GFP 
could only be observed upon Cre excision (Novak et al., 2000). When BLG-
Cre;Z/EG mice were crossed with Runx1fl/fl, Runx2fl/fl and Runx1fl/fl;Runx2fl/fl 
animals, monitoring of the GFP signal allowed to evaluate the effect of Runx1 
and/or Runx2 deletion upon specific subpopulation of MMECs (Table 6. 1). If 
analysis of 12 weeks old BLG-Cre;Z/EG mice showed an 18% of GFP positivity in 
regards to total Lin- cells, the signal appeared to be significantly reduced in the 
absence of Runx1 (12%) or Runx2 (11%), yet rescued upon loss of both genes 
(17%). In line with the literature (Selbert et al., 1998), when the percentage of 
GFP+ cells was calculated in respect to the two epithelial compartments of the 
mammary gland, BLG-Cre was found to be more expressed by luminal (38%) 
versus basal (4%) cells. Interestingly, a significant reduction in the percentage of 
GFP+ luminal MMECs was observed in both Runx1fl/fl (26%) and Runx2fl/fl (19%) 
mice, as well as in the Runx1fl/fl;Runx2fl/fl cohort (21%). In regards to the basal 
compartment, results showed decreased positivity displayed by Runx2fl/fl (2%) 
mice, versus a significant increase of GFP+ cells upon combined excision of 
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Runx1 and Runx2 (23%), as compared to control (4%) (Table 6. 1). This analysis 
offered important insights in interpreting the changes of the luminal and basal 
MMECs subpopulations displayed by all cohorts of BLG-Cre;Catnbwt/wt mice upon 
loss of the Runx genes. On one hand, in view of the high level of BLG-Cre 
expression reported in the luminal layer (38%), the results obtained from the 
GFP expression analysis mirrored the reduction of luminal cells seen upon 
deletion of Runx1 and Runx2. On the other hand, considering the low levels of 
BLG-Cre expression present in the basal layer (4%), these data helped clarify the 
changes affecting the basal compartment of Runx-deficient BLG-Cre;Catnbwt/wt 
mice. Thus, albeit BLG-Cre;Catnbwt/wt mice showed a higher percentage of total 
basal cells as compared to Runx1fl/fl;Runx2fl/fl mice (26% and 16%, respectively), 
analysis of GFP expression revealed a higher proportion of positivity within the 
latter group (Table 6. 1).  
Table 6. 1 BLG-Cre mediated effects of Runx1 and Runx2 loss in the mammary epithelium. 
 
 
 
Altogether these data indicate that BLG-Cre mediated deletion of both Runx1 
and Runx2 confers basal cells a selective advantage over the wild type 
counterpart. As part of future directives, it will be necessary to validate these 
findings by crossing all Runx-deficient BLG-Cre;Catnbwt/lox(ex3) cohorts with a 
reporter strain of mice. This will allow a thorough investigation of how deletion 
of the Runx genes impinges on the survival capability of Wnt/β-catenin activated 
MMECs. Presently, it is obvious that there exists an important role played by 
Runx1 and Runx2 in the mammary epithelial cell hierarchy, wherein these genes 
appear to govern the intersection between fundamental cell fate decisions 
between the luminal and basal lineages. Thus, a deeper understanding on the 
function exerted by these genes is worth of further investigation. 
Runx1 wt/wt ;Runx2 wt/wt Runx1 fl/fl ;Runx2 wt/wt Runx1 wt/wt ;Runx2 fl/fl Runx1 fl/fl ;Runx2 fl/fl
Epithelial 45 29 43 32
Luminal 19 13 10 16
Basal 26 16 33 16
Runx1 wt/wt ;Runx2 wt/wt Runx1 fl/fl ;Runx2 wt/wt Runx1 wt/wt ;Runx2 fl/fl Runx1 fl/fl ;Runx2 fl/fl
% Lin- 18 12 11 17
% Luminal 38 26 19 21
% Basal 4 7 2 23
Cohorts
%Lin-
BLG-Cre;Z/EG 
GFP+ cells
Cohorts
Virgin (12 week)
Virgin (7-8 week) BLG-Cre;Catnb wt/wt
232 
 
7 Conclusions 
[The following discussion has been in part adapted from Riggio and Blyth (2017)]. 
Cancer is a very heterogeneous disease which exploits a multitude of strategies, 
referred to as “hallmarks”, in order to convert a normal tissue into a malignant 
one (Hanahan and Weinberg, 2011). Even though these hallmarks have 
significantly contributed to our comprehension of the disease, cancer still 
remains a black box. Within the latter, breast cancer represents the leading 
cause of tumour-related death in women worldwide (Torre et al., 2016). The 
reason behind this could be ascribed to several factors, including: a family 
history at risk; the lifetime exposure to hormones; the reproductive path of a 
woman (including the decision of not having children, the trend to have late 
pregnancies and the low rate of breast feeding); and the adoption of bad life-
style behaviours (e.g. alcohol and high-calorie food intake, tobacco, stress and 
long-working hours) (Eccles et al., 2013). Notwithstanding the causative role 
played by each factor, cancer (and therefore breast cancer) is primarily a 
genetic disease. However, differently from most genetic diseases, cancer is 
caused by somatic mutations, and not solely by germ-line mutations. In addition, 
whilst genetic diseases often require a single mutation to arise, cancer is the 
result of a “multi-hit” process, whereby different genetic alterations accumulate 
over time in one or a few cell(s)-of-origin (Vogelstein, 1983). Importantly, this 
sequence of genetic events uniquely defines the genomic landscape of each type 
of cancer. In regards to breast cancer, only a few ‘mountains’, that is frequently 
altered genes, and many more ‘hills’, that is infrequently mutated genes, were 
shown to characterize the genomic landscape of the disease (Wood et al., 2007). 
However, whilst the function of frequently mutated genes is well-documented, 
the identity and role played by infrequently altered genes is still elusive. 
Following the discovery in the last five years of RUNX1 somatic mutations in 
biopsies of breast cancer patients (Banerji et al., 2012; Cancer Genome Atlas, 
2012; Ellis et al., 2012), a new ‘hill’ has been finally unveiled. As the sole 
presence of genetic alterations is not necessarily indicative of a causative role 
played by a gene in the aetiology of the corresponding disease, it remained to be 
seen whether RUNX1 genetic alterations were passenger or driver events in the 
context of breast tumourigenesis. When NGS data was coupled with structural 
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analysis to look at the pattern and pathogenicity of the identified mutations, the 
majority of RUNX1 genetic alterations were predicted to cause loss-of-function 
of the protein (van Bragt et al., 2014) and confer a selective growth advantage 
to the insulted cells. In view of this, RUNX1 was ascribed among the list of 
breast cancer driver genes together with its heterodimerization partner CBFβ 
(Nik-Zainal et al., 2016; Pereira et al., 2016). Notwithstanding the utility of 
these predictive analyses, the ultimate proof of the causative role played by 
RUNX1 in the initiation, maintenance and/or progression of breast cancer could 
only be achieved by studying its function in vivo. As such, using two genetic 
models of breast cancer, characterized by two distinct oncogenes (i.e. PyMT and 
β-catenin) driven by different mammary-specific Cre-recombinases (i.e. MMTV-
Cre and BLG-Cre, respectively), deletion of Runx1 resulted in a significantly 
accelerated onset of mammary tumourigenesis. These results are the first to 
provide compelling functional evidence for a tumour suppressive function played 
by RUNX1 in the context of breast tumourigenesis.  
In an effort to delve into the root of RUNX1’s behaviour, and in view of the fact 
that ‘pathological changes are merely physiological modified ones’ (Beatson, 
1896), attention has focused on the role played by the gene in the physiology of 
the murine mammary gland. Expression of Runx1 was found to fluctuate during 
mammary gland post-natal development, increasing in virgin and involuting 
mice, whilst decreasing during pregnancy and lactation (Blyth et al., 2010). 
These results were indicative of a function played by RUNX1 specifically during 
mammary gland pubertal growth, as well as remodelling of the organ occurring 
at weaning. When expression of the gene was analysed in extracted murine 
mammary cells, Runx1 was found to be present in both epithelial compartments, 
albeit showing a preferential enrichment for the basal versus the luminal one 
(McDonald et al., 2014). As no expression was reported in the fat pad, these 
findings hinted towards a specific requirement for the gene in the epithelium of 
the mammary gland. Studying the effects of Runx1 deletion in the basal 
epithelium via the use of the K14-Cre driver was hampered by the ubiquitous 
expression of the K14 promoter and the peculiar function played by the gene in 
the development of dental epithelium (Yamashiro et al., 2002). This resulted in 
the generation of small sized mice characterized by the presence of crooked 
teeth (data not shown). Nonetheless, when whole-mount analysis of inguinal 
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mammary glands from 20 week old mice was analysed, this revealed the 
presence of delayed mammary epithelial ductal trees as compared to Runx1-
proficient mice. Based on these preliminary observations and as ductal 
morphogenesis is under the tight control of ovarian hormones and paracrine 
molecules, it would be interesting to investigate whether Runx1 deletion could 
impinge on the hormonal paracrine circuits taking place in the mammary gland. 
In view of the caveats displayed by the K14-Cre model, most of the studies 
herein focused on the effects of BLG-Cre mediated excision of Runx1. Expression 
of BLG-Cre recombinase was shown to be temporally regulated in the mammary 
gland, with minimal levels recorded in pubertal/adult mice (7%), while maximal 
expression observed during lactation (70-80%). The reason behind this 
fluctuation was ascribed to hormones, as BLG encodes for a milk-secreted 
protein released by luminal cells during lactation (Selbert et al., 1998). 
Nonetheless, results from a former PhD student in our lab (N. Ferrari, 
unpublished) are indicative of a different pattern of BLG-Cre expression, 
evaluated through the use of the EGFP reported gene. This revealed in fact a 
higher percentage of BLG-Cre levels (18%) detected in 12 week virgin females. 
Although animals presented with normal-looking mammary trees able to undergo 
pregnancy, lactation and involution, a significant decreased of the luminal 
population was found to affect the mammary epithelial cell hierarchy upon BLG-
Cre mediated deletion of Runx1 (N. Ferrari, unpublished). RUNX1 has in fact 
been shown to be a crucial orchestrator of the luminal compartment, wherein it 
might favour the ductal ER+ program over the alveolar one through repression of 
Elf5 (van Bragt et al., 2014). As an enrichment of the p53 signature was 
displayed by luminal cells in the absence of the gene, RUNX1 expression 
appeared fundamental for the survival and maintenance of a subset of luminal 
cells (van Bragt et al., 2014). To investigate this further, BLG-Cre mediated 
excision of Runx1 is currently being studied in our lab in the context of a p53-
null background. If loss of Runx1 causes death of luminal cells, then loss of p53 
should rescue the phenotype, allowing survival and oncogenic transformation of 
Runx1-deleted cells. 
In support of a peculiar function played by the gene in the luminal epithelium of 
the mammary gland is also the fact that fluctuation of Runx1 levels during the 
reproductive stages of the organ is reminiscent of ERα and PR expression. Both 
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HRs were in fact found to be elevated during puberty and involution, yet absent 
at pregnancy and lactation (Shyamala et al., 2002; van Keymeulen et al., 2017). 
In addition, as the presence of both HR+ sensor and HR- effector cells could be 
observed in the luminal compartment, seemingly RUNX1 IHC staining showed a 
mosaic pattern of expression, with positive cells found adjacent to negative 
ones. Altogether, these observations could lead to the hypothesis that RUNX1 
expression in the luminal layer of the murine gland might be restricted to HR+ 
sensor cells. In support of the latter, a tantalizing interplay between RUNX1 and 
the ER signalling pathway has recently emerged, whereby the gene appears to 
modulate oestrogen-ER gene transcription via both a tethering and non-tethering 
mechanism of action (Riggio and Blyth, 2017). This was shown to be particularly 
true for the AXIN1 locus, with RUNX1 acting as a positive regulator of AXIN1 
expression, whilst oestrogen-ER complexes suppressing it (Chimge et al., 2016). 
This antagonist relationship provided mechanistic evidence for a tumour 
suppressive function exerted by RUNX1 in HR+ sensor cells, wherein the gene’s 
role might be to fine-tune oestrogens-ERα-mediated proliferation. As a 
dependency for hormonal cues is required for incipient PyMT-driven lesions, yet 
not by established tumours (Berebbi et al., 1990), this could offer important 
insights into how the formation of mammary lesions shown by the MMTV-PyMT 
model was accelerated in the absence of Runx1. Seemingly, this could also 
explain the precocious appearance of Runx1-deleted Wnt/β-catenin-driven pre-
neoplastic lesions, which also displayed high levels of ER and PR expression. To 
investigate this further, the first thing to do will be to confirm if expression of 
RUNX1 is indeed restricted to ER+ mammary epithelial cells. This could be 
achieved via the use of a Runx1-CreER inducible line, wherein expression of 
Runx1 could be monitored over time through visualization of a Cre-dependent 
reporter gene (Samokhvalov et al., 2007). In conjunction with the latter, the 
employment of co-immunofluorescence or FACS techniques might allow to 
visualize the presence of double positive RUNX1/ER mammary epithelial cells 
and detect a concomitant enrichment for Runx1 and Esr-1 expression in sorted 
luminal cells, respectively. Secondly, it will be important to assess if deletion of 
Runx1 in the context of an activated oncogene caused an aberrant proliferation 
of ER+ cells and/or of neighbouring ER- cells. Lastly, in support of the intriguing 
link between RUNX1 and hormone signalling is the recent reclassification of the 
five intrinsic subtypes of breast cancer (luminal A, luminal B, basal-like, HER2+ 
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and normal-like) (Perou et al., 2000; Sorlie et al., 2001) into 10 Integrative 
Clusters of the disease (Curtis et al., 2012; Dawson et al., 2013). Accordingly, 
RUNX1 mutations were reported to occur within Integrative Cluster 3, comprised 
of Luminal A tumours and characterized by a high prevalence of PIK3CA and 
CDH1 mutations. Albeit displaying the best prognosis above all clusters, Luminal 
A breast tumours were shown to have the highest likelihood of local and/or 
distant relapse in the long term (Haque et al., 2012). Therefore, these findings 
may offer not only valuable clues on the most relevant genetic context wherein 
to study the consequences of RUNX1 loss, but could also hold the key for the 
generation of more refined GEMMs of luminal breast cancer.  
Prior to breast cancer, the first hints for a tumour suppressive role played by 
RUNX1 came from the haematopoietic field. Here, the gene was found to be 
absolutely required for the conversion of endothelial cells to HSCs, yet 
dispensable for the maintenance and survival of the latter population in the 
adult organ. Accordingly, while Runx1 knock-out mice displayed an embryonic 
lethal phenotype (Wang et al., 1996), deletion of Runx1 in the adult 
haematopoietic compartment allowed mice to survive for more than 5 months. 
These, however, reported mild to severe haematopoietic abnormalities due to 
an expanded HSC pool, stemming from the presence of a myeloproliferative 
phenotype, as opposed to a block in lymphoid development (Growney et al., 
2005). In line with the latter, homozygous loss of RUNX1 was observed in 
patients with M0 (undifferentiated) acute myeloid leukaemia cells (AML) 
(Roumier et al., 2003), yet not with acute lymphoid leukaemia (Osato et al., 
1999). This suggested that persistence of AML cells, characterized by a high self-
renewing ability and a limited differentiation capability, could only occur in the 
absence of RUNX1. For the above reasons, RUNX1 was proposed to act as a major 
cell fate and differentiation determinant, whose absence appears to increase 
self-renewal potential by maintaining the cells in a more undifferentiated state 
(Growney et al., 2005). Interestingly, very similar observations were recently 
made in the breast field, wherein inhibition of RUNX1 in the human MCF-10A line 
was shown to trap cells in a bipotent state, thus preventing their differentiation 
into the ductal and lobular phenotypes (Sokol et al., 2015). Evidence for an 
expanded stem/progenitor pool of cells was also proposed in the Wnt/β-catenin-
driven breast cancer GEMM, as corroborated by the increase of a basal 
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subpopulation upon deletion of Runx1 (Chapter 6). This phenotype, however, 
displayed a remarkable exacerbation when combined deletion of both Runx1 and 
Runx2 was achieved, resulting in the formation of enlarged mammary anlages 
(Chapter 5), increased tumour burden and significantly decreased overall 
survival displayed by the mice (Chapter 4). Based on preliminary analyses, an 
expanded pool of Sca-1+ basal cells appeared to lay the foundation of this 
peculiar phenotypic behaviour (Chapter 6). Particularly abundant in TEBs and 
deemed to be responsive to hormonal cues, these results pointed again towards 
an exquisite tumour suppressive function exerted by the Runx genes in HR+ 
mammary cells. Similar to TEBs, cumulative evidence also suggest that 
corresponding human TDLUs are the most preferential site for neoplastic 
transformation (Russo et al., 2005; Visvader, 2009). Importantly, susceptibility 
of TDLUs to breast cancer appears to be intimately linked to the differentiation 
status of the epithelial tissue, which is in turn profoundly influenced by the 
presence or absence of pregnancy. As such, nulliparous women, characterized by 
a less differentiated epithelium, are believed to be at higher risk of breast 
cancer than parous ones, which on the contrary are less susceptible to neoplastic 
transformation in view of the higher prevalence of differentiated cells (Russo et 
al., 2005). Due to the remarkable parallels between the murine and the human 
cellular hierarchies (Visvader, 2009), it is tempting to envision RUNX1 and RUNX2 
as guardians of mammary epithelial cell fate decisions and differentiation 
potential. As impairment of the mammary epithelial cell hierarchy is key for the 
aetiology of breast cancer, a deeper understanding on the function exerted by 
the RUNX family of genes is worth of further investigation. 
In this regard, if the absence of Runx1 caused an acceleration of breast 
tumourigenesis, it should also be noted that deletion of the gene resulted in 
delayed growth of established PyMT- and β-catenin-driven mammary lesions. 
This is not the first time a chameleon-like role has been proposed for RUNX1, 
acting as a tumour suppressor and an oncogene not only in different tissues, but 
also in different tissue-contexts (Chuang et al., 2013). Over the past recent 
years multiple breast cancer associated genetic events were reported to affect 
the gene, including deep deletion, mutations (truncating, inframe and 
missense), but also amplification events (Rooney, Riggio et al., 2017). In support 
of a pro-oncogenic role played by the gene, different transcriptomic studies 
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reported RUNX1 mRNA upregulation in the TN subtype of breast cancer (Karn et 
al., 2011; Rody et al., 2011). In addition, expression of the protein was found by 
our lab to significantly correlate with poor overall survival of ER- and TN breast 
cancer patients (Ferrari et al., 2014). Preliminary analysis of MDAMB231 TN cells 
also showed an in vitro and in vivo impairment of cell proliferation upon Runx1 
knock-down (Riggio and Ferrari, unpublished). Importantly, whilst trying to 
dissect the dualistic behaviour shown by RUNX1, several factors should be taken 
into account. Firstly, the RUNX1-CBFβ complex functions as an organizing 
platform which recruits additional co-factors (co-activators or co-repressors) to 
regulate gene transcription, contributing to its physiological capability as both a 
transcriptional activator and repressor (Blyth et al., 2005). Furthermore, not 
only is the RUNX1 gene transcribed from two distinct promoters, but also the 
originating mRNAs can be subjected to alternative splicing, giving rise to 
multiple isoforms which appear to possess unique functions and differing 
patterns of tissue-specificity (Levanon et al., 1996; Miyoshi et al., 1995). It is 
therefore conceivable that RUNX1’s complex role might be due to the presence 
of differentially expressed isoforms. Additionally, the function of RUNX1 can be 
markedly affected by post-translational modifications, including 
phosphorylation, acetylation and ubiquitination (Bae and Lee, 2006). As such, 
RUNX1’s transcriptional activity was shown to be enhanced by extracellular 
signal-regulated kinase-mediated phosphorylation (Tanaka et al., 1996), whereas 
ubiquitin-dependent degradation is responsible for the tight control of RUNX1 
protein levels (Huang et al., 2001), an event shown to be inhibited through CBFβ 
heterodimerization. Accordingly, Cbfβ-null mice display poorly detectable 
RUNX1 levels, leading to the hypothesis that perhaps the effective amount of 
RUNX1 within the cells might be dependent upon existing CBFβ levels. Finally, 
RUNX1 can drive both proliferation and differentiation, two biological processes 
always thought of as antagonists (Coffman, 2003). Thus, a deeper investigation 
into the regulatory network impinging on its expression, stability and activity 
will pave the way towards a better understanding of the context-dependent role 
displayed by RUNX1 in breast cancers.  
In conclusion, far from being a “modern” disease, cancer is probably the oldest 
malady that humans have ever encountered, with proof of its existence tracing 
back to Egyptian mummies. Despite the remarkable advances made in the 
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research field, cancer remains “the defining plague of our generation” 
(Siddharta, 2010). With a total of 55,200 new cases diagnosed in the UK in 2014, 
and 11,433 reported deaths in the same year, almost 78% of breast cancer 
patients are believed to survive the disease for 10 or more years 
(https://www.cancerresearchuk.org/; accessed October 2017). Nonetheless, to 
avoid the remaining 22% of women succumbing to this malignancy and improve 
the quality of life of surviving patients, a deeper understanding of the molecular 
mechanisms underpinning the biology of the mammary gland and of breast 
cancer is imperative. To achieve this aim, as the disease appears to be the result 
of the concerted interaction between multiple low-frequently altered genes 
(e.g. RUNX1), the identity of all these players needs to be investigated. 
Elucidation of the signalling pathways controlled by breast cancer-associated 
genes through the use of different in vitro and in vivo experimental models 
might help add an extra dowel to the incomplete puzzle of breast cancer. 
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